Recombinant production and characterisation of two Fasciola hepatica cathepsin L proteases by Collins, Peter Raymond
Recombinant Production and 
Characterisation of two Fasciola hepatica 
Cathepsin L Proteases
Peter R. Collins 
Ph.D.
2005
Recombinant Production and Characterisation of two 
Fasciola hepatica Cathepsin L Proteases
Peter R. Collins, B.Sc.
A thesis submitted in partial fulfilment of the requirements for the degree of Ph.D.
Supervisors:
Dr. Sandra O’Neill, School of Nursing, Dublin City University, Ireland 
Prof. John P. Dalton, Institute for the Biotechnology of Infectious Diseases, University
of Technology, Sydney, Australia
Submitted June 2005
Declaration of Originality
I hereby certify that this material, which I now submit for assessment on the programme 
of study leading to the award of Ph.D. is entirely my own work and has not been taken 
from the work of others save and to the extent that such work has been cited and 
acknowledged within the text of my work.
Signed; f ?
Date:
Student ID No.: 96065125
Acknowledgments
I would like to thank my supervisors, Dr. Sandra O’ Neill and Prof. John Dalton for all 
their help and encouragement over the course of this project and, of course, for the 
opportunity to work on it in the first place. I would also like to especially thank Dr. 
Sheila Donnelly, Dr. Colin Stack, and Dr. Mary Sekiya for all their hands-on help and 
understanding. Thanks also to everyone I’ve worked with during this project at DCU, 
UCD and UTS -  there’s too many of you to list, but you all know who you are, and 
you’ve all helped enormously. Finally, thanks to IBID and IDP Education Australia for 
the great opportunity I was given to spend a year in UTS as part of this project.
I would like to dedicate this thesis to my parents, who have always been there when I 
needed support and encouragement and have made this thesis possible.
Abstract
The cysteine proteases of the liver fluke, Fasciola hepatica, are of great importance to 
the virulence of the organism. Previous work has established the involvement of these 
enzymes in catabolism, migration through host tissues and defence against host immune 
attack. They have therefore been identified as important vaccine targets.
In this study, sequence analyses compare the F. hepatica cathepsins LI and L2 
with each other and with other cathepsin Ls of F. hepatica and the related parasite, F. 
gigantica. Groupings of enzymes based on propeptide and active site cleft sequences 
are established, indicating possible functional diversity in both species. Comparisons 
with other trematode and mammalian cathepsin Ls were also performed, focusing on a 
propeptide motif involved in enzyme processing.
Production of the recombinant enzymes was by expression in the Pichia pastoris 
yeast expression system, providing sufficient quantities of enzyme for characterisation 
studies. Enzyme activity against fluorogenic substrates and native collagens was 
compared, demonstrating differences in substrate specificity and therefore possible 
function between the two enzymes. Processing and activation of the enzymes was also 
investigated, with inactive mutant enzymes produced for this purpose. Finally, details 
are given of various collaborations with other laboratories utilising the recombinant 
enzymes produced during this project.
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Chapter 1: Introduction -  Cysteine Proteinases of Trematodes
1.1 The Trematode Parasites
1.1.1 Introduction to Trematodes and Trematode biology
The digenetic trematodes, commonly known as the flukes, are parasitic 
flatworms of the phylum Platyhelminthes. As the name ‘digenetic’ implies, the 
digeneans generally have complex life-cycles involving at least two hosts. However, 
this is not always the case and there is great variation in life-cycles from species to 
species. Trematodes are parasites of all classes of vertebrates, with a particular bias 
among many of the species towards the parasitism of marine fishes. Nearly every organ 
of the vertebrate body may be parasitized by the adult or juvenile stages of some 
trematode species. Many of the fluke species are of great economic and medical 
importance, with losses of both productivity and life among domestic animals and 
chronic illness amongst humans (Roberts and Janovy, 2000). Of the species found in 
the subclass Digenea, the family generally regarded as the most serious problem for 
human health are the blood flukes, or schistosomes. In the case of livestock, the liver 
flukes are of great economic importance, although they too can affect the human 
population.
The general life cycle of a trematode parasite involves three hosts. Eggs are 
released into the environment from the definitive host and hatch into the first larval 
stage, the miracidium, which penetrates the first intermediate host. Development takes 
place within this host culminating in the release of a second larval stage, the cercaria, 
which penetrate the second intermediate host. Here, the cercaria encysts into the 
infectious metacercaria stage, which lies dormant until consumed along with the second 
intermediate host by the definitive host. The metacercariae then excyst within the 
definitive host and develop to the adult stage, migrating through the host’s body to
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reside in different locations, depending on the species. Release of eggs continues the 
cycle. Variations on this basic life cycle are found among the trematode parasite 
species, with differing degrees of truncation such as the deletion of the second 
intermediate or even the definitive host (Poulin and Cribb, 2002). The following 
section is intended to provide some brief background on the major digenetic trematodes 
of economic and medical importance, in particular the liver fluke, Fasciola hepatica, as 
the organism and its enzymes will be the main focus of this thesis.
1.1.2 The liver flukes: Fasciola spp.
The liver flukes, Fasciola hepatica and F. gigantica are helminth parasites of the 
family Fasciolidae, which also contains an as yet unclassified Japanese isolate liver 
fluke, often referred to in the literature simply as ‘Fasciola sp.’, as well as the giant 
intestinal fluke, Fasciolopsis buski. Both F. hepatica and F. gigantica are the causative 
agents of fasciolosis in agricultural animals, such as sheep and cattle, and have recently 
emerged as important pathogens of humans (O’Neill et al., 1998; Spithill et al., 1998; 
Dalton and Mulcahy, 2001; Rokni et al., 2002). While F. hepatica is found mainly in 
temperate regions, its larger relative F. gigantica is primarily found in tropical regions.
The life cycle of F. hepatica (see Figure 1.1) follows the same basic plan as that 
of other trematode parasites, although without a second intermediate host: (a) eggs are 
passed into the environment from the definitive host in the faeces; (b) miracidia hatch 
from the eggs and penetrate the intermediate snail host, such as Lymnaea truncatula; (c) 
development and multiplication of sporocyst and redia stages to cercaria takes place in 
the snail before the cercaria emerge and encyst on vegetation; (d) the encysted 
metacercaria are consumed by the definitive host (usually a ruminant) along with the 
vegetation and excyst, migrate and develop into adult worms, finally residing in the 
host’s bile duct (Andrews, 1999). F. gigantica shares a similar life cycle, and both
2
Mediate host
Miracidium 
penetrating 
snail
Sporocyst
Figure 1.1: The life cycle of Fasciola hepatica. Eggs pass into the environment from the definitive 
mammalian host; miracidia hatch from the eggs and penelrate the intermediate snail host; sporocyst and 
redia stages develop through to cercaria in the snail before the cercaria emerge and encyst on vegetation; 
cncystcd mctaccrcaria arc consumed by the definitive host and excyst, migrate and develop into adult 
worms in the bile duct. Adapted from Andrews (1999).
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organisms are hermaphroditic, although sexual reproduction in the definitive host is 
usually by cross-fertilization (Andrews, 1999). Migration of the juvenile flukes through 
the gut mucosa and liver parenchyma causes the symptoms of the acute stage of 
fasciolosis, namely extensive haemorrhaging and liver damage. Chronic symptoms 
occur due to damage caused to the bile ducts by the presence of the adult worms (Rokni 
et al., 2002).
1.1.3 The blood flukes: Schistosoma spp.
Helminth parasites of the family Schistosomatidae are generally referred to as 
the blood flukes and include organisms such as Schistosoma mansoni, S. japonicum, S. 
haematobium, S. indicum, and S. bovis. Schistosomiasis is regarded as the second most 
serious parasitic disease of humans after malaria, causing chronic morbidity and death, 
and affects an estimated 250 million people across around 75 countries, predominantly 
in tropical and subtropical regions. S. mansoni is widespread in Africa, the Caribbean 
and South America, while S. haematobium is found in Africa and the eastern 
Mediterranean and S. japonicum is located mainly in Asia (Roberts and Janovy, 2000; 
Hu et al., 2004).
The schistsomes differ from most of the platyhelminths in that they show sexual 
dimorphism rather then being hermaphroditic. Their life cycles are also highly 
truncated, with the effective removal of the definitive host and development from 
cercaria to egg-producing adult all occurring within the second vertebrate host (Poulin 
and Cribb, 2002). Briefly, the miracidia penetrate freshwater snails and develop 
through two generations of sporocyst to cercaria, which directly penetrate the skin of the 
vertebrate host once released. The cercariae lose their tails to become schistosomulae 
and migrate through the lungs to the hepatic portal system, to mature and pair up to 
produce eggs (Hu et al., 2004).
4
1.1.4 The Oriental lung fluke Paragonimus westermani
The oriental lung fluke, Paragonimus westermani, is a member of the 
Plagiorchiidae family and is the causative parasite of human lung paragonimiasis 
(Pezzella et al., 1981). It can also, in rare cases, cause both cerebral (Park, H. et al., 
2001; Choo et al., 2003) and hepatic infections (Kim et al., 2004). It is endemic in 
Africa, South America and Asia, in particular in Korea and Japan (Park, H. et al., 2001).
P. westermani follows the general trematode life cycle pattern of two 
intermediate hosts and one definitive vertebrate host, Infection of humans is from the 
second intermediate decapod host, usually crustaceans such as freshwater crabs, 
crayfish or shrimps. The metacercariae encyst in these animals and can be passed on if 
they are consumed either raw or undercooked (Choo et al., 2003). The metacercariae 
excyst in the small intestine and migrate trough the tissues to the lungs, where the adults 
reside, although this migration of juveniles can be erratic leading to various ectopic 
infections of other organs (Pezzella et al., 1981; Kim et al., 2004; Choo et al., 2003).
1.1.5 The Chinese liver fluke: Clonorchis sinensis
Clonorchis sinensis, a member of the Opisthorchiidae family, is the causative 
agent of clonorchiasis and is found in many regions of eastern Asia, including China, 
Korea and Vietnam, where an estimated 7 million people are infected (Nagano et al., 
2004). Like P. westermani, C. sinensis is a food-borne pathogen. In this case the 
secondary intermediate host is usually a freshwater fish, in which the cercariae encyst to 
metacercariae underneath the scales or within the muscle tissue (King and Scholz, 
2001). Consequently, infection occurs with consumption of raw or undercooked fish. 
Once consumed, the excysted juveniles migrate from the intestine up through the bile 
duct where they mature to adults (King and Scholz, 2001). This migration therefore
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shows a marked difference from the Fasciola spp., whose juveniles migrate through the 
liver tissue, although the adults reside in the bile ducts in both cases.
1.2 Cysteine Proteases of Parasitic Trematodes
1.2.1 Classification of Cysteine Proteases
The cysteine proteases of most importance secreted by trematode parasites are 
members of two clans -  Clan CA, the papain-like cysteine proteases and Clan CD, the 
legumain-like cysteine proteases (Sajid and McKerrow, 2002). In the latter group, it is 
members of the Cl 3 family that are of importance, including the asparaginyl 
endopeptidases which have been isolated from the schistosomes (Merckelbach et al., 
1994; Brindley et al., 1997; Caffrey et al., 2000) and F. hepatica (Tkalcevic et al.,
1995). These asparaginyl endopeptidases have been implicated in the breakdown of 
ingested host haemoglobin to usable amino acids, although this seems to be through an 
indirect activity, the post-translational modification of other proteases such as cathepsin 
L, B and D-like enzymes, rather than through direct catabolic activity (Brindley et al., 
1997; Brindley and Dalton, 2004).
The larger group, Clan CA, includes the cathepsin B and cathepsin L-like family 
Cl and the calpain-like family C2. Calpain-like enzymes have been isolated for the two 
major Schistosoma spp. In the case of S. mansoni, the calpain-like enzyme has been 
shown to be expressed in both the sporocyst and adult stages of the parasite life cycle 
and is thought to be a membrane bound enzyme important in parasite metabolism 
(Andresen et al., 1991). A large subunit of the S. japonicum calpain has also been 
recombinantly expressed and shown to be a potential vaccine candidate, providing a 
partially protective response in mice (Zhang et al., 2001).
By far the largest and most important class of these enzymes for trematode 
parasites are the papain-like enzymes of family C l, more specifically subfamily CIA.
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These are generally subdivided into cathepsin B-like and cathepsin L-like proteases, all 
sharing a similarity of structure and function with that of papain (Sajid and McKerrow, 
2002).
Papain was the first cysteine protease to be isolated, in 1879, from the papaya 
fruit, Caricapapaya, from which its name was taken. It was also the first cysteine 
protease to have its three dimensional structure determined (Drenth et al., 1968) and is 
therefore the archetype for all cysteine proteases, in particular those of the C1 family. It 
consists of a single chain nonglycosylated polypeptide with three disulphide bonds and 
which folds to form a globular protein of two domains. These two interacting domains 
delineate the active site cleft at the surface of the enzyme, where the substrate binds and 
is cleaved (Drenth et al., 1968; Ménard and Storer, 2004).
Papain has been shown to have endopeptidase, amidase and esterase activités, 
with a preference for residues with bulky non-polar side-chains, such as phenylalanine, 
in the P2 position (Ménard and Storer, 2004). Along with the majority of the members 
of Clan CA, the basis of the catalytic mechanism of papain is the catalytic triad 
consisting of Cys25, His159 and Asn175 (papain numbering). Also of importance is Gin19, 
sometimes referred to as the ‘oxyanion hole’ and highly conserved across the papain­
like cysteine proteases, which stabilises the oxyanion of the tetrahedral intermediate 
formed during peptide bond hydrolysis (Barrett, 1994; Sajid and McKerrow, 2002; 
Polgâ, 2004).
1.2.2 General structure and function of cathepsin B and cathepsin L-like cysteine 
proteases (subfamily CIA)
The trematode cysteine proteases of subfamily CIA share many structural and 
functional characteristics with their mammalian counterparts. All are synthesised as 
inactive preproenzymes consisting of a prepeptide signal sequence, a propeptide and a
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mature enzyme region (see Figure 1.2; also Sajid and McKerrow, 2002; Dalton et al., 
2004a). In the case of the mammalian cysteine proteases, it has been shown that the 
prepeptide signal sequence is removed following translocation into the endoplasmic 
reticulum and that the TV-terminal propeptide extension is involved in several functions 
(Wiederanders, 2003); these include intracellular targeting of the enzyme (Coulombe et 
aL, 1996; Menard et al., 1998; Rozman et al., 1999), action as an intermolecular 
chaperone aiding the correct folding of the mature enzyme (Baker et al., 1992; Shinde et 
al., 1997) and prevention of uncontrolled proteolysis by binding to the enzyme substrate 
cleft in a reverse, non-productive direction (Coulombe et al., 1996; Cygler and Mort,
1997). It has been demonstrated for the propeptide of human cathepsin L and other 
papain-like cysteine proteases that the free propeptide also acts as a specific and potent 
inhibitor of the active mature enzyme at neutral pH but does not bind well in alkali 
conditions (Coulombe et al., 1996; Baker et al., 1992; Ogino et al., 1999; Guo et al., 
2000).
The cathepsin L and cathepsin B-like cysteine proteases all share a general 
structure with the archetype of the group, papain. The mature protein takes the form of 
a two-domain globular protein, with the active site cleft separating the two domains at 
the surface (Drenth et al., 1968; Baker, 1977; McGrath et al., 1995; Coulombe et al., 
1996; Podobnik et al., 1997). The TV-terminal domain consists mainly of bundled a- 
helices, while the C-terminal domain contains a (3-barrel structure and a long helix runs 
through the middle of the molecule starting at the catalytic cysteine (Rawlings and 
Barrett, 2004). These enzymes also possess the catalytic triad of Cys25, His159 and 
Asn175 (papain numbering) (Barrett, 1994; Rawlings and Barrett, 1994; Polga, 2004) 
and most members of the family are irreversibly inhibited by E64 and its analogues 
(Barrett et al., 1982; Rawlings and Barrett, 2004).
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AB
Figure 1.2: Typical structure of papain-like cysteine proteases. A, schematic diagram of papain 
showing the prepeptide signal sequence, propeptide and mature regions. The location of the residues of 
the active site triad are indicated (papain numbering). B, structure of human procathepsin LI with the 
propeptide shown in red and the mature region shown in blue. C, structure of mature human cathcpsin L 
with the side chains of Cys25 and His159 (human cathepsin L numbering) indicated in yellow and green 
respectively. Adapted from Turk and Guncar (2003).
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1.2.3 Cathepsin B-like cysteine proteases
The first major category of proteases within subfamily CIA are the cathepsin B- 
like cysteine proteases and are present in a wide variety of species, including many 
trematode and other parasitic species (Karrer et al., 1993; Sajid and McKerrow, 2002).
Compared to the other major members of the papain superfamily, cathepsin B 
differs most in structure from the general papain-like pattern. Analyses of the crystal 
structure of mammalian cathepsin Bs show that it possesses an extended insertion of 
twenty amino acid residues, termed the occluding loop (Musil et al., 1991). This loop 
blocks the C-terminal end of the active site cleft, reducing endopeptidase activity and 
preventing binding of macromolecular inhibitors and contributes to the enzyme subsites, 
giving cathepsin Bs an extra dipeptidyl carboxypeptidase activity unique among the 
papain superfamily (Illy et al., 1997; Sajid and McKerrow, 2002; Mort, 2004). Two 
histidine residues within the loop, His110 and His111 (human cathepsin B numbering) are 
responsible for this exopeptidase activity, serving to anchor the carboxylate at the P’2 
position of the substrate, thereby directing the C-terminal dipeptide into position in the 
active site for cleavage (Sajid and McKerrow, 2002; Mort, 2004). The loop is also 
responsible for inhibition by the E-64 derived cathepsin B specific inhibitor, CA074. 
Studies have shown that deletion of the occluding loop prevents inhibition by CA074, 
abolishes the exopeptidase activity, allows bulkier inhibitors such as the cystatins to 
bind to the active site and increases endopeptidase activity (Illy et al., 1997; Sajid and 
McKerrow, 2002). The occluding loop also defines the pH dependency of inhibition of 
cathepsin B by its propeptide (Quarasihi et al., 1999).
In addition to the occluding loop, cathepsin B further differs from the papain 
model with a truncated propeptide, only two-thirds the length of that of other family Cl 
enzymes (Musil etal., 1991; Podobnik et al., 1997; Turket al., 1996). However, despite 
this truncation, the propeptide still functions in a similar manner to that of the other
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papain-like cysteine proteases, with importance in folding of the mature region, 
processing of the enzyme to its mature form and prevention of uncontrolled proteolysis 
(Mach et al., 1994a; Turk et al., 1996; Quraishi and Storer, 2001; Mort, 2004). In 
addition, the free propeptide has been demonstrated to form a stable complex with the 
mature enzyme at neutral pH, providing a mechanism for activity of the processed 
protease to be mediated by regional acidity and allowing it to survive extracellularly in 
conditions that would lead to the inactivation of other lysosomal cysteine proteases 
(Mach et al., 1994b; Mort 2004). Secreted cathepsin B has been implicated in tumour 
invasion and metastasis (Lorenzo et al., 2000).
The endopeptidase activity of cathepsin B, which may be an evolutionary 
holdover from its origin as a more conventional papain-like cysteine protease (Illy et al.,
1997), maintains the preference for large hydrophobic residues in the P2 position found 
in other members of the Cl A subfamily, but uniquely can accommodate an arginine 
side chain in this position due to the presence of a glutamate residue within the S2 
subsite (Mort, 2004). From a practical point of view, activity against a substrate such as 
the fluorogenic compound Z-Arg-Arg-AMC can be used to distinguish cathepsin Bs 
from other members of the papain superfamily, which lack such activity.
A second cathepsin B-like enzyme, previously identified variously as cathepsin 
P, cathepsin Z, cathepsin Y, and cathepsin B2, is now known as cathepsin X (Menard 
and Sulea, 2004). While cathepsin X most closely resembles cathepsin B, it possess 
several distinct and unique features: the propeptide is even further truncated then that of 
cathepsin B, down to only about one-third the length of other subfamily CIA 
propeptides; the enzymes possess a unique carboxypeptidase activity and lack any 
significant endopeptidase activity; finally, a unique three residue insertion, termed the 
mini-loop, is present within the active site and provides a signature motif for cathepsin 
Xs (Santamaria et al., 1998; Menard and Sulea, 2004). Cathepsin X-like proteases have
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been identified in nematode worms, such as Caenorhabditis elegans and Onchocerca 
volvulus, but not so far in the trematodes (Sajid and McKerrow, 2002). For example, 
the cathepsin X of C. elegans, referred to as Ce-CPZ-1 (reflecting the alternate 
nomenclature of cathepsin Xs as cathepsin Zs), is expressed in the hypodermal cells of 
all developmental stages, as well as specifically in the gonads and pharynx of the adult, 
and is believed to be involved in moulting and essential to the development of the 
organism (Hashmi et al., 2004).
The last member of this group is cathepsin C, also known as dipeptidyl 
peptidase I, which again differs greatly from the general pattern of papain-like cysteine 
proteases (Tort, et al., 1999; Turk et al., 2004). Cathepsin Cs have a large molecular 
size, possess an extra domain, form tetramers, have a requirement for halide ions for 
activity, and are aminopeptidases (Turk, et al., 2000; Turk et al., 2001; Turk et al., 
2004).
1.2.4 Cathepsin L-like cysteine proteases
Enzymes of the second major category of papain-like cysteine proteases, the 
cathepsin L-like proteases, have structures more closely matching the general profile of 
the group. Again, they are present in a wide variety of species and many have been 
isolated from trematode and other parasite species (Sajid and McKerrow, 2002). Unlike 
the cathepsin Bs, these proteases have full length propeptides containing a prominent 
structural motif, referred to as the ERFNIN motif, which forms the main a-helical 
backbone of the propeptide (Karrer et al., 1993; Tort et al., 1999).
Cathepsin L itself was first isolated as a mammalian lysosomal cysteine 
protease, hence the ‘L’ designation, and conforms closely to the general structure of 
papain-like cysteine proteases (Coulombe, 1996; Kirschke, 2004a). Mammalian 
cathepsin Ls have been shown to have major biological functions in processes such as
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lysosomal proteolysis, spermatogenesis, antigen presentation, and tumour invasion and 
metastasis (Kirschke, 2004a). While the enzyme normally resides in the lysosome, it is 
secreted in small amounts from normal cells, and is overexpressed and secreted in 
tumour cells, with involvement in cleavage of human C3 (Jean et al., 1997; Frade, 1999) 
and generation of endostatin (Felbor et al., 2000). Efforts have been made to use single 
chain variable fragment (ScFv) antibodies against cathepsin L to inhibit its secretion 
from human melanoma cells (Guillaume-Rousselet, et al., 2002).
Cathepsin K (previously identified variously and confusingly as cathepsin O, 
cathepsin X and cathepsin 02) closely resembles cathepsin L and has been isolated 
from the osteoclasts of many mammalian species (Drake et al., 1996; Shi et al., 1995; 
Bromme, 2004b). The enzyme is involved in bone resorption as well as arthritis, with 
high levels of expression found in synovial fibroblasts of rheumatoid arthritic joints 
(Hou et al., 2001; Bromme, 2004b). This is due to its ability to cleave collagens and 
aggrecans, the major building blocks of cartilage, resulting in the cartilage destruction 
of arthritic diseases (Kafienah et al., 1998; Hou et al., 2001; Hou et al., 2003).
Cathepsin K activity is regulated and enhanced by glycosaminoglycans such as the 
chondroitin sulphates and heparin (Li et al., 2000; Li et al., 2002; Li et al., 2004). There 
is also evidence for the presence of kinase activity of cathepsin K (Godat et al., 2004). 
This wider substrate specificity compared to cathepsin Ls is due to differences in the S2 
pocket, particularly with the residues Tyr and Leu which replace the Leu and 
Ala205 present in mammalian cathepsin Ls (Lecaille et al., 2002; Lecaille et al., 2003).
Cathepsin S shows close similarity to cathepsins K and L, sharing similar S2/P2 
subsite specificity (Kirschke, 2004b). Substrate preference in cathepsin S is for 
branched hydrophobic residues in the P2 position, similar to cathepsin K, and crystal 
structures of human cathepsin S show a large S2 pocket, consistent with its broader 
substrate specificity at this site compared to cathepsins B, L or K (McGrath et al., 1998;
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Kirschke, 2004b). Cathepsin S is stable and active at pH 7.5, unlike cathepsin L and to 
a greater degree than cathepsin K (Kirschke, 2004b). It displays collagenolytic and 
elastinolytic activity and has been shown to play a role in antigen presentation 
(McGrath et al., 1998; Kirschke, 2004b). Levels of the enzyme are increased in the 
brains of Down syndrome and Alzheimer’s disease patients, and may play a role in the 
pathogenicity of the latter disease (Lemere et al., 1995; Munger et al., 1995; Kirschke, 
2004b).
Cathepsin F is unusual among the cathepsin L-like cysteine proteases in that it 
possesses a highly extended propeptide region, nearly three times the length of that of 
cathepsin L, which contains a cystatin-like domain towards the //-terminus (Wang et al., 
1998; Brômme, 2004a). The protein sequence is also quite dissimilar from other 
cathepsin L-like proteases, with its closest neighbour being cathepsin W with which it 
shares approximately 42% similarity (Santamaria et al., 1999; Wang et al., 1998; 
Brômme, 2004a). The central a-helix of the propeptide is also different, produced by 
the so-called ERFNAQ motif which it also shares with cathepsin W, rather than the 
ERFNIN found in other members of the family (Wang et al., 1998; Brômme, 2004a). 
Human cathepsin F has the usual preference of hydrophobic residues in the P2 position 
of its substrates and shows extremely high potency against the fluorogenic substrates Z- 
Phe-Arg-AMC and Z-Leu-Arg-AMC (Wang et al., 1998). It is produced by 
macrophages and is implicated in the mediation of MHC Class II maturation and 
peptide loading (Shi et al., 2000). It has also been shown to be critical for the 
modification and fusion of low density lipoprotein (LDL) particles during atherogenesis 
and may be a target for the treatment of atherosclerotic diseases (Ôômi et al, 2004).
Cathepsin W, also known as lymphopain, is most closely related to cathepsin F, 
and the two may form a subgroup of cathepsin F-like proteases (Tort et al., 1999;
Dalton and Brindley, 2004). Both share the modified ERFNAQ motif in their
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propeptides, although the propeptide of cathepsin W is of a normal length without the 
extra cystatin-like domain of cathepsin F (Dalton and Brindley, 2004). The enzyme is 
produced in cytotoxic T cells and natural killer (NK) cells and has been isolated to the 
endoplasmic reticulum of the latter cell type (Wex et al., 2001; Dalton and Brindley, 
2004; Ondr and Pham, 2004). Little further characterisation of the mammalian 
cathepsin Ws has been carried out.
Finally, cathepsin O is unique among the cathepsin-L like proteases in 
completely lacking the ERFNIN motif from its propeptide (Velasco and Lopez-Otin, 
2004). It is widely expressed, being overexpressed in human carcinomas, and is 
involved in normal lysosomal protein degradation and turnover (Velasco et al., 1994).
1.2.5 Trematode Cysteine Proteases
Papain-like cysteine proteases are of great importance to the metabolism and 
host-parasite interactions of the trematode parasites. Enzymes from both the cathepsin 
B-like and Cathepsin L-like groups have been isolated from these parasites (Tort et al., 
1999; Sajid and McKerrow, 2002; Dalton et al., 2004a). The study of cysteine proteases 
of parasites is of great interest, particularly in providing the basis for various therapies 
to combat parasite infection in both humans and animals. The enzymes have been 
investigated as drug targets, with efforts made to design specific inhibitors to prevent 
their activity and hence disable a major part of the parasite metabolism (McKerrow et 
al., 1995; Li et aL, 1996). There has also been studies of their use as vaccines, using 
either native purified or recombinant versions of the molecules directly (Dalton and 
Mulcahy, 2001; Marcet et al., 2002; Almeida et al-, 2003; Pearce, 2003), or their genes 
as DNA vaccines (Kofta et al., 2000).
Further to their use in treatment of parasitic disease, the papain-like cysteine 
proteases have been used in the diagnosis of disease in both animals (Gorman et ai.,
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1997; Cornelissen et al., 2001) and humans (Chappell et al., 1989; O’Neill et al., 1998; 
Camevale et al., 2001; Rokni et al., 2002; Nagano et al., 2004).
Cathepsin B-like enzymes which are expressed in trematodes include the 
cathepsin Bs of S. mansoni (Lipps et al., 1996; Dalton et al., 1996a), S. japonicum 
(Merckelbach et al., 1994), F. hepatica (Tkalcevic et al., 1995; Wilson etal., 1998; Law 
et al., 2003), and C. sinensis (Dalton et al., 2004a), and the cathepsin Cs of S. 
japonicum , S. mansoni, and F. hepatica (Tort et al., 1999; Turk et al., 2004). It seems, 
therefore, that cathepsin Bs and cathepsin B-like enzymes may be found throughout the 
trematode parasites.
In the case of the cathepsin L-like proteases, however, there is a strong 
divergence in the predominance of the two main trematode examples, cathepsin Ls and 
cathepsin Fs. Cathepsin Ls have been identified in F. hepatica, F. gigantica (see 
Section 2.3.4, Table 2.2 for references), S. mansoni (Dalton et al., 1996; Brindley et al., 
1997; Brady et al., 2000) and S. japonicum (Day et al., 1995) whereas cathepsin Fs are 
found in P. westermani (Park, H. et al., 2001; Park, H. et al., 2002; Shin et al., 2005) 
and C. sinensis (Park, S. Y. et al., 2001; Lee et al., 2003; Nagano et al., 2004). These 
enzymes form separate clades (see Figure 1.3), trematode cathepsin L and trematode 
cathepsin F. Members of the cathepsin L clade have been found in Fasciola and 
Schistosoma spp. This lineage also contains the digestive enzymes of insects and 
crustaceans and has probably evolved to perform this function, later giving rise to the 
mammalian lysosomal cathepsins L, S and K. (Tort et al., 1999). It is also of note that 
the cathepsin L clade of the Fasciola spp. shows significant diversity, with multiple 
cathepsin L sequences identified in both F. hepatica and F, gigantica as belonging to a 
monophyletic group (Irving et al., 2003). This large gene family may enable production 
of greater quantities of proteolytic enzyme, thereby increasing the parasite’s efficiency 
in penetrating and feeding on host tissues (Dalton et al., 2004b). The divergent
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Figure 1.3: Rooted phylogcntic comparison o f the cathepsin L supcrfamily. Key: Cs, Clonorchis 
sinensis; Pw, Paragonimus westermani; Fg, Fasciola gigantica; Fh, Fasciola hepatica; Sj, Schistosoma 
japonicurrr, Sm, Schistosoma monsoni; CL, cathepsin L; CF, cathepsin F; CP, cysteine peptidase. The 
terms cathepsin, trypanosomatid and filarial refer to mammalian, Trypanosoma cruzi and Onchorcerca 
volvulus peptidase orthologues, respectively. The peptidase acronyms correspond to the following 
Protein Data Bank Accession nos. (shown in parentheses). Cathepsin F (NM 003793), cathepsin K 
(NM 000396), cathepsin L (M20496), cathcpsin S (M90696), cathepsin W (NM 001335), CsCPl 
(AF093243), CsCPa (U85984), CsCPb (U85983), CsCPc (AB020036), CwCLa (AF362769), filarial L 
(AF331036), PwCPa (D21124), PwCPb (AF71801 ), PwCLb (U70537), PwCPc (U69120), SmCF 
(U07345), trypanasomatid L (M84342), FgCLa(AF419329), FgCLb (AF239264), FgCLl (AF112566), 
FhCLa (AF271385), FhCLb (AB009306), FhCLc (L33772), FhCLI (Z22765), FhCLIa (U62288), 
FhCLIC (AF239625), FhCLID (AF239266), FhCF2 (U62280), FhCL3 (AJ270093), FCP (S70380), 
SjCL2 (U38476) and SmCL2 (Z32529). Adapted from Dalton et aL (2005; unpublished).
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evolution of these sequences may also have been an adaptive response to the evolution 
of new host species, as the approximate time of divergence coincides with the 
appearance of ancestor species to modem ruminants (Irving et al., 2003).
While members of the trematode cathepsin F clade have been identified in C. 
sinensis, P. westermani and S. mansoni, none have so far been identified in Fasciola 
spp. (see Figure 1.3). These enzymes appear to be much more closely related than 
members of the cathepsin L clade, with the possibility of a corresponding greater 
conservation of function (Park et al., 2002; Kang et al., 2004). These enzymes 
eventually gave rise to the mammalian cathepsin F clade (see Section 1.2,4), although 
the majority of the trematode cathepsin Fs lack the cystatin-like domain N-terminal 
extension to their propeptides, suggesting alternate functions or localizations for the 
trematode enzymes.
1.2.6 Processing of Papain-like cysteine proteases
Human lysosomal procathepsin L provides a good example of the activation of a 
papain-like cysteine protease which has been widely studied. The enzyme is stabilized 
at high pH by the propeptide, which protects the protein from the denaturing effects of 
the alkali (Menard et al., 1998). The generation of the fully mature and active enzyme 
occurs with the removal of the propeptide at the lower lysosomal pH of 5.5 (Coulombe 
et al., 1996; Menard et al., 1998; Mason and Massey, 1992; Ishidoh and Kominami,
1994).
This cleavage of the proregion of cysteine proteases has been shown to occur 
autocatalytically in vitro under acidic conditions, with examples found among the 
human cathepsins L, K and B, and other subfamilies (Menard et al., 1998; Mach et al., 
1994b; McQueney et al., 1997; Yamasaki et al., 2002). The stability of the propeptide- 
mature protease complex is dependent on electrostatic interactions and therefore
reduction of the environmental pH weakens the bonds between the propeptide and the 
catalytic site. As a consequence of this, the proenzyme may adopt a looser 
conformation in which the propeptide is less tightly bound into the active site cleft and, 
therefore, is more susceptible to proteolysis (Rozman et al., 1999; Jerala et al., 1998).
The fine details and precise mechanism of this proteolytic conversion of papain­
like cysteine proteases from proenzyme to mature active enzyme is still actively 
debated. It has been shown from the three-dimensional structures of procathepsin L 
(Coulombe et al., 1996) and procathepsin B (Musil et al., 1991; Turk et al., 1996; 
Podobnik et al., 1997) that the N-terminus of the mature enzyme is quite far removed 
from the active site, thus making it difficult to visualize an autocatalytic event. Further 
to this, circular dichroism studies have revealed that activation does not involve 
significant conformational changes in the structure of procathepsin L (Menard et al.,
1998) or procathepsin B (Rozman et al., 1999). It is therefore assumed that the initial 
event in autocatalysis may involve an active proenzyme, possibly created by the 
reduced pH, which cleaves another proenzyme in the vicinity of the 7V-terminus and sets 
off a chain reaction (Menard et al., 1998; Rozman et al., 1999).
However, more recent studies on procathepsin B and procathepsin S identified 
autoproteolytic intermediates of processing when cystatin was included in in vitro 
activation reactions, which supported the view that the segment of the propeptide that 
binds the active site cleft is susceptible to cleavage (Quraishi and Storer, 2001). It has 
therefore been suggested that an initial slow intramolecular cleavage event within this 
segment of the propeptide triggers a more rapid cascade of intermolecular cleavages at 
the 7V-terminus (Quraishi and Storer, 2001).
Earlier studies on the processing of yeast-expressed recombinant papain 
identified a conserved heptapeptide (Gly-Xaa-Asn-Xaa-Phe-Xaa-Asp) motif located 
between residues -42 and -36 in the propeptide (papain numbering) which may be a site
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of initial cleavage in the pH-dependent autoactivation of the enzyme (Vemet et al.,
1995). It was suggested that the lowering of the pH perturbed the negative charge of 
Asp'36 resulting in a conformational change that switched on the processing events by 
allowing proteolysis to occur at the Ala'37/Asp'36 bond. Following this primary cleavage 
further removal of the remaining amino acids of the propeptide may result from the 
proteolytic activity of the intermediate species, resulting in fully active mature protease 
(Vemet etal., 1995).
1.3 Fasciola hepatica cathepsins LI and L2
1.3.1 Functions and importance of F. hepatica cathepsins LI and L2
Some of the most significant secretory products of F. hepatica are the cathepsin 
L-like cysteine proteinases (Dalton and Heffernan, 1989). These proteinases play 
pivotal roles in the pathogenicity of the parasite. The enzymes take part in acquisition 
of nutrients by the catabolism of host proteins to absorbable peptides (Tort et al., 1999). 
They facilitate the migration of the parasite through the host intestine and liver by 
cleavage of interstitial matrix proteins such as fibronectin, laminin, and native collagen 
(Berasain et al., 1999). They are implicated in evasion of attack by host immune 
effector cells through the cleavage of immunoglobulins in a similar manner to papain 
(Smith etal., 1993b; Carmona etal., 1993).
Recently, F. hepatica cathepsin LI has been shown to be involved in 
immunomodulation by the suppression of ThI responses in infected laboratory animals, 
thereby making them susceptible to concurrent bacterial infections (Brady et al., 1999; 
O’Neill et al., 2000; O’Neill et al., 2001). It is therefore not surprising that these 
proteases have been recognized as important targets at which parasite intervention 
strategies, in particular vaccine development, should be directed (Smith et al., 1994; 
Dalton and Mulcahy, 2001). In this regard, it has been previously shown in our
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laboratory that the induction of anti-cathepsin L immune responses by vaccination with 
purified enzyme prior to a challenge infection of F. hepatica larvae elicits high levels of 
protection in cattle against development of disease (Dalton et al., 1996b; Mulcahy et al., 
1998; Dalton and Mulcahy 2001).
1.3.2 Structure of F. hepatica cathepsins LI and L2
Isolation of the cDNAs encoding both F. hepatica cathepsins LI and L2 
revealed that they share a basic structure with their mammalian homologs; each is 
synthesized as an inactive preproenzyme consisting of a prepeptide signal sequence, a 
propeptide and a mature enzyme region (Roche et al., 1997; Dowd et al., 1997). It is 
assumed by analogy with the related mammalian cysteine proteases that the prepeptide 
signal sequence is removed following translocation into the endoplasmic reticulum and 
that the TV-terminal propeptide extension is involved in multiple functions including 
intracellular targeting of the enzyme (Coulombe et al., 1996; Menard et al., 1998; 
Rozman et al., 1999), correct folding of the mature enzyme (Baker et al., 1992; Shinde 
et al., 1997; Cappetta et al., 2002) and prevention of uncontrolled proteolysis 
(Coulombe et al., 1996; Cygler and Mort, 1997). The free propeptides of the F. 
hepatica procathepsin Ls also act as specific and potent inhibitors of the cognate mature 
enzyme at neutral pH but do not bind to the enzyme at pH 5.5-3.5 (Roche et al., 1999), 
another feature which these enzymes have in common with their mammalian 
counterparts (Coulombe et al., 1996; Baker et 1992; Ogino et al., 1999; Guo et al., 
2000). Phylogenetic studies have shown that the F. hepatica cathepsin LI belongs to an 
enzyme lineage that eventually gave rise to the mammalian cathepsin Ls, Ks, and Ss 
(Tort et al., 1999) and these structural and functional similarities reflect this.
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1.4 Aims of this thesis: Sequence analysis, production, and characterization of 
F. hepatica CL1 and CL2
• Sequence analysis
o Direct comparison of F. hepatica cathepsin LI and L2 sequences
o Comparison of F. hepatica and F. gigantica cathepsin L sequences 
currently deposited in the online databases
o Identification of features of Fasciola cathepsin L clades, particularly 
propeptide sequences and S2 subsite residues
o Comparison of F. hepatica cathepsin LI and L2 sequences with selected 
plant, trematode and mammalian equivalents
• Secretion of cathepsin L by the parasite
o Immunoblot analysis of F. hepatica excretory-secretory (ES) products
o Localisation of mature cathepsin Ls and cathepsin L propeptides within 
gut of F. hepatica
• Production of recombinant enzymes
o Transfer of procathepsin LI and L2 cDNAs from Saccharomyces 
cerevisiae expression vector to Pichia pastoris yeast expression system
o Expression and purification of enzymes from yeast medium
o Analysis of effects of environmental conditions on enzyme production
o Generation and production of inactive procathepsin LI and L2 mutants
• Characterization of recombinant enzymes
o Study of autocatalytic processing of procathepsin LI and L2
o Use of inactive mutants to investigate intermolecular processing
o Comparison of activity and substrate specificity of cathepsin LI and L2 
by use of fluorogenic substrate assays
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o Comparison of activity of cathepsin LI and L2 against native matrix 
proteins, using collagens as examples
o Determination of pH optima of cathepsin LI and L2
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Chapter 2: Materials and Methods
2.1 Materials
2.1.1 Chemical reagents
Amresco Inc.. Solon. Ohio. USA:
High melting point agarose, low melting point agarose.
Bio-Rad Laboratories Ltd., Hemel Hempstead, Hertfordshire. UK:
40% acrylamide/bisacrylamide solution, DC Protein Assay Reagent A, DC Protein 
Assay Reagent B.
New England Biolabs (UK) Ltd.. Hitchin, Hertfordshire. UK:
100 bp DNA ladder, 1 kb DNA ladder, Broad range prestained protein marker.
Pierce Biotechnology Ltd.. Rockford, Illinois. USA:
BCA Protein Assay Reagent A, BCA Protein Assay Reagent B.
Promega UK Ltd.. Southampton. UK:
Blue/orange 6X loading dye, dATP, dCTP, dGTP, dTTP, 100 bp DNA ladder, 1 kb 
DNA ladder, Broad range protein molecular weight markers, Nuclease-free water.
Qiagen Ltd.. Crawley. West Sussex. UK:
Ni-NTA agarose.
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Sigma-Aldrich Ireland Ltd., Dublin. Ireland:
Acetic acid, 7-Amino-4-methylcoumarin, Ammonium persulphate, Bromophenol blue 
sodium salt, Calcium chloride, Chloroform, Citric acid, Coomassie Brilliant Blue R- 
250, Diethyl pyrocarbonate, N,A^-Dimethyl-formamide, Dimethyl sulphoxide, DL- 
Dithiothreitol, Ethanol, Ethidium bromide solution, Ethylenediaminetetraacetic acid 
disodium salt dihydrate, Glass beads acid-washed 425-600 [am, D-(+)-Glucose 
monohydrate, Glycerol, Glycine, HEPES, Hydrochloric acid, Imidazole, Isopropyl-P-D- 
1-thiogalactopyranoside, Magnesium sulphate, Manganese(II) chloride, 2- 
Mercaptoethanol, Methanol, PIPES, Potassium acetate, Potassium chloride, Potassium 
hydroxide, Potassium phosphate dibasic, Potassium phosphate monobasic, 2-Propanol, 
Rubidium chloride, SIGMAFast 3,3’-diaminobenzidine tablets, Sodium acetate,
Sodium chloride, Sodium citrate monobasic, Sodium citrate tribasic dihydrate, Sodium 
dodecyl sulphate, Sodium hydroxide pellets, Sodium phosphate dibasic, Sodium 
phosphate monobasic monohydrate, N ,N ,N \N ’-Tctramethylethylenediamine, 
Tris(hydroxymethyl)aminomethane, Triton X-100, Tween-20.
2.1.2 Enzymes
New England Biolabs (UK) Ltd., Hitchin, Hertfordshire, UK:
Avril, BSA, NEBuffer 3, NEBuffer 4, PstI, Sail, SnaBI.
Promega UK Ltd., Southampton. UK:
ImProm-II reverse transcriptase, 5X ImProm-II reaction buffer, Magnesium chloride, 
Recombinant RNasin ribonuclease inhibitor.
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Sigma-Aldrich Ireland Ltd., Dublin. Ireland:
Collagenase from Clostridium histolyticum (Sigma Blend Type H), KlenTaq LA DNA 
polymerase, 10X KlenTaq PCR buffer, 10X PCR buffer without MgC^, MgCh, 
REDTaq Genomic DNA polymerase.
2.1.3 Media components
BD Biosciences Ltd.. Cowley. Oxford, UK:
Bacto agar, Bacteriological peptone, Difco yeast nitrogen base w/o amino acids and 
ammonium sulphate, Difco yeast nitrogen base with ammonium sulphate and w/o amino 
acids, Tryptone, Yeast extract.
Invitrogen Ltd.. Paisley. UK:
Geneticin.
Sigma-Aldrich Ireland Ltd.. Dublin. Ireland:
Ampicillin sodium salt, Ammonium sulphate, D-Biotin, L-Histidine, L-Glutamic acid, L- 
Methionine, L-Lysine, L-Leucine, L-Isoleucine, D-Sorbitol.
2.1.4 Proteins, peptides and antibodies
Bachem (UK) Ltd.. St. Helens. Merseyside. UK:
Boc-Ala-Gly-Pro-Arg-AMC • HC1, Boc-Val-Leu-Lys-AMC, Boc-Val-Pro-Arg-AMC, 
Tos-Gly-Pro-Arg-AMC ■ HC1, Tos-Gly-Pro-Lys-AMC, Z-Phe-Ala-diazomethylketone 
(CHN2), Z-Phe-Arg-AMC • HC1, Z-Pro-Arg-AMC • HC1.
Bio-Rad Laboratories Ltd.. Hemel Hempstead, Hertfordshire. UK:
Goat anti-mouse IgG (H+L)-horseradish peroxidase
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Peptides International Inc., Louisville, Kentucky, USA:
Z-Leu- Arg- AMC.
Roche Products (Ireland) Ltd., Dublin, Ireland:
Mouse monoclonal Anti-His6 IgG
Sigma-Aldrich Ireland Ltd., Dublin, Ireland:
Anti-rabbit IgG (whole molecule)-peroxidase antibody produced in goat, Bovine serum 
albumin, Collagen from bovine nasal septum (Type II), Collagen from human placenta 
(Type V I), Gelatin (porcine), Z-Arg-AMC ■ HC1, Z-Arg-Arg-AMC • HC1.
2.1.5 Vectors, strains and kits
Geneart GmbH. Regensburg, Germany:
03-1024pPCR-Script.
Invitrogen Ltd., Paisley, UK:
Escherichia coli Top 10F’, Multi-Copy Pichia Expression Kit, pPIC9K, Pichia 
EasyComp Kit, Pichiapastoris GS115.
Promega UK Ltd.. Southampton, UK:
pGEM-T Easy Vector System I, Wizard DNA Clean-up Kit, Wizard PCR Preps DNA 
Purification System.
Qiagen Ltd., Crawley, West Sussex, UK:
QiaQuick Gel Extraction Kit, Qiagen Midi Plasmid Prep Kit.
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Vectors previously developed in the laboratory:
pAAH5.FheCLl, PAAH5.FheCL2.
2.1.6 Oligonucleotide primers
All oligonucletide primers were synthesised by Sigma-Genosys Ltd., 
Cambridge, UK.
Table 2.1: Sequences of oligonucleotide primers: restriction or mutation sites are underlined, His6-tag
sequences are marked in bold, restriction enzyme clamps and linkers are marked in italics.
Name: Sequence: Features/Notes:
FheCLIF
5’-GCGGCTACGTA 
TCGAATGATGATTTGTGGCAT-3 ’
Binds 5’-end of FheCLl and FheCL2 
propeptide coding sequences. Includes 
SnaBI restriction site.
FheCLlR
5'-GCG CCTAGG TCA 
GTGGTGGTGGTGGTGGTG GGGCCC 
CGG AAATCGTGCCACCAT-3 ’
Binds 3’-end of FheCLl and FheCL2 
coding sequences. Includes Avril 
restriction site, stop codon and His6-tag 
sequence.
FheCLlmutF 5 ’ -GTGGCTCCGGTTGGGC ATTC-3 ’
Binds active site region of FheCLl, 
Includes T->G mismatch.
FheCLlmutR 5 ’-GAATGCCCAACCGGAGCCAC-3 ’
Binds active site region of FheCLl. 
Includes A->C mismatch.
M13F 5 ’-CGCCAGGGTTTTCCCAGTCACGAC-3 ’
Binds towards 5’-end of lacZ gene in M13 
or pUC based vectors.
M13R 5 ’-TCACACAGGAAACAGCTATGAC-3 ’
Binds towards 3’-end of lacZ gene in Ml 3 
or pUC based vectors.
a-factor 5 ’ -TACT ATTGCCAGC ATTGCTGC-3 ’
Binds to P. pastoris a-factor signal 
sequence.
5’AOXl 5 ’ -GACTGGTTCC AATTGAC AAGC-3 ’
Binds to 5’-end of P. pastoris alcohol 
oxidase 1 promoter.
3’AOXl 5 ’-GCAAATGGCATTCTGACATCC-3 ’
Binds to 3’-end of P. pastoris alcohol 
oxidase 1 promoter.
16dT 5 ’-TTTTTTTTTTTTTTTT-3 ’
Oligo-dT to bind poly(A) tails of mRNA in 
RT-PCR.
28
2.2 Solutions and Media
2.2.1 Solutions
5 OX TAE:
242 g tris
57.1 ml acetic acid 
100 ml 0.5 M EDTA
Solution adjusted to pH 8.0 with HC1 and brought to 1 L with CIH2O. Stored at room 
temperature.
TE:
10 mM tris/HCl, pH 8.0
1 mMEDTA
IPX Phosphate buffered saline (PBS):
400 g NaCl 
lOgKCl 
58 g Na2HP04 
10 g KH2PO4
Solution adjusted to pH 7.3 with MCI or NaOH and brought to 1 L with dl ^ O. Stored 
at room temperature.
Lysis buffer:
50 mM glucose 
10 mMEDTA 
25 mM tris
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5 M potassium acetate solution, pH 4.8:
60 ml 5 M potassium acetate
11.5 ml glacial acetic acid
28.5 ml d ll20
TFB1:
30 mM potassium acetate 
10 mM CaCl2 
50 mM MnCl2 
100 mM RbCl 
15% glycerol
Solution adjusted to pH 5.8 with 1M acetic acid and filter sterilised with a 0.2 j.im filter. 
Stored at room temperature.
TFB2:
10 mM PIPES, pH 6.5 
75 mM CaCl2 
10 mM RbCl 
15% glycerol
Solution adjusted to pH 6.5 with 1 M KOII and filter sterilised with a 0.2 (am filter. 
Stored at room temperature.
SE:
1 M sorbitol
25 mM EDTA, pH 8.0
Provided in Multi-Copy Pichia Expression Kit (Invitrogen)
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SEP:
19 ml of SE
1 ml of 1 M DTT
SCE:
1 M sorbitol
10 mM sodium citrate buffer, pH 5.8
1 mM EDTA
Provided in Mulli-Copy Pichici Expression Kit (Invitrogen) 
CaS:
1 M sorbitol
10 mM tris/HCl, pH 7.5
10 mM CaCl2
Provided in Multi-Copy Pichia Expression Kit (Invitrogen) 
40% PEG:
40% PEG 3350 (reagent grade) in water
Provided in Multi-Copy Pichia Expression Kit (Invitrogen)
CaT:
20 mM tris/HCl, pH 7.5 
20 mM CaCl2
Provided in Multi-Copy Pichia Expression Kit (Invitrogen)
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PEG/CaT:
Mix 40% PEG with CaT in a 1 ;1 ratio 
Solution I:
Sorbitol solution containing ethylene glycol and DMSO for the preparation of
competent P. pastoris cells
Provided in Pichia EasyComp Kit (Invitrogen)
Solution 11:
PEG solution for the transformation of competent P. pastoris cells 
Provided in Pichia EasyComp Kit (Invitrogen)
Solution III:
Salt solution for washing and plating transformed P. pastoris cells 
Provided in Pichia EasyComp Kit (Invitrogen)
Denaturing solution:
0.5 M NaOH
1.5 MNaCl
Stored at room temperature.
Neutralising solution:
1.5 MNaCl
0.5 M tris/HCl, pH 7.4 
Stored at room temperature.
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20X SSC (500 mP:
87.65 g NaCl
50.25 g trisodium citrate
500 ml dll20
Stored at room temperature.
I OX electrophoresis buffer:
250 mM tris 
1.92 M glycine 
1% SDS
Solution adjusted to pH 8.3 with HC1. Stored at room temperature.
5X reducing loading buffer:
0.625 M tris/HCl, pH 6.8 
50% glycerol 
10% SDS
0.1% bromophenol blue 
5% 2-mercaptoethanol
4X non-reducing loading buffer with SDS:
0.5 M tris/HCl, pH 6.8 
40% glycerol 
0.08% bromophenol blue 
8% SDS
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4X non-reducing loading buffer without SDS:
0.5 M tris/HCl, pH 6.8
40% glycerol
0.08% bromophenol blue
Towbin transfer buffer:
6.06 g tris
28.8 g glycine 
600 ml dH20 
200 ml methanol
Solution brought to 1 L with dH20. pH should be between 8.1 and 8.5. Stored at room 
temperature.
Column buffer:
50 mM sodium phosphate buffer, pH 8.0 
300 mM NaCl 
10 mM imidazole
Solution adjusted to pH 8.0 with HC1. Stored at 4°C.
Wash buffer:
50 mM sodium phosphate buffer, pH 8.0 
300 mM NaCl 
20 mM imidazole
Solution adjusted to pH 8.0 with HC1. Stored at 4°C.
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Elution buffer, pH 7:
50 mM sodium phosphate buffer, pH 7.0 
300 mM NaCl 
250 mM imidazole
Solution adjusted to pH 7.0 with HC1. Stored at 4°C.
Elution buffer. pH 6:
50 mM sodium phosphate buffer, pH 6.0 
300 mM NaCl 
250 mM imidazole
Solution adjusted to pH 6.0 with HC1. Stored at 4°C. 
Breaking buffer:
50 mM sodium phosphate, pH 7.4
1 mM EDTA 
5% glycerol
Stored at room temperature.
AE buffer:
50 mM sodium acetate, pH 5.3
1 mM EDTA
Stored at room temperature.
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2.2.2 Media
Luria broth (LB):
10 gtryptone 
5 g yeast extract 
lOgNaCl
Dissolved in 1 L dH20 and autoclaved for 20 min at 121°C. Stored at 4°C.
LB agar (20 plates):
5 g tryptone
2.5 g yeast extract 
5 g NaCl
7.5 g agar
Dissolved in 500 ml di^O and autoclaved for 20 min at 121°C. Cooled to ~55°C before 
addition of any antibiotics and poured. Stored at 4°C.
IPX YNB:
134 g yeast nitrogen base with ammonium sulphate without amino acids 
OR:
34 g yeast nitrogen base without ammonium sulphate and amino acids 
1PP g ammonium sulphate
Dissolved in 1 L dH20, with heating if necessary. Solution sterile filtered with a P.2 (.im 
filter. Stored at 4°C.
5PPX B:
20 mg D-biotin 
100 ml dH20
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Solution sterile filtered with a 0.2 jam filter. Stored at 4°C.
100X II:
200 g L-histidine 
100 ml dH20
Solution heated to no more than 50°C until dissolved, then sterile filtered with a 0.2 Jim 
filter. Stored at 4°C.
IPX D:
200 g D-glucose
Dissolved in 1 L dII2P and autoclaved for 20 min at 121 °C or sterile filtered with a 0.2 
|j.m filter. Stored at 4°C.
IPX M:
50 ml methanol 
95P ml dl l20
Solution sterile filtered with a P.2 (.un filter. Stored at 4°C.
IPX GY:
1PP ml glycerol 
9PP ml dH20
Solution autoclaved for 2P min at 121°C or sterile filtered with a P.2 jam filter. Stored 
at 4°C.
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1QQXAA:
500 mg L-glutamic acid 
500 mg L-methionine 
500 mg L-lysine 
500 mg L-leucine 
500 mg L-isoleucine 
100 ml dH20
Solution sterile filtered with a 0.2 |am filter. Stored at 4°C.
Yeast cxtract peptone dextrose medium (YPD):
10 g yeast extract 
20 g peptone
Dissolved in 900 ml dH20 , autoclaved for 20 min at 121°C and cooled. The following 
was then added:
100 ml 10X D
YPD agar (20 plates):
5 g yeast extract 
10 g peptone 
10gagar
Dissolved in 450 ml dl l20 , autoclaved for 20 min at 121°C and cooled to ~55°C. The 
following was then added:
50 ml 10XD
Any antibiotics required were added and the plates poured.
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SOS medium:
1 M sorbitol 
0.3X YPD
10 mM CaCl2
Provided in Multi-Copy Pichia Expression Kit (Invitrogen)
Regeneration dextrose (RD) top agar:
186 g sorbitol 
10 g agar
Dissolved in 700 ml dl^O  and autoclaved for 20 min at 121°C. Placed in a water bath 
at 60°C
The following mixture was prepared and prewarmed to 45°C before addition to the 
main mix.
100 ml 10X D 
100 ml 10X YNB
2 ml 500X B
10 ml 100XAA 
88 ml sdll20
RDB agar (20 plates):
93 g sorbitol 
10 g agar
Dissolved in 350 ml dl^O  and autoclaved for 20 min at 121°C. Placcd in a water bath 
at 60°C
The following mixture was prepared and prewarmed to 45°C before addition to the 
main mix.
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50 ml 10X D 
50 ml 10X YNB
1 ml 500X B 
5 ml 100X AA 
44 ml sdH20  
Plates poured.
RDI IB aaar (20 plates):
93 g sorbitol 
10gagar
Dissolved in 690 ml d ll20  and autoclaved for 20 min at 121°C. Placed in a water bath 
at 60°C
The following mixture was prepared and prewarmed to 45°C before addition to the 
main mix.
50 ml 10XD 
50 ml 10X YNB
1 ml 500X B 
5 ml 100X AA 
5 ml 100XH 
44 ml sdH20  
Plates poured.
Minimal dextrose (MD) agar (20 plates):
7.5 g agar
Dissolved in 400 ml d ll20 , autoclaved for 20 min at 121 °C and cooled to 60°C. The 
following was then added:
40
50 ml 10X YNB
1 ml 500X B 
50 ml 10XD 
Plates poured.
Minimal methanol (MM) agar (20 plates'):
7.5 g agar
Dissolved in 400 ml dl bO, autoclaved for 20 min at 121°C and cooled to 60°C. The 
following was then added:
50 ml 10X YNB
1 ml 500X B 
50 ml 10XM 
Plates poured.
YNB/2% methanol agar (20 plates):
7.5 g agar
Dissolved in 250 ml dP^O, autoclaved for 20 min at 121°C and coolcd to 60°C. The 
following was then added:
50 ml 10X YNB 
200 ml 10XM 
Plates poured.
Buffered glycerol-complex medium (BMGY):
10 g yeast extract
20 g peptone
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Dissolved in 700 ml dl-^O, autoclaved for 20 min at 121°C and cooled. The following 
was then added:
100 ml 1 M potassium phosphate buffer, pH 6.0 
100 ml 10X YNB
2 ml 500X B 
100 ml 10XGY
Buffered methanol-complex medium (BMMY):
10 g yeast extract 
20 g peptone
Dissolved in 700 ml dl ^O, autoclaved for 20 min at 121°C and cooled. The following 
was then added:
100 ml 1 M potassium phosphate buffer, pH 6.0 (or other required pi 1)
100 ml 10X YNB
2 ml 500X B 
100 ml 10XM
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2.3 Methods
2.3.1 In-vitro cultivation of parasites and preparation of excretory-secretory (ES) 
products
Adult F. hepatica were obtained from infected cattle at a local abattoir and 
cultures in vitro in RPMI 1640 containing 30 mM HEPES, 1 % glucose and 25 mg/ml 
gentamycin as described by Dalton and Heffeman (1989). The medium was collected 
after 6 h, cleared by centrifugation at 14,000 x g  for 30 min at 4°C and stored at -20°C. 
This preparation was termed excretory-secretory (ES) products.
2.3.2 Preparation of anti-propeptide and anti-mature cathepsin L antisera
Native mature cathepsin LI (nFheCLl) and L2 (nFheCL2) was previously 
purified in the laboratory from excretory-secretory (ES) products of adult F. hepatica by 
gel permeation and ion exchange chromatography and antiserum prepared in rabbits 
(Smith et al., 1993a; Dowd et al., 1994). Recombinant cathepsin LI propeptide was 
also previously generated and purified in the laboratory (Roche et al., 1999). Antiserum 
to this propeptide was prepared by immunizing New Zealand White rabbits five times 
with 20 (j,g of protein formulated in Freund’s Complete and Incomplete Adjuvant.
2.3.3 Immunofluorescence and immunoelectron microscopy
Immunofluorescence and immunoelectron microscopy experiments were 
performed in Prof. Aaron Maule’s laboratory at Queen’s University Belfast, UK, using 
anti-propeptide and anti-mature cathepsin LI antisera from our laboratory (Collins et 
al., 2004). Adult F. hepatica were recovered from infected cattle at a local abattoir, 
washed, and transported to the laboratory in mammal saline (0.9% NaCl) at 37 °C. 
Parasites were rinsed in mammal saline and allowed to regurgitate their gut contents 
before being flat-fixed in 4% paraformaldehyde (PFA) in PBS (pH 7.2) for 4 h. They
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were washed in antibody diluent (ABD: PBS with, 0.1% bovine serum albumin, 0.3% 
Triton X-100, 0.1% sodium azide) for 24 h before being incubated for 48 h at 4 °C in 
antiserum prepared against purified mature cathepsin LI (diluted 1:3000) and 
subsequently washed in ABD (24 h, 4 °C). Swine anti-rabbit tetramethyl rhodamine 
isothiocyanate (TRITC; 1:100; Dako Ltd.) was used to visualize bound primary 
antibody before the worms were washed in ABD (24 h, 4 °C) and mounted on glass 
microscope slides in PBS/glycerol (1:9) containing 2.5% 2,4-diazabicylco 2.2.2 octane. 
Specimens were viewed using a Leica TCS-NT confocal scanning laser microscope.
For electron microscopy worms were washed in mammal saline and fixed for 1 h in 2% 
double-distilled glutaraldehyde (GTA) (Agar Scientific) in 0.1 M sodium cacodylate 
buffer (pH 7.2) containing 3% sucrose at 4 °C. Following thorough washing in buffer, 
specimens were dehydrated through graded ethanol to propylene oxide, infiltrated and 
embedded in Agar 100 resin (Agar Scientific). Ultrathin sections (80-90 nm) were cut 
on a Reichert Ultracut E ultramicrotome, collected on bare 200-mesh nickel grids and 
dried at room temperature. For immunogold labeling sections were etched with 10% 
hydrogen peroxide for 5 min and rinsed thoroughly with 20 mM Tris-HCl buffer (pH 
8.2) containing 0.1 % bovine serum albumin and Tween 20 (1:40 dilution). Grids were 
incubated in normal goat serum (1:20 dilution) for 30 min and then transferred to 
primary antibody diluted to 1:20,000 with 0.1% bovine serum albumin/Tris-HCl buffer 
for 12-18 h. Grids were then washed in bovine serum albumin/Tris-HCl and transferred 
to a 20 [4.1 drop of 10 nm gold-conjugated goat anti-rabbit IgG (Bio Cell International) 
for 2 h at room temperature. Following another buffer wash, grids were lightly fixed 
with 2% double-distilled GTA for 3 min, and finally washed with buffer and rinsed with 
distilled water. Grids were double stained with uranyl acetate (5 min) and lead citrate (3 
min) and examined in a FEI (Philips) CM 100 transmission electron microscope, 
operating at 100 keV. Controls consisted of (i) incubation of whole-mounts/sections
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with secondary antibody in the absence of primary antibody and (ii) incubation with 
preimmune serum followed by the secondary antiserum.
2.3.4 Sequence analysis
The F. hepatica cathepsin LI protein sequence was aligned with several related 
cathepsin sequences using ClustalX 1.81. Protein sequences used included Carica 
papaya, Fasciola hepatica cathepsin LI, F. hepatica cathepsin L2, F. gigantica 
cathepsin LI, Schistosoma mansoni cathepsin L2, Caenorhabditis elegans CPL-1, 
mouse cathepsin L, rat cathepsin L, and human cathepsin L.2 Sequences were numbered 
according to the papain numbering used by Vernet et al. (1995) where the propeptide 
residues are recorded as a negative beginning from the cleavage site between propeptide 
and mature enzyme. Sequences were also compared with ClustalW (http://npsa- 
pbil.ibcp.fr) to determine similarity and identity to FheCLl and FheCL2.
Multiple cathepsin L protein sequences from F. hepatica and the closely related 
organism F. gigantica were aligned using ClustalX 1.81. Phylogenetic trees were 
generated from the alignment by the boot-strapped (1000-trial) neighbour-joining 
method using MEGA (Kumar et al., 2001). Accession numbers for all analysed 
sequences are given in Table 2.2.
Table 2.2: Accession numbers of sequences analysed. For F. hepatica and F. gigantica sequences, the 
alternate name is from Irving gt aj, 2003.______________________________________________________
Name: Species:
GenBank 
Accession no.:
Alternate
names:
Reference:
FheCLl Fasciola hepatica U62288 FhCatLl Roche et al. (1997)
FheCL2 Fasciola hepatica U62289 FhCatL2 Dowd et al. (1997)
FheCL3 Fasciola hepatica AJ279091 FhCatL8 Harmsen et al. (2004)
FheCL4 Fasciola hepatica L33772 FhCatL4 Wijffels et al. (1994)
FheCL5 Fasciola hepatica AF271385 FhCatL5 Smooker et al. (2000)
FheCL6 Fasciola hepatica AB009306 FhCatL6 Yamasaki and Aoki (1993)
FheCL7 Fasciola hepatica Z22765 FhCatL7 Heussler and Dobbelaere (1994)
FheCL8 Fasciola hepatica L33771 FhCatL3 Wijffels et al. (1994)
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FheCL9 Fasciola hepatica AJ279092 FhCatL9 Comelissen et al. (2001)
FheCLlO Fasciola hepatica AJ279093 FhCatLlO Harmsen et al. (2004)
FheCLl 1 Fasciola hepatica AY029229 FhCatLl 1 Camevale et al. (2001)
FheCLl 2 Fasciola hepatica S43991 — Wijffels et al. (1994)
FheCLl 3 Fasciola hepatica AY277628 — Kofta et al. (2000)
FheCLl 4 Fasciola hepatica Z22763 — Heussler and Dobbelaere (1994)
FheCLl 5 Fasciola hepatica Z22764 — Heussler and Dobbelaere (1994)
FheCLl 6 Fasciola hepatica Z22766 — Heussler and Dobbelaere (1994)
FheCLl 7 Fasciola hepatica Z22767 — Heussler and Dobbelaere (1994)
FheCLl 8 Fasciola hepatica Z22769 — Heussler and Dobbelaere (1994)
FheCLl 9 Fasciola hepatica AY519971 — —
FheCL20 Fasciola hepatica AF490984 — —
FheCL21 Fasciola hepatica AY519972 — —
FgiCLl A Fasciola gigantica AF112566 FgCatL-A Grams et al. (2001)
FgiCLIB Fasciola gigantica AF239264 FgCatL-B Grams et ah (2001)
FgiCLIC Fasciola gigantica AF239265 FgCatL-C Grams et al. (2001)
FgiCLID Fasciola gigantica AF239266 FgCatL-D Grams et al. (2001)
FgiCLlE Fasciola gigantica AF239267 FgCatL-E Grams et al. (2001)
FgiCLl F Fasciola gigantica AF239268 FgCatL-F Grams et al- (2001)
FgiCL2 Fasciola gigantica AF510856 FgCatL2 Irving et al. (2003)
FgiCL3 Fasciola gigantica AF419329 — —
FgiCL4 Fasciola gigantica ABO 10923 — Yamasaki et al. (2002)
FgiCL5 Fasciola gigantica ABO 10924 — Yamasaki et al. (2002)
SmaCL2 Schistosoma mansoni Z32529 SmCL2 Michel et al- (1995)
CelCPLl Caenorhabditis elegans N P507199 CPL-1 Hashmi et al. (2002)
MmuCL Mus musculus P06797 — Joseph et al. (1988)
RnoCL Rattus norvegicus KHRTL — Ishidoh et al. (1987)
HsaCL Homo sapiens M20496 — Joseph et al. (1988)
CpaPap Carica papaya P00784 Papain Cohen et al. (1986)
2.3.5 Polymerase chain reaction (PCR)
PCR was used for the amplification of DNA sequences using specific
oligonucleotide primers. Cloning and mutation of gene sequences, addition of
restriction sites and His6-tags and analysis of transformants were performed by PCR. In
general, 25 or 50 (j.1 reaction mixes were prepared in either 200 jal thin-walled PCR
tubes or 500 \x\ tubes, depending on the model of thermal cycler used. Two different
Taq polymerase enzyme preparations were used: (a) for Sigma REDTaq, reaction mixes
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were prepared with final concentrations of IX PCR buffer, 1.5 mM MgC^, 0.2 mM 
dNTP mix, 0.8 |uM of each primer, 0.02-0.05 U/pl of REDTaq DNA polymerase; (b) 
for the high fidelity polymerase KlenTaq LA, reaction mixes were prepared with final 
concentrations of IX KlenTaq PCR buffer, 0.2 mM dNTP mix, 0.8 pM of each primer, 
0.1 U/|_tl of KlenTaq LA DNA polymerase. DNA template quantities varied depending 
on the nature of the reaction. All reactions were brought to a total or 25 or 50 pi with 
nfLkO. The standard PCR programme used was a hot start of 95°C for 5 min, followed 
by 35 cycles of 95°C for 1 min, 55°C for 1 min and 72°C for 1 min and finished with a 
further 7 min at 72°C.
Details of any variations on the general method are given below where 
appropriate.
2.3.6 Agarose gel electrophoesis
Separation and visualisation of DNA and RNA was carried out by agarose gel 
electrophoresis (Sambrook et al., 1989). For solution and media compositions, see 
section 2.2. Gels between 50 and 120 ml were prepared, depending on number and 
volume of samples. This was done by adding 1% agarose to the correct volume of IX 
TAE and heating in a microwave on low power, mixing occasionally, until the agarose 
was fully dissolved. The agarose solution was allowed to cool until hand hot. For 
every 20 ml of agarose solution prepared, 1 pi of 10 mg/ml ethidium bromide was 
added and mixed in well. The solution was poured into an appropriately sized gel rig 
and combs added to form wells. The solution was allowed to set at room temperature 
for standard gels and at 4°C for low melting point agarose gels. Once set, gels were 
transferred to a gel tank the tank filled with IX TAE until the gel was covered. 100 bp 
and 1 kb ladders were prepared by mixing 5 pi of DNA with 5 pi of IX TAE and 2 pi 
of 6X blue/orange loading dye. Samples were similarly prepared. Wells were loaded
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and electrophoresis performed at 120 to 150 V for standard gels, 100 V for low melting 
point agarose gels, for 30-60 min. Gels were recorded under a UV lamp and camera 
system.
2.3.7 Preparation of competent E. coli cells
The rubidium chloride protocol used was taken from the Promega Protocols and 
Application Guide (3rd edition) and is adapted from Hanahan (1985). See section 2.2 
for solution and media compositions. LB medium (2.5 ml) was inoculated with a single 
colony of E. coli Top 10F’ cells from an LB agar plate and grown overnight at 37°C 
with shaking at 225 rpm. The entire overnight culture was then used to inoculate 250 
ml of LB medium containing 20 mM MgS04. This culture was then grown in a 1L 
flask until the ODgoo reached between 0.4 and 0.6. The cells were pelletted by 
centrifugation at 4,500 x g  for 5 min at 4°C. For this step, the culture was split into two 
250 ml centrifuge bottles and centrifuged in a Sorvall GSA rotor.
The cell pellet was gently resuspended in 100 ml of ice-cold TFB1, 50 ml per 
centrifuge bottle. The resuspended cells were combined and incubated on ice for 5 min 
at 4°C. The cells were again pelletted by centrifugation in a Sorvall GSA rotor at 4,500 
x g  for 5 min at 4°C. The pellet was gently resuspended on ice in 10 ml ice-cold TFB2 
and then incubated on ice for 60 min. Finally, 200 |j.l aliquots were placed in 1.5 ml 
tubes and stored at -80°C until needed.
2.3.8 Transformation of competent E. coli cells
See section 2.2 for media compositions. Competent E. coli Top 10F’ cells were 
thawed slowly on ice and divided into 100 (j.1 aliquots in 1.5 ml tubes. DNA was added 
to a maximum of 20 (jl or 0.5 fig, and mixed. Positive controls were prepared with 
either pGEM-T Easy or pPIC9K plasmid DNA as appropriate. Competent cells alone
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were used as negative controls. Tubes were incubated on ice for 30 min, then heat 
shocked in a heating block at 42°C for 2 min. Cells were then cooled on ice for 1 min. 
Cells were added to 1 ml LB medium without antibiotics in a 20 ml tube and grown for
1 h at 37°C with shaking at 225 rpm. 100 (j.1 of cells were plated in duplicate on LB 
agar plates containing 100 jag/ml ampicillin and incubated overnight at 37°C.
2.3.9 Small scale isolation of plasmid DNA from E. coli cultures by alkaline lysis
Plasmid DNA isolation was carried out using the alkaline lysis method 
(Sambrook et al., 1989). See section 2.2 for solution and media compositions. Between
2 and 5 ml LB medium containing 100 |J.g/ml ampicillin in a 50 ml conical tube was 
inoculated with one colony from an agar plate and grown overnight at 37°C with 
shaking at 225 rpm. The culture was transferred in 1 ml aliquots into 1.5 ml tubes and 
centrifuged in a benchtop microcentrifuge at 12,000 x g  for 1 min. The supernatant was 
decanted and the cell pellet resuspended with 100 (j,l of lysis buffer, with vigorous 
vortexing. Tubes were left at room temperature for 5 to 10 min and then 200 (il of 
freshly prepared 0.2 N NaOH/1% SDS was added at room temperature. Following an 
incubation on ice for 10 min, 200 (il of 5 M potassium acetate, pH 4.8, was added and 
the tubes gently inverted to mix. Tubes were incubated on ice for 10 min, followed by 
centrifugation at 12,000 x g  for 5 min. The supernatant was transferred to a new 1.5 ml 
tube and the pellet discarded.
Phenol-chloroform extraction was performed by adding 400 |al 
phenol:chloroform (1:1) and vortexing the tube for 1 min. Tubes were then centrifuged 
at 12,000 x g  for 5 min. The upper aqueous layer was transferred to a new 1.5 ml tube 
and 200 (al of chloroform added. Tubes were vortexed for 30 s and centrifuged at
12,000 x g  for 2 min. The upper aqueous layer was transferred to a new 1.5 ml tube.
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The purified DNA was concentrated by ethanol precipitation, resuspended in 40 (4l of 
niT^O and stored at -20°C until required.
2.3.10 Concentration of DNA solutions by ethanol precipitation
At least 2.5 volumes of ice-cold 95% ethanol was added to each tube containing 
DNA to be concentrated and the tubes frozen at -20°C for at least 1 h. Tubes were 
centrifuged at 12,000 x g  for 10 min. The supernatant was discarded and the pellets 
washed with 100 (4,1 of 70% ethanol. Tubes were centrifuged at 12,000 x g for 5 min 
and the supernatants again discarded. The pellets were allowed to air dry before being 
resuspended with the required volume of niT^O (usually 5 to 50 (4.1).
2.3.11 Determination of DNA and RNA concentrations
A spectrophotometric method was used to determine the concentrations of DNA 
and RNA preparations (Sambrook et al., 1989). A 50 (4g/ml solution of dsDNA has an 
OD260 = 1, to within a small degree of error. As the ratio of absorbance to DNA 
concentration is linear up to an OD260 = 2, the concentration of any sample may be 
calculated directly from the absorbance. A similar principal may be applied to RNA, 
where a 40 (4g/ml solution has an OD260 = 1 •
A diluted sample of DNA or RNA was prepared in nfH20  or DEPC-treated 
water. The OD260 of the diluted sample was determined and the concentration 
calculated based on the following equations:
fig / ml DNA = - ^ x (OD260 measured)x {dilution factor)
fj,g!ml RNA = x (OD260 measured)*, (dilution factor)
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Purity of the sample was also determined by reading the OD280 and calculating the ratio 
of OD26o:OD28o (values of between 1.7 and 2.0 are expected for pure nucleic acid).
2.3.12 Preparation of E. coli and P. pastoris glycerol stocks
See section 2.2 for media compositions. For all E. coli Top 10F’ stocks, 10 ml 
LB medium containing 100 (ig/ml ampicillin in a 50 ml conical tube was inoculated 
with a single colony from an LB agar plate, also containing 100 (ag/ml ampicillin. This 
culture was grown overnight at 37°C with shaking at 225 rpm. 200 jal of sterile filtered 
glycerol was added to 800 (4,1 aliquots of culture in 1.5 ml tubes. Tubes were then 
vortexed briefly and stored at -80°C until required.
For all P. pastoris stocks, 20ml YPD medium in a 100 ml baffled flask was 
inoculated with a single colony from a YPD agar plate. This culture was grown for 48 h 
at 30°C with shaking at 250 rpm. 200 fal of sterile filtered glycerol was added to 800 |_il 
aliquots of culture in 1.5 ml tubes. Tubes were then vortexed briefly and stored at - 
80°C until required.
2.3.13 Construction of expression vector encoding cDNA for wildtype 
procathepsin LI (FheproCLl)
The full length F. hepatica preprocathepsin LI cDNA was previously cloned 
into the S. cerevisiae expression vector pAAH5 in our laboratory (Roche et al., 1997). 
The procathepsin LI encoding cDNA was amplified from the pAAH5.FheCLl vector 
by PCR with Sigma REDTaq. Primers were used to incorporate a SnaBI restriction site 
at the 5’-end of the gene and an Avrll restriction site and His6-tag sequence at the 3’- 
end. These primers were labelled FheCLIF and FheCLlR for the forward and reverse 
primers respectively (see Table 2.1). The PCR reaction mix was prepared in 0.5 ml 
tubes, with 5 reaction tubes prepared. A reaction using primers specific for the pAAH5
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plasmid was used as a positive control, and one replacing the plasmid with nfFLO was 
used as a negative control. The PCR was run at 95°C for 5 min, followed by 40 cycles 
at 95°C for 1.5 min, 50°C for 1.5 min and 72°C for 1.5 min and finished with a further 7 
min at 72°C.
The PCR products were separated on a 1% low melting point agarose gel and 
bands of approximately 980 kb were cut out and purified using the Promega Wizard 
PCR Preps DNA purification system. Both pPIC9K vector DNA and the FheproCLl 
PCR product were double digested with the SnaBI and Avrll restriction enzymes using 
appropriate buffering conditions as per the manufacturers instructions. Restriction 
digestion was carried out in 0.5 ml tubes in a water bath at 37°C for 3 h. The mixes 
were then cleaned with a Promega Wizard DNA clean-up kit, with final elution in 40 (j.1 
nfH20 . The DNA concentration of both the vector and insert digest preparations was 
determined.
The vector and insert were ligated in two reaction with T4 DNA ligase. The first 
of these contained a molar ratio of vector:insert of 1:3, while the second was at 1:1. A 
re-ligation control mix containing double digested vector but no insert was also 
prepared. The ligation reactions were incubated overnight at 4°C. The ligation 
reactions were then transformed into competent E. coli Top 10F’ cells and grown on LB 
agar plates containing 100 |ig/ml ampicillin overnight at 37°C. Several transformant 
colonies were selected from each ligation and replica plated on LB agar plates 
containing 100 |J.g/ml ampicillin and grown at 37°C overnight. Each selected colony 
was also inoculated into 2ml LB medium containing 100 fag/ml ampicillin and grown 
overnight at 37°C with shaking at 225 rpm. Plasmid DNA was purified from these 
cultures by the alkaline lysis method.
The selected transformants were screened for correct insertion of the FheproCLl 
sequence by several methods: (a) purified plasmid DNA, along with control samples of
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pPIC9K vector, was single digested with PstI restriction enzyme, using appropriate 
buffering conditions as per the manufacturer’s instructions; restriction digestion was 
carried out in 0.5 ml tubes in a water bath at 37°C for 1.5 h; these samples were then 
separated on a 1% agarose gel along with a sample of the FheproCLl PCR product to 
allow comparison; (b) PCR reactions with the pPIC9K a-factor forward and 3’AOXl 
reverse primers (see Table 2.1) using Sigma REDTaq were performed; reaction mixes 
were again separated on 1% agarose gels to confirm appropriately sized products; (c) 
samples of purified plasmids which indicated correct insertion of the FheproCLl DNA 
were sent for sequencing by Oswel DNA Sequencing, University of Southampton, UK, 
to confirm the insert was in the correct orientation and open reading frame and had no 
significant errors. Glycerol stocks of each transformant corresponding to plasmid DNA 
sent for sequencing were prepared. One plasmid was selected for transformation into P. 
past or is.
2.3.14 Transformation of P. pastoris GS115 with pPIC9K.FheproCLl construct
Transformation of P. pastoris with the pPIC9K. FheproCLl expression vector 
construct was performed by the spheroplasting method (Higgins and Cregg, 1998). The 
transformation method was based on that provided in the Multi-Copy Pichia Expression 
Kit manual, Version F (Invitrogen). See section 2.2 for solution and media 
compositions.
pPIC9K.FheproCLl and pPIC9K control DNA samples were linearised by 
restriction digested with Sail using appropriate buffering conditions as per the 
manufacturer’s instructions, with tubes incubated at 37°C in a water bath for 2.5 h. 
Linearised DNA was cleaned using the Promega Wizard DNA clean up kit and the 
concentration determined. Yeast was prepared for spheroplasting by two growth steps. 
Firstly, a starter culture of 10 ml YPD in a 100 ml baffled flask was inoculated with a
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single colony of P. pastoris GS115 from a YPD agar plate and grown overnight at 30°C 
with shaking at 250 rpm. Three 500 ml baffled flasks containing 200 ml of YPD were 
inoculated with 5,10 and 20 \i\ respectively of cells from the starter culture. Secondly, 
these cultures were grown overnight as before and the culture with an OD600 of between 
0.2 and 0.3 the following morning was harvested by centrifugation at 1,500 x g for 10 
min at room temperature. The supernatant was decanted and discarded.
The cells were washed by gentle resuspension with 20 ml of sdHiO, transfer to a 
new sterile 50 ml conical tube and centrifugation at 1,500 x g for 5 min at room 
temperature. The supernatant was discarded and the cells washed again, replacing the 
sdH20  with 20 ml fresh SED. A third wash was performed with 20 ml of 1 M sorbitol 
and the cells gently resuspended by swirling with 20 ml of SCE buffer. The suspension 
was split between two sterile 50 ml conical tubes. One tube was used to determine 
optimal incubation time with zymolase. For this, a spectrophotometer was blanked at 
ODgoo with 800 fal 5% SDS and 200 (al SCE. 200 fil of cells were added to a tube 
containing 800 ml 5% SDS as a zero time point. 7.5 j.il of zymolase slurry was added to 
the remaining cells. The cells were incubated at 30°C and 200 |_U samples taken at time 
points up to 50 min. These samples were also added to tubes containing 800 (j,l 5% 
SDS. The ODgoo was read for all tubes and % spheroplasting was determined for each 
time point using the equation:
% spheroplasting = 100-
r ODm  at time t  ^
ODm  at time 0
x 100
The time point which gave approximately 70% spheroplasting was chosen as optimal.
7.5 jal of zymolase slurry was added to the second tube of cells, which were incubated at 
30°C for the optimal time as determined. Spheroplasts were harvested by centrifugation
at 750 x g for 10 min at room temperature and the supernatant discarded. Spheroplasts 
were washed very gently with 10 ml 1 M sorbitol and collected by centrifugation at 750 
x g  for 10 min at room temperature. The wash was repeated with 10 ml of CaS solution 
and the spheroplasts gently resuspended with 0.6 ml of CaS solution. Spheroplasts were 
transferred in 100 |jl aliquots in 20 ml tubes and used for transformation immediately.
Linearised pPIC9K.FheproCLl and pPIC9K control plasmids were added to 
separate spheroplast tubes and incubated at room temperature for 10 min. Then, 1 ml of 
PEG/CaT solution was added to each tube and mixed gently. Tubes were incubated for 
a further 10 min at room temperature. The suspension was centrifuged at 750 x g  for 10 
min at room temperature and the supernatant carefully removed. The transformed cells 
were resuspended in 150 fil of SOS medium and incubated at room temperature for 20 
min. Finally, 850 (j.1 of 1 M sorbitol was added to each tube.
Transformed spheroplasts were plated by mixing 100 |_il aliquots of the 
spheroplast suspension with 10 ml of molten RD top agar which was poured onto RDB 
agar plates. Once the top agarose was hardened, plates were inverted and grown at 
30°C for 7 days before further screening was carried out. For cell viability controls, 100 
jal of untransformed spheroplasts was mixed with 900 jal of 1 M sorbitol. 100 jal 
aliquots were plated in RD top agar on RDB and RDHB agar plates and grown as 
before.
2.3.15 Screening of P. pastoris GS115 pPIC9K.FheproCLl transformants
After initial screening on histidine-deficient (RDB) agar plates, transformants 
were screened for multiple inserts and for Mut phenotype based on the protocols 
provided in the Multi-Copy Pichia Expression Kit manual, Ver. F (Invitrogen). See 
section 2.2 for media compositions.
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For each RDB agar plate of transformants, the layer of top agar containing the 
transformants was removed with a sterile spreader and transferred to a sterile 50 ml 
conical tube containing 15 ml sdFkO. This tube was vortexed for 2 min and the agar 
allowed to settle. The cell density of the supernatant was determined by the use of a 
haemocytometer and the supernatant diluted to a cell density of 5 x 105 cells/ml with 
sdHhO. Spread plates were prepared with 200 (j,l aliquots of cells on four YPD agar 
plates containing 0.25 mg/ml of geneticin and four containing 0.5 mg/ml of geneticin. 
Plates were inverted and grown at 30°C for 7 days.
Individual colonies from the YPD agar plates containing 0.5 mg/ml of geneticin 
were selected as they were likely to have greater numbers of inserts present. These 
colonies were replica plated onto pairs of MM and MD agar plates, along with colonies
o
of P. pastoris GS115 HSA as a control for the Mut phenotype and P. pastoris GS115 
(3-Gal as a control for the Mut+ phenotype. The grids printed in the Multi-Copy Pichia 
Expression Kit manual, Ver. F (Invitrogen), page 43 were used as a guide. Plates were 
inverted and grown at 30°C for 4 days. Suitable colonies were then selected for 
induction to confirm expression of recombinant protein.
2.3.16 Construction of expression vector encoding cDNA for inactive mutant 
procathepsin LI ([Gly JFheproCLl) and transformation into P. pastoris GS115
Mutants were generated using the pPIC9K.FheproCLl construct as a template 
by a PCR-based site-directed mutagenesis method known as gene splicing by overlap 
extension (SOEing) (Ho et al., 1989). The mutants were generated in our laboratory by 
Dr. Colin Stack (Collins et al., 2004).
The construction of the inactive FheproCLl mutant involved changing the active 
site cysteine (Cys ) residue to a glycine residue in a two-step PCR process. The 
primers used were FheCLIF, FheCLlR, FheCLlmutF and FheCLlmutR (see Table
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2.1). Each reaction used one flanking primer that hybridized at one end of the target 
sequence (primer FheCLIF or FheCLlR) and one overlapping internal primer that 
hybridizes at the site of the mutation and contains the mismatched base (primer 
FheCLlmutR and FheCLlmutF). In the first round of amplification, two sections of the 
cDNA were amplified using primers FheCLlF+FheCLlmutR and 
FheCLlmutF+FheCLlR. These two PCR products, with an overlap of 21 bp at one end
of each fragment, were then combined in a second PCR to amplify the entire
26  ■ 1 [Gly JFheproCLl cDNA. Primers for this reaction were the two outside primers used
in each of the first round reactions (primers FheCLIF and FheCLlR). All PCRs used
high-fidelity Taq polymerase and run for 25 cycles at 94°C for 30 s, 55°C for 1 min and
72°C for 2 min.
The PCR product was then inserted into the Avrll/SnaB I site of expression 
vector pPIC9K and the plasmid insert was sequenced to verify the presence of the 
correct gene sequence and mutation. Two selected plasmids were linearised by 
digestion with Sail and introduced to P. pastoris cells by spheroplasting (Higgins and 
Cregg, 1998). Transformants were selected for their ability to grow on histidine- 
deficient agar plates and on agar plates containing minimal media and methanol. 
Insertion of the gene into P. pastoris was confirmed by PCR using primers specific to 
the yeast genome (Linder et al., 1996).
During the screening process, another procathepsin L mutant was identified that 
exhibited a slower migration on the SDS-PAGE. The cDNA encoding this proenzyme 
was sequenced and shown to have in addition to the Cys26 to Gly26 mutation a proline 
substituted for a leucine residue at position -12 in the propeptide. This clone was 
termed [Pro’12Gly26]FheproCLl and used for further studies
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2.3.17 Construction of expression vector encoding cDNA for wildtype 
procathepsin L2 (FheproCL2)
The full length F. hepatica preprocathepsin L2 cDNA was previously cloned 
into the S. cerevisiae expression vector pAAH5 in the laboratory (Dowd et al., 1997). 
The procathepsin L2 encoding cDNA was amplified from the pAAH5.FheCL2 vector 
by PCR with Sigma REDTaq. As with the amplification of FheproCLl, primers were 
used to incorporate a SnaBI restriction site at the 5’-end of the gene and an Avrll 
restriction site and His6-tag sequence at the 3’-end. Primers FheCLIF and FheCLlR 
were again used for this purpose. Five identical PCR reactions were prepared as for the 
amplification of FheproCLl from pAAH5.FheCLl. A reaction replacing the pAAH5 
plasmid with pPIC9K.FheproCLl was used as a positive control, and one replacing the 
plasmid with nfH20  was used as a negative control. The standard PCR programme was 
used (see Section 2.3.5).
The PCR products were separated on a 1% low melting point agarose gel and 
bands of approximately 980 kb were cut out and purified using the Promega Wizard 
PCR Preps DNA purification system. Both pPIC9K vector DNA and the FheproCL2 
PCR product were double digested with the SnaBI and Avrll restriction enzymes, 
cleaned and the DNA concentrations determined as described for FheproCLl.
The vector and insert were ligated in two reactions with T4 DNA ligase, with 
molar ratios of vector:insert of 1:3 and 1:2 respectively. A re-ligation control using 
double digested vector but no insert was also prepared. The ligation reactions were 
incubated overnight at 4°C and transformed into competent E, coli Top 10F’ cells. 
Several transformants were selected and grown as for FheproCLl and plasmid DNA 
was purified from these cultures by the alkaline lysis method.
The selected transformants were screened for correct insertion of the FheproCL2 
sequence by both single digestion with PstI and double digestion with SnaBI and Avrll
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as for FheproCLl (see Section 2.3.13). Samples of pPIC9K vector were also digested 
as controls. All samples were separated on a 1% agarose gel and compared with the 
pPIC9K vector banding pattern. Samples of purified plasmids which indicated correct 
insertion of the FheproCL2 DNA were sent for sequencing by Oswel DNA sequencing, 
University of Southampton, UK, to confirm the insert was in the correct orientation and 
open reading frame and had no significant errors. Glycerol stocks of each transformant 
corresponding to plasmid DNA sent for sequencing were prepared. Two plasmids were 
selected for transformation into P. pastoris.
2.3.18 Construction of expression vector encoding cDNA for inactive mutant 
procathepsin L2 ([Gly26]FheproCL2)
The inactive mutant form of FheproCL2, in which the active site cysteine 
(Cys ) residue was replaced with a glycine residue, was synthesised by Geneart GmbH, 
Regensburg, Germany. The synthetic gene (labelled 03-1024) was assembled from 
synthetic oligonucleotides based on the original full length FheCL2 cDNA sequence 
(GenBank accession number U62289) with a single base change corresponding to the 
desired mutation. The fragment was cloned into the pPCR-Script Amp plasmid 
(Stratagene, CA, USA) and amplified by transformation into a bacteria. The purified 
03-102^pPCR-Script plasmid DNA construct was verified by sequencing and 10 jug 
lyophilised for shipping. On receipt, the lyophilised plasmid was resuspended with 100 
|_il of TE, pH 8.0 to give a 100 ng/|_il stock and stored at -20°C.
The inactive procathepsin L2 encoding cDNA was amplified from the 03- 
102^pPCR-Script vector by PCR with KlenTaq LA. As with the amplification of 
FheproCLl, primers were used to incorporate a SnaBI restriction site at the 5’-end of 
the gene and an Avrll restriction site and His6-tag sequence at the 3’-end. Primers
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FheCLIF and FheCLlR were again used for this purpose. The standard PCR 
programme was used (see Section 2.3.5).
The PCR products were separated on a 1% low melting point agarose gel and 
bands of approximately 980 kb were cut out and purified using the QiaQuick Gel 
Extraction Kit. To allow for ligation into the pGEM-T Easy vector, a poly-A overhang 
was added to the PCR products by preparing a PCR reaction with Sigma REDTaq and 
the entire DNA preparation, but not including primers and only incubating at 72°C for 
20 min in place of the normal PCR programme. The mix was then ligated directly into 
the pGEM-T Easy vector with T4 DNA ligase, incubated overnight at 4°C. The ligation 
reaction was then transformed into E. coli Top 10F’ and grown on LB agar plates 
containing 100 |ig/ml of ampicillin, 0.1 mM IPTG and 40 jag/ml of X-Gal. 
Transformants containing the insert were selected by colony pick PCR using the M13F 
and M13R primers (see Table 2.1) and Sigma REDTaq, and replacing the DNA 
template with individual colonies. A transformant including an insert of the correct size 
was selected and inoculated into two 12.5 ml aliquots of LB medium containing 100 
fag/ml of ampicillin in 50 ml conical tubes and grown overnight at 37°C with shaking at 
225 rpm. Plasmid DNA was purified from these cultures using the Qiagen Midi 
Plasmid Prep Kit.
Both pPIC9K vector DNA and the pGEM-T. [Gly26]FheproCL2 construct were 
double digested with the SnaBI and Avrll restriction enzymes, cleaned and the DNA 
concentrations determined as described for FheproCLl (see Section 2.2.13). The vector 
and insert were ligated with T4 DNA ligase, with a molar ratios of vector :insert of 1:3. 
The ligation reactions were incubated overnight at 4°C and transformed into competent
E. coli Top 10F’ cells. Several transformants were selected and screened for insertion 
of the [Gly26]FheproCL2 sequence by colony pick PCR using the 3’AOXl and 5’AOXl 
primers (see Table 2.1). Several transformants which contained inserts of the correct
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size were grown as before and plasmid DNA was purified using the Qiagen Midi 
Plasmid Prep Kit. Samples of purified plasmids which indicated correct insertion of the 
[Gly26]FheproCL2 DNA were sent for sequencing by Australian Genome Research 
Facility (AGRF) Ltd., Brisbane, Australia, to confirm the insert was in the correct 
orientation and open reading frame and had no significant errors. Glycerol stocks of 
each transformant corresponding to plasmid DNA sent for sequencing were prepared. 
Two plasmids were selected for transformation into P. pastoris.
2.3.19 Transformation of P. pastoris GS115 with pPIC9K.FheproCL2 and 
pPIC9K. [Gly26]FheproCL2 constructs
P. pastoris GS115 competent cells were prepared and transformed using the 
Pichia EasyComp Kit (Invitrogen). Methods used were based on the protocols provided 
in the Pichia EasyComp Kit manual, Ver. E (Invitrogen). See section 2.2 for media 
compositions. All provided solutions were equilibrated to room temperature before use.
pPIC9K expression vector constructs as well as pPIC9K and 
pPIC9K.FheproCLl control DNA samples were linearised by restriction digested with 
Sail using appropriate buffering conditions as per the manufacturer’s instructions, with 
tubes incubated at 37°C in a water bath for 2.5 h. Linearised DNA was cleaned using 
the Promega Wizard DNA clean up kit and the concentration determined. The DNA 
was concentrated by ethanol precipitation and resuspended in 5 |_tl of niL^O.
A starter culture was prepared by inoculating 10 ml of YPD medium in a 100 ml 
baffled flask with a single colony of P. pastoris GS115 from a YPD agar plate. The 
culture was grown overnight at 30°C with shaking at 250 rpm. Cells were then diluted 
to an OD600 of between 0.1 and 0.2 with fresh YPD medium and 10 ml transferred 
grown in a 100 ml baffled flask at 30°C with shaking at 250 rpm until an OD600 of 
between 0.6 and 1.0 had been reached. Cells were pelletted by centrifugation at 500 x g
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for 5 min at room temperature and the supernatant discarded. Cells were resuspended 
with 10 ml of Solution I (provided) and the centrifugation repeated. Cells were 
resuspended in 1 ml of Solution I and sterile 1.5 ml screw-cap tubes prepared with 200 
ml aliquots of the now-competent cells.
Linearised pPIC9K expression vector constructs and pPIC9K control plasmids 
were added to separate 50 (al aliquots of competent P. pastor is GS115 cells and gently 
mixed with 1 ml of Solution II (provided). Tubes were incubated at 30°C in a water 
bath for 1 h, with mixing every 15 min. The cells were heat shocked in a heating block 
at 42°C for 10 min. Cells were pelletted by centrifugation at 3,000 x g  for 5 min at 
room temperature and the supernatant discarded. The pellets were washed by 
resuspension in 1 ml of Solution III (provided) followed by centrifugation at 3,000 x g 
for 5 min at room temperature and the supernatant discarded. The cells were finally 
resuspended in 100 |al of Solution III. Each suspension was then plated onto an RDB 
agar plate using a sterile spreader and grown at 30°C for between 3 and 6 days.
2.3.20 Screening of P. pastoris GS115 pPIC9K.FheproCL2 and 
pPI9K. [Gly26]FheproCL2 transformants
After initial screening on histidine-deficient (RDB) agar plates, transformants 
were screened for expression by the colony blot rapid screening method (Higgins and 
Cregg, 1998). This involves growth and colony lysis on nitrocellulose membrane, 
followed by antibody probing of bound proteins. See section 2.2 for media 
compositions.
Individual colonies from the RDB agar plates were replica plated onto duplicate 
YPD agar plates, along with a colony per plate of P. pastoris GS115 transformed with 
pPIC9K.FheproCLl as an expression control. The grids printed in the Multi-Copy 
Pichia Expression Kit manual, Ver. F (Invitrogen), page 43 were used as a guide.
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These plates were inverted and grown at 30°C for 2 days. Nitrocellulose membrane was 
cut to size for a Petri dish and colonies transferred from one set of YPD agar plates by 
gently laying the membrane onto the plate and rubbing down with a sterile spreader. 
Each membrane was then lifted and placed colony side up on a YNB/2% methanol agar 
plate. Plates were inverted and incubated at 30°C for 2 days. The remaining set of 
duplicate YNB agar plates were stored at 4°C.
Five Petri dishes were prepared containing 3mm filter paper soaked, but not 
saturated, in colony lysis solutions (see below). Each nitrocellulose membrane was the 
transferred colony side up the Petri dishes as follows, ensuring no bubbles were formed: 
(a) 10% SDS for 10 min, (b) Denaturing solution for 5 min, (c) Neutralising solution for 
5 min, repeated with a second fresh dish for 5 min and (d) 2X SSC for 15 min. All 
steps were incubated at room temperature with gentle agitation. The membranes were 
washed twice for 10 min each with 15 ml of PBS/0.5% Tween-20. They were then 
blocked by incubation for 1 h at room temperature in 15 ml of 5% milk in PBS/0.5% 
Tween-20, followed by two washes of 5 min each with 15 ml PBS/0.5% Tween-20.
The membranes were probed with 15 ml of a 1/1000 dilution of mouse monoclonal anti- 
His6 IgG in PBS/0.5% Tween-20 for 1 h at room temperature, followed by two washes 
of 5 min each with 15 ml PBS/0.5% Tween-20. A 1/1000 dilution of goat anti-mouse 
IgG-peroxidase conjugate in 15 ml PBS/0.5% Tween-20 was added and the membranes 
incubated at room temperature for a further 1 h. The membranes were washed three 
times for 5 min each with 15 ml PBS/0.5% Tween-20 and bound antibody visualised 
with 3,3’-diaminobenzidine (DAB) in urea buffer. The membranes were rinsed with 
water and allowed to dry.
The most strongly stained colonies were selected for induction to confirm 
expression of recombinant protein.
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2.3.21 Determination of protein concentration
Determination of protein concentrations was carried out by two similar 
colourimetric methods, both using a clear 96-well micro-titre plate. Standards for both 
assays were prepared in 0.2 mg/ml increments between 0 and 2 mg/ml with bovine 
serum albumin (BSA) in an appropriate buffer. Buffers were chosen to match the 
samples being tested to take into account any variations in the colour reactions due to 
the buffer rather than the protein present.
In the bicinchoninic acid (BCA) protein assay, BSA standards were pipetted in 
10 (0,1 aliquots in duplicate or triplicate into a clear 96-well micro-titre plate. A 1/10 
dilution of each sample was prepared if concentration of protein was expected to be 
higher than 2 mg/ml. 10 (j.1 aliquots of samples in duplicate or triplicate where 
quantities of sample allowed were pipetted onto the plate. BCA working reagent was 
prepared by mixing BCA Reagent A: Reagent B in the ratio 50:1. BCA working 
reagent was then added to both standard and sample wells at 200 (.il/well. Plates were 
incubated at 37°C for 30 min. Absorbances at 562 nm were read in a micro-titre plate 
reader. Duplicate and triplicate values were averaged. Standard curves were generated 
and protein concentrations determined using Microsoft Excel.
For the DC (detergent compatible) assay, BSA standards were pipetted in 5 fil 
aliquots in duplicate or triplicate into a clear 96-well micro-titre plate. A 1/10 dilution 
of each sample was prepared if concentration of protein was expected to be higher than
2 mg/ml. 5 |il aliquots of samples in duplicate or triplicate where quantities of sample 
allowed were pipetted onto the plate. DC Reagent A was added to both standard and 
sample wells at 25 (j,l/well, followed by DC Reagent B at 200 jal/well. Plates were left 
on the bench at room temperature for 15 min. Absorbances at 562 nm were read in a 
micro-titre plate reader. Duplicate and triplicate values were averaged. Standard curves 
were generated and protein concentrations determined using Microsoft Excel.
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2.3.22 Expression of recombinant proteins by methanol induction
c
The basic methanol induction protocol was based on the Mut intracellular or 
secreted protocol provided in the Multi-Copy Pichia Expression Kit manual, Ver. F 
(Invitrogen). See section 2.2 for media compositions.
In the basic protocol, a 1 L baffled flask containing 100 ml of BMGY broth, 
buffered to pH 6.0, was inoculated with a single colony of P. pastoris transformant or 
from a glycerol stock. The culture was grown overnight at 30°C with shaking at 250 
rpm until the OD600 reached between 2 and 6. The cells were harvested by 
centrifugation at 2000 x g for 5 min and the supernatant decanted and discarded. The 
pellet was resuspended with 20 ml of BMMY broth, buffered to pH 6.0, in a 100 ml 
baffled flask to induce expression. The methanol concentration was brought to 1% by 
the addition of 100 p.1 sterile filtered methanol. The induced cultures were grown at 
30°C with shaking at 250 rpm for 6 days. Samples of 1 ml of culture were taken at 
daily intervals, centrifuged at 12,000 x g  and the pellet and supernatant stored separately 
at -80°C. Sterile filtered methanol was added daily to a final concentration of 1%. The 
culture was harvested by centrifugation at 5000 x g  for 10 min and recombinant protein 
purified by Ni-NTA affinity chromatography. Daily samples were analysed by 12% 
SDS-PAGE and fluorogenic substrate assay (see Section 2.3.31)
The basic methanol induction protocol was modified as necessary, with scale-up 
of cultures performed maintaining the proportion of total initial growth culture to total 
induction culture. The initial growth cultures were scaled up to a maximum of 35% of 
flask volume and the induction cultures to a maximum of 20% of flask volume to 
maintain sufficient aeration. Any cultures with greater volumes were split between 
multiple flasks. Environmental conditions and induction times were changed as 
necessary. After pilot expressions, the number of samples taken was reduced, with only 
analysis by 12% SDS-PAGE being performed.
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2.3.23 Effect of environmental conditions on recombinant protein expression
In order to assess the effect on production of various environmental conditions, 
the basic methanol induction protocol was modified accordingly. In each case, a single 
initial growth culture was prepared and split evenly before centrifugation to ensure 
variations in conditions were checked against identical cultures. For variations in 
medium pH, cells were resuspended in BMMY broth, buffered to pH 4.5, 6.0, 7.0 and
8.0 in various experiments. Inhibition was investigated by daily addition of the 
cathepsin L inhibitor Z-Phe-Ala-diazomethylketone (Z-FA-CHN2) to the induction 
culture to a final concentration of 25 (iM. For temperature variations, the initial growth 
culture was grown at 30°C as normal, but the induction cultures were grown at 20°C, 
25°C and 30°C with shaking at 250 rpm. Samples were analysed by 12% SDS-PAGE.
2.3.24 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE was performed based on the method of Laemmli (1970) and carried 
out using either the Atto or Bio-Rad mini-gel systems. See section 2.2 for solution 
compositions. Plates were first arranged in the relevant casting rig for the system being 
used and checked for leaks. Either 12% or in some cases 10% resolving gels were 
prepared based on the recipes given in Table 2.3, with the addition of 10% ammonium 
persulphate and TEMED being left until just before pouring. The resolving gel was 
poured, allowing room for the stacking gel, and topped with isopropanol to ensure a flat 
surface and prevent air from interfering with the polymerisation.
5% stacking gels were prepared based on the recipe in Table 2.3, again leaving 
addition of 10% ammonium persulphate and TEMED until just before pouring. Once 
the resolving gels were fully polymerised, isopropanol was decanted from the gels and 
the stacking gel poured. Appropriate combs were then used to form loading wells and 
the stacking gel allowed to polymerise. The combs were removed from the gels and the
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gels transferred from the casting rig to the electrophoresis chamber. The chamber was 
then filled with IX electrophoresis buffer.
Table 2.3: Components of SDS-PAGE resolving and stacking gels, with volumes suitable for the 
preparation of up to four complete mini-gels._____________ ________________ ______________
10% resolving 12% resolving 5% stacking
40% acrylamide/bisacrylamide 7.5 ml 9 ml 1.25 ml
1M tris/HCl pH 8.8 11.2 ml 11.2 ml —
1M tris/HCl pH 6.8 — — 1.25 ml
dH20 10.8 ml 9.3 ml 7.25 ml
10% SDS 300 pi 300 pi 100 nl
10% ammonium persulphate 150 pi 150 pi 100 pi
TEMED 50 (0.1 50 pi 50 pi
Samples were prepared by mixing 20 |o.l of sample with 5 pi 5X SDS-PAGE 
reducing buffer and boiled for 2 min. Markers were prepared by boiling for 2 min and 
10 pi aliquots were loaded onto the gel. Appropriate volumes of prepared sample, 
usually 15 (j.1, were then loaded onto the gel and electrophoresis performed at between 
100 V and 150 V for 60-90 min. Gels were carefully removed and stained with 0.1% 
Coomassie Brilliant Blue R-250 in 40% methanol/10% acetic acid for at least 2 h, more 
usually overnight. Gels were destained with 40% methanol/10% acetic acid for 1 h, 
followed by slow destaining in water. Stained gels were photographed and digitally 
scanned on a flatbed scanner between two clear acetates to record results.
2.3.25 Native and Semi-native polyacrylamide gel electrophoresis
See section 2.2 for solution compositions. For native PAGE, 10% resolving gels
were prepared as for SDS-PAGE, replacing 10% SDS with dE^O. No stacking gels
were used. The electrophoresis chamber was filled with IX electrophoresis buffer
without SDS. Samples were prepared by mixing 15 pi of sample with 5 pi 4X SDS-
PAGE non-reducing buffer without SDS, with no boiling step. No markers were used,
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as they would not run correctly in a native gel. Appropriate volumes of prepared 
sample, usually 15 fj,l, were then loaded onto the gel and electrophoresis performed at 
between 100 and 150 V for 60-90 min. Gels were carefully removed and stained and 
destained as for SDS-PAGE. Stained gels were photographed and scanned on a flatbed 
scanner between two clear acetates to record results.
For semi-native PAGE, all gels were prepared as for standard SDS-PAGE, and 
IX electrophoresis buffer was used as normal. Samples were prepared by mixing 15 jllI 
of sample with 5 .^1 4X SDS-PAGE non-reducing buffer with SDS, with no boiling step. 
No markers were used, as these would not match the semi-native preparation of the 
samples. Appropriate volumes of prepared sample, usually 15 ,^1, were then loaded 
onto the gel and electrophoresis performed at between 100 and 150 V for 60-90 min. 
Gels were carefully removed and stained and destained as for SDS-PAGE. Stained gels 
were photographed and digitally scanned on a flatbed scanner between two clear 
acetates to record results.
2.3.26 Gelatin substrate polyacrylamide gel electrophoresis (GS-PAGE)
GS-PAGE was carried out using either the Atto or Bio-Rad mini-gel systems. 
See section 2.2 for solution compositions. Plates were first arranged in the relevant 
casting rig for the system being used and checked for leaks. Either 10% or in some 
cases 12% resolving gels were prepared based on the recipes given in Table 2.4. The 
3% gelatin was melted in a microwave on low power or water bath at 37°C before 
addition to the mixture, which was then cooled briefly on ice. As for SDS-PAGE gels, 
the addition of 10% APS and TEMED was left until just before pouring. The resolving 
gel was poured, allowing room for the stacking gel, and topped with isopropanol to 
ensure a flat surface and prevent air from interfering with the polymerisation.
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Table 2.4: Components of GS-PAGE resolving and stacking gels, with volumes suitable for the 
preparation of up to four complete mini-gels._____________ ________________ _____________
10% resolving 12% resolving 5% stacking
40% acrylamide/bisacrylamide 7.5 ml 9 ml 1.25 ml
1M tris/HCl pH 8.8 11.2 ml 11.2 ml —
1M tris/HCl pH 6.8 — — 1.25 ml
dH20 9.8 ml 8.3 ml 7.25 ml
3% gelatin 1 ml 1 ml —
10% SDS 300 jlxI 300 |j.l 100 nl
10% APS 150 m-1 150 nl 100 JU.1
TEMED 50 nl 50 yi\ 50 m-1
5% stacking gels were prepared as for SDS-PAGE, based on the recipe in Table
2.4. The combs were removed from the gels and the gels transferred from the casting 
rig to the electrophoresis chamber. The chamber was then filled with IX 
electrophoresis buffer. Samples were prepared by mixing 15 [d of sample with 5 |jl 4X 
SDS-PAGE non-reducing buffer with SDS, with no boiling step. Appropriate volumes 
of prepared sample, usually between 5 and 15 (4,1, were then loaded onto the gel and 
electrophoresis performed at between 100 and 150 V for 60-90 min.
Gels were carefully removed and washed with 0.1M sodium phosphate pH 6.0 
with 2.5% Triton X-100 for 30 min to remove SDS. This wash was repeated twice 
more with fresh buffer. Gels were then rinsed with 0.1M sodium phosphate pH 6.0 to 
remove excess Triton X-100. Gels were incubated overnight at 37°C in 0.1M sodium 
phosphate pH 6.0 and stained and destained as for SDS-PAGE. Stained gels were 
photographed and digitally scanned on a flatbed scanner between two clear acetates to 
record results.
For experiments in which activity at different pH was required, gels were loaded 
with identical samples and cut into strips with one sample per strip after electrophoresis 
had been performed. Each strip was treated individually as above, with the exception
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that 0.1M sodium phosphate pH 6.0 was replaced with either a 0.1M sodium phosphate 
or a 0.1 M sodium acetate buffer at an appropriate pH.
2.3.27 Purification of His6-tagged recombinant proteins by Ni-NTA affinity 
chromatography
All recombinant proteins were purified from yeast media by affinity 
chromatography using Ni-NTA agarose. All procedures were performed at 4°C. See 
section 2.2 for solution compositions. Columns were prepared with between 1 ml and 
15 ml Ni-NTA agarose resin, depending on the volume of the culture and the predicted 
yield. The resin bed was allowed to settle and the ethanol from storage of the resin 
allowed to run through. The column was equilibrated by passing through 10 column 
volumes of column buffer, pH 8.0.
Culture was prepared by centrifugation at 5000 x g  for 10 min in 250 ml 
centrifuge bottles in a Sorvall GSA rotor. This was followed by filtration of the 
supernatant through a 0.45 |J.n filter, using a syringe filter system for smaller volumes 
and a vacuum filtration system for larger volumes. Filtered supernatant was then 
combined with column buffer, pH 8.0 in the ratio 1:4 (supernatant:buffer). This was 
passed over the column and the run-through collected. The column was washed with 15 
column volumes of wash buffer, pH 8.0. Bound protein was eluted using between 1 and 
5 column volumes of elution buffer, pH 7.0, followed by a second elution with elution 
buffer, pH 6.0.
Purified recombinant proteases were dialysed against either PBS, pH 7.3 or 
20mM HEPES, pH 7.5 and stored at -80°C. Samples (250 (il) were taken at each stage 
of the process and analysed by SDS-PAGE to confirm removal of impurities. 
Concentration of the purified recombinant protein was determined by either the BCA or 
DC assay.
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2.3.28 Immunoblotting (Western blots)
Immunoblots were prepared by transferring proteins to nitrocellulose membrane. 
See section 2.2 for solution compositions. Proteins to be probed were first resolved by 
12% SDS-PAGE. The gel was carefully removed and rinsed in Towbin transfer buffer 
for 5-10 min. In many cases, a duplicate gel was prepared and stained for comparison 
with the final blot. Whattman paper was cut into 8 pieces, each slightly larger than the 
gel and soaked in Towbin transfer buffer for 5 min. Nitrocellulose membrane (NCM) 
was cut to size and soaked in Towbin transfer buffer for 5 min. The layers were 
arranged on a semi-dry transfer cell as follows, ensuring no bubbles were formed: 4 
sheets of Whattman paper, NCM, polyacrylamide gel, 4 sheets of Whattman paper. 
Proteins were transferred at 15 Y for 20-30 min.
The NCM was then blocked for between 45 min and 1 h at room temperature 
with 15 ml of either 5% milk or 0.5% BSA in PBS/0.5% Tween-20. Either 1% 
milk/PBS/0.5% Tween-20 or 0.5% BSA/PBS/0.5% Tween-20 was prepared as a wash 
buffer. The NCM was then probed with 15 ml of 1 ° antibody diluted in wash buffer for 
between 45 min and 1 h at room temperature. The NCM was washed three times for 5 
min each, followed by incubation in 15 ml of 2° antibody-peroxidase conjugate diluted 
in wash buffer for between 45 min and 1 h at room temperature. The NCM was again 
washed three times for 5 min each and bound antibody was visualised with DAB in urea 
buffer as described by the manufacturer’s instructions. Blots were rinsed with water 
and allowed to dry. Blots were digitally scanned using a flatbed scanner to record 
results.
2.3.29 Preparation of recombinant protein for A^-terminal sequencing
See section 2.2 for solution compositions. Recombinant proteins were resolved 
by 12% SDS-PAGE. The gel was carefully removed and rinsed in Towbin transfer
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buffer for 10-15 min. Whattman paper was cut into 8 pieces, each slightly larger than 
the gel and soaked in Towbin transfer buffer for 5 min. Polyvinylidene difluoride 
(PVDF) membrane was cut to size and soaked briefly in methanol, followed by Towbin 
transfer buffer for 5 min. The layers were arranged on a semi-dry transfer cell as 
follows, ensuring no bubbles were formed: 4 sheets of Whattman paper, PVDF 
membrane, polyacrylamide gel, 4 sheets of Whattman paper. Proteins were transferred 
at 15 V for 20 min. The membrane was then washed with dP^O and stained with 
0.025% Coomassie Brilliant Blue R-250 in 40% methanol (Higgins and Cregg, 1998). 
Protein bands of interest were subjected to TV-terminal sequencing at Genoshpere 
Biotechnologies, Paris, France.
2.3.30 Comparison of rFheproCLl with F. hepatica ES products
Aliquots of F. hepatica ES products were compared with samples taken from P. 
pastoris medium after induction of rFheproCLl expression for 72 h at pH 8.0. Samples 
were analysed by 12% SDS-PAGE and by immunoblotting. Proteins were transferred 
to NCM and probed with either a 1/800 dilution of rabbit anti-FheCLl serum, a 1/1200 
dilution of rabbit anti-FheCLl propeptide serum, or a 1/1,000 dilution of control 
preimmunised rabbit serum. The secondary antibody used was a 1/10,000 dilution of 
goat anti-rabbit IgG-peroxidase conjugate.
2.3.31 Fluorometric substrate assay for recombinant cathepsin L activity
Cathepsin L activity was determined by fluorometric substrate assay, based on 
that described by Dowd et al. (1994). Samples to be tested were assayed in a total 
volume of 1 ml 0.1 M sodium phosphate buffer, pH 6.0 containing 2.5 mM EDTA, 2 
mM DTT and 10 fxM Z-Phe-Arg-AMC (Z-FR-AMC) in 1.5 ml tubes. The reaction was 
incubated at 37°C for between 10 and 30 min and stopped by the addition of 200 |il of
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10% acetic acid. Fluorescence was recorded at an excitation wavelength of 370 nm and 
an emission wavelength of 440 nm. The activity of the samples were calculated from a 
standard curve of AMC ranging from 0 to 10 |_iM in concentration. AMC standards 
were prepared from a 500|jM stock in 100% DMF by dilution with 0.1M sodium 
phosphate buffer, pH 6.0 containing 2.5 mM EDTA, 2 mM DTT. Standards were 
incubated and 10% acetic acid added as for the samples. Standard curves were 
generated and activity determined using Microsoft Excel. Activity was calculated and 
presented as nmol AMC min' 1 ml'1.
For many experiments, a variation on this assay was performed using opaque 
white or black 96-well microtitre plates. The assay was carried out as for the larger 
scale version, but with a total volume of 200 jj.1 substrate/buffer and addition of 50 (4,1 of 
10% acetic acid to stop the reaction.
2.3.32 In vitro autoactivation of recombinant cathepsin Ls
Processing of rFheproCLl was carried out by incubating 5 (4g of the purified 
recombinant enzyme in 0.1 M sodium citrate buffer, pH 5.0 containing 1 mM DTT and
2 mM EDTA at 37°C. Samples were taken at various time points up to 2 h and the 
proteolytic cleavage of the propeptide visualised by 12% SDS-PAGE. Samples were 
also assayed for enzyme activity with the standard fluorogenic substrate assay described 
above. Cleavage products in both purified recombinant and 2 h activated rFheproCLl 
were subjected to TV-terminal sequencing by Genosphere Biotechnologies, Paris, France.
Processing of rFheproCL2 was carried out in a similar manner, replacing the 
buffer with 0.1 M sodium acetate, pH 4.5. Samples were visualised on 12% SDS- 
PAGE and assayed for activity with the standard fluorogenic substrate assay.
For both enzymes, a control experiment was carried out using either 0.1 M 
sodium acetate buffer, pH 4.5 or PBS, pH 7.3 and taking samples at time points up to 24
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h. For later experiments, 2h and 24 h activated recombinants were prepared by 
incubation at a final concentration of 100 (ig/ml in 0.1 M sodium acetate buffer, pH 4.5 
containing 1 mM DTT and 2 mM EDTA at 37°C for the relevant time.
2.3.33 In vitro processing of inactive mutants by rFheproCLl and rFheproCL2
Exogenous processing of r[Gly26]FheproCLl and r[Pro'12Gly26]FheproCLl by 
wildtype rFheproCLl was carried out by mixing 7.5 ^g of purified mutant enzyme with 
0.5 (ig of 2h activated wildtype enzyme. The mix was incubated in 0.1 M sodium 
acetate buffer, pH 5.0 containing 1 mM DTT and 2 mM EDTA at 37°C and samples 
taken at time points up to 3 h. Samples were analysed by 12% SDS-PAGE and 
cleavage products subjected to N -terminal sequencing by Genosphere Biotechnologies, 
Paris, France.
To confirm that the mutant enzymes were expressed as correctly folded proteins, 
a similar experiment was performed in parallel with mutant enzyme preparations that 
had been unfolded by heating at 95°C for 3 min before addition of wildtype enzyme.
Cross-processing was investigated by incubating all three mutants 
(r[Gly26]FheproCLl, r[Pro‘12Gly26]FheproCLl and r[Gly26]FheproCL2) with wildtype
24 h activated rFheproCLl and rFheproCL2 enzymes in similar conditions. After 
incubation for 3 h at 37°C, samples were visualised by 12% SDS-PAGE.
2.3.34 Inhibition of rFheproCLl activity by recombinant propeptide and Z-Phe- 
Ala-diazomethylketone
Recombinant cathepsin LI propeptide was previously generated and purified in 
the laboratory as described by Roche et al. 1999. A fluorogenic substrate assay was 
carried out in a white 96-well microtitre plate. Purified rFheproCLl was assayed in 
triplicate in the standard buffer with the addition of between 0 and 5 (iM of recombinant
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cathepsin LI propeptide or between 0 and 5 |oM of the cathepsin L inhibitor Z-FA- 
CHN2. Plates were incubated for 30 min at 37°C and reactions stopped by the addition 
of 50 (0,1/we 11 of 10% acetic acid. Fluorescence was recorded at an excitation 
wavelength of 370 nm and an emission wavelength of 440 nm. Average fluorescence 
values were compared directly using Microsoft Excel.
Effect of buffer pH on inhibition of protease activity was investigated by 
preincubating 2 h activated rFheproCLl with 0.1M sodium citrate buffers, pH between
3.0 and 7.0, containing 2.5 mM EDTA, 2 mM DTT in addition to either 0, 1 or 0.1 (oM 
propeptide or 0, 1.5 or 0.15 (iM Z-FA-CHN2 for 30 min at room temperature. These 
samples were then assayed in triplicate in 200 (ol total volume of buffer containing 10 
)j,M Z-FR-AMC. Plates were incubated for 15 min at 37°C and reactions stopped by the 
addition of 50 [ol/well of 10% acetic acid. Fluorescence was recorded at an excitation 
wavelength of 370 nm and an emission wavelength of 440 nm. Percentage inhibition 
values were calculated from the fluorescence values directly using Microsoft Excel.
2.3.35 Activity profiles for recombinant proteins at varying pH values
Fluorogenic substrate assays were performed with buffers at a range of pHs 
replacing the 0.1 M sodium phosphate, pH 6.0 in the standard assay. Assays were 
carried out in a black 96-well microtitre plate. The three sets of buffers used were as 
follows: 0.1 M sodium acetate, pH 3.0, 3.5, 4.0, 4.5, 5.0, 5.5 and 6.0, 0.1 M sodium 
phosphate, pH 5.5, 6.0, 6.5, 7.0, 7.5 and 8.0 and 0.1 M tris/HCl, pH 7.5, 8.0, 8.5, 9.0,
9.5, 10.0 and 10.5. All buffers included 50 mM NaCl to give an even ionic strength. 24 
h activated rFheproCLl or rFheproCL2 was assayed with each buffer in triplicate.
AMC standards were prepared as for the standard assay. Fluorescence was recorded at 
an excitation wavelength of 370 nm and an emission wavelength of 440 nm after 15 min 
of incubation at 37°C. Standard curves were generated and activity determined using
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Microsoft Excel. Activity was calculated and presented as nmol AMC min' 1 ml'1 and 
graphed as activity vs. buffer pH.
Samples of 24 h activated recombinants were also analysed by 10% GS-PAGE, 
with overnight incubations at 37°C in 0.1 M sodium acetate buffers, pH 4.0, 5.0, 6.0,
7.0 and 7.75, containing 50 mM NaCl and 1 mM DTT.
2.3.36 Analysis of mRNA produced by P. pastoris transformants
For each recombinant enzyme and mutant, a 6 day 2.5X scaled up methanol 
induction was performed, with 2 ml samples take at time points 0 and 96 h. Samples 
were centrifuged at 12,000 x g  for 2 min and the supernatants transferred to new 10 ml 
conical tubes. Total RNA was isolated from the cell based on the protocol provided in 
the Multi-Copy Pichia Expression Kit manual, Yer. F (Invitrogen) and Schmitt et al. 
1990. See section 2.2 for solution compositions. All solutions were prepared with 
DEPC-treated water. Cell pellets were resuspended in 400 (al of AE buffer and 
transferred to 1.5 ml tubes. 40 jal of 10% SDS was added and the tubes vortexed for 20 
s, followed by the addition of 600 (J.1 of phenol and a further 20 s of vortexing. The 
tubes were incubated at 65 °C in a water bath for 4 min, followed by incubation in a dry 
ice/ethanol bath for 1 min. The tubes were vortexed at 12,000 x g  for 2 min at 4°C and 
the upper aqueous phase transferred to new 1.5 ml tubes. 600 \il of phenol ¡chloroform 
(1:1) was added and the tubes vortexed for 20 s. After centrifugation at 12,000 x g  for 2 
min at 4°C, the upper phase was transferred to new 1.5 ml tubes and 40 p,l of 3 M 
sodium acetate, pH 5.3, added. 750 (j.1 of 100% ethanol at -20°C was added and the 
tubes centrifuged at 12,000 x g  for 15 min at 4°C. The supernatant was removed and 
the pellets washed with 500 (_il of 80% ethanol, followed by centrifugation at 12,000 x g  
for 10 min at 4°C. The pellets were allowed to air-dry and were resuspended with 40 (al 
each of DEPC-treated water. Concentration of RNA in each sample was determined.
First strand cDNA was synthesised by reverse transcriptase PCR (RT-PCR) on 1 
|og of total RNA from each recombinant. Total RNA was combined with 20 pmol 16dT 
primer (see Table 2.1) in a 200 jul thin walled PCR tube and incubated at 70°C for 5 
min, followed by 4°C for 5 min. To this was added 15 |il of a RT-PCR mix to give final 
concentrations of IX ImProm-II reaction buffer, 6.4 mM MgCb, 0.5 mM dNTP mix, 1 
U/|o.l RNasin and 0.05 U/|il of ImProm-II reverse transcriptase. The PCR programme 
was run at 25°C for 5 min, 42°C for 60 min and 70°C for 15 min. A standard PCR was 
performed on the synthesised cDNA using the primers FheCLIF and FheCLlR (see 
Table 2.1) and Sigma REDTaq. The standard PCR programme was used. Samples 
were analysed on a 1% agarose gel.
2.3.37 Analysis of intracellular expression of recombinant proteins
For each recombinant enzyme and mutant, a 6 day 2.5X scaled up methanol 
induction was performed, with 1 ml samples take at time points 0 and 72 h. Samples 
were centrifuged at 12,000 x g  for 2 min and the supernatants transferred to new 1.5 ml 
tubes. The cells were lysed based on the protocol provided in the Multi-Copy Pichia 
Expression Kit manual, Ver. F (Invitrogen). See section 2.2 for solution compositions. 
The cells were resuspended in 100 jal of breaking buffer and an equal volume of acid- 
washed 0.5 mm diameter glass beads (estimated visually by displacement) was added. 
The mix was vortexed for 30 s, followed by incubation on ice for 30 s. This was 
repeated for a total of 8 cycles. The mix was centrifuged at 12,000 x g  for 10 min at 
4°C and the cell lysate transferred to new 1.5 ml tubes.
Cell lysates were analysed by 12% SDS-PAGE and immunoblotting with a 
1/500 dilution of mouse monoclonal anti-His6 IgG. The secondary antibody used a 
1/1000 dilution of a goat anti-mouse IgG-peroxidase conjugate. Corresponding P. 
pastoris medium samples were analysed in parallel for comparison.
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2.3.38 Substrate comparison
Fluorogenic substrate assays were performed with a range of fluorogenic 
substrates replacing Z-FR-AMC in the standard assay. Assays were carried out in a 
black 96-well microtitre plate. The substrates used were Boc-VLK-AMC, Z-FR-AMC, 
Z-LR-AMC, Z-R-AMC, Z-RR-AMC, Z-PR-AMC, Boc-VPR-AMC, Tos-GPK-AMC, 
Tos-GPR-AMC and Boc-AGPR-AMC. 24 h activated rFheproCLl or rFheproCL2 was 
assayed with each substrate in triplicate. AMC standards were prepared as for the 
standard assay. Fluorescence was recorded at an excitation wavelength of 370 nm and 
an emission wavelength of 440 nm after 10, 20 and 30 min of incubation at 37°C. 
Standard curves were generated and activity determined using Microsoft Excel. A 
graph of relative fluorescence vs. substrate was generated for each enzyme.
2.3.39 Collagen digestion
Collagen Types II (bovine nasal septum) and VI (basement membrane) 
suspensions were prepared in PBS, pH 7.3 to a final concentration of 1 mg/ml. Each 
collagen (15 (j,g) was incubated with 0.5 jag of 24 h activated rFheproCLl or 
rFheproCL2 in PBS, pH 7.3, overnight at 37°C. Negative controls of each collagen in 
PBS alone and positive controls with 0.5 |_tg collagenase blend H were similarly 
prepared. Samples were analysed by 12% SDS-PAGE and on semi-native gels.
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Chapter 3: Sequence analysis and cloning of F. hepatica procathepsins LI and L2
3.1 Sequence analysis of pre-procathepsins LI and L2
The main focus of this thesis is the characterisation and analysis of the major 
Fasciola hepatica cysteine proteases, cathepsins LI and L2. Before cloning of the 
genes encoding these proteins was carried out, the amino acid sequences of pre- 
procathepsins LI and L2 (accession numbers U62288 and U62289 respectively) were 
aligned using ClustalX 1.81 (see Figure 3.1). The sequences were found to have 
78.22% identity and 92.63% similarity to each other (see Table 3.3), indicating a very 
close relationship between the two enzymes and a commonality in function within the 
parasite.
The sequences were also aligned with other F. hepatica and F. gigantica 
sequences. Details of the 21 F. hepatica and 10 F. gigantica sequences used are given 
in Table 2.2. A bootstrap neighbour-joining phylogenetic tree was generated from the 
alignment using MEGA2 (Kumar et al., 2001). This tree indicated that the sequences 
fell into 4 distinct clades; importantly, three of these contained sequences of cDNAs 
isolated from adult parasites, whereas one contained sequences derived from 
metacercarial or newly excysted juvenile stage cDNAs (see Figure 3.2). Therefore, this 
analysis has identified stage-specific cathepsin L proteases. For the purposes of this 
thesis, these groups were labelled as ‘Adult Group 1’, ‘Adult Group 2’, ‘Adult Group 
3’ and ‘Metacercarial Group’. F. hepatica pre-procathepsin LI was located in the Adult 
Group 1, while pre-procathepsin L2 was located in the Adult Group 3.
The position of three of the sequences in the tree (FgiCL5, FheCL14 and 
FheCL17) were not reliable. The FgiCL5 sequence is complete and may be an 
intermediate between Adult Group 1 and Adult Group 2 as it falls between these groups.
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Figure 3.1: Alignment of F. hepatica pre-procathepsins LI and L2 protein sequences. Alignment 
was performed using ClustalX 1.81. The signal sequence is indicated in bold and the propeptide is in 
italics. The cleavage point between the propeptide and the mature region is indicated by an arrow. The 
active site triad, situated in the S, subsite, is marked in black and residues implicated in subsite 
interactions, as per Turk et a}. (1998), are in grey, with subsite designations listed above. FheCLl residues 
which differ from the original U62288 sequence deposited in the public database are underlined.
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Figure 3.2: Bootstrap neighbour-joining phylogenetic tree of Fasciola cathepsin L sequences. The
tree was generated and visualised using MEGA2. Numbers indicate bootstrap support at a given node. 
The major clades are indicated. Three sequences (FgiCL5, FheCL14 and FheCL17) do not fall easily into 
specific groups as they are either missing large sections of data or contain mixed features of different 
groups. The F. hepatica cathepsins LI and L2 are indicated by an asterisk. Accession numbers for all 
sequences are given in Table 2.2.
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Both FheCL14 and FheCL17 are incomplete sequences, with no data available up to 
position 20 of the mature protein sequence or for residues after position 185, and likely 
account for the position ambiguity of these two sequences.
This tree was compared with a similar one generated by Irving et al. (2003), 
which used fewer sequences, and was divided into similar clades. The addition of extra 
sequences to the tree, some of which did not include the full propeptide sequence or 
were otherwise incomplete, reduced the bootstrap support for many of its branches. 
However, the general structure of the groups was the same as that noted by Irving et al. 
(2003).
Analysis of the alignments showed that the region of most variation in the 
enzymes was located adjacent to the junction between the propeptide and the mature 
enzyme (residues -21 to 5; see Figure 3.1). This region is highly conserved within each 
group, with few variations; these are listed in Table 3.1. However, differences were 
found between each group; for instance, the sequence from positions -5 to -1 is Glu- 
Ala-Asn-Asn-Arg for Adult Group 1, Lys-Ala-Asn-Lys-Arg for Adult Group 2, Lys- 
Ala-Asn-Lys-Leu for Adult Group 3, and Glu-Ala-Glu-Gly-Asn for the Metacercarial 
Group. Any variations within each group were mainly limited to differences between F. 
hepatica and F. gigantica (see Table 3.1).
Table 3.1: Features of cathepsin L clades. The propeptide sequence for each group leading up to the 
junction with the mature region is given in full along with the start of the mature region itself. The 
cleavage point is indicated with a downwards arrow. Variations are shown below the main sequence, 
with those found only in F. gigantica indicated in bold italics. Residues which are completely conserved 
across all groups are underlined.______________________________________________________________
Group: Pro/mature junction (-21 to 5):
Adult 1 TEM PRASDILSHGIPYEANNR|AVPDK  
S V T
Adult 2 TEMPRAS ELLSHGIPYKANKR|AVPDR  HR DI  E
Adult 3 IEIPR SSELLSR G IPYK A NK LJ.A VPESF P
Metacercarial M EM SPVSESLSDGISYEAEGN|DVPAS  I E  V K
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A divergence between the three Adult Groups and the Metacercarial Group was 
also located at position 1 of the mature region (see Table 3.1). While all three Adult 
Groups contained an alanine residues at this location, the Metacercarial Group 
sequences were unique in possessing an aspartate residue here. Notwithstanding that 
only three metacercarial sequences are available, this divergence was common to both
F. hepatica and F. gigantica sequences.
We also examined residues within the active site of these enzymes that are
• * • 26  * involved in substrate specificity. While peptide bonds are cleaved by Cys (with the
involvement of His163 and Asn183) which is situated in the Si subsite, enzyme specificity
is determined by residues in the S2 subsite. Experiments published by Dowd et al.
(1997) and Smooker et al. (2000) indicated that three residues were important in the
determination of substrate specificity of cathepsins L. These residues are located at
positions 70, 162 and 164 (Fasciola numbering) of the mature protein and are
particularly involved in determining the preference for residues at the S2 positions of a
substrate. When the F. hepatica and F. gigantica sequences were compared at these
three residues, no variations were found within each group (see Table 3.2). However,
• 70 162this set of three residues did differ between groups, with a pattern of Leu -Asn - 
Ala164 for Adult Group 1, Leu70-Asn162-Gly164 for Adult Group 2, Tyr70-Thr162-Ala164 
for Adult Group 3 and Trp70-Thr162-Ala164 for the Metacercarial Group. It was also 
noted that two of these residues, at positions 70 and 162, were conserved between Adult 
Groups 1 and 2, while the residues at positions 162 and 164 were conserved between 
Adult Group 3 and the Metacercarial Group. These observations suggest that 
differences in the substrate specificity exists between the cathepsin Ls present in each 
group.
No variations in the residues at positions 70, 162 or 164 were found within 
groups between the F. hepatica and F. gigantica sequences. Further analysis showed
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that enzymes within each group also tended to have the same residues within their 
subsites, based on the residues implicated in subsite interactions by Turk et al. (1998; 
see Table 3.2). Variations towards the end of the area of the propeptide which dips into 
the active site cleft (residues -21 to -13) may correspond with changes in the subsites.
Table 3.2: Subsite variations between cathepsin L clades. Variations in amino acid residues are 
indicated for each position of the Si, S2, S3 and Sr pockets. Residues which are totally conserved 
between all groups, such as those of the active site triad, are not included. Variations found in only a 
minority of sequences within a group are given in brackets, with those found only in F. gigantica in bold 
italics.
Group:
Sii S2: S3: Sr :
22 70 157 160 161 162 164 210 64 67 139 140 144 187 188
Adult 1
N
(Q)
L S/L
R/A
(S)
V/L N A L
N
(Y/M)
S
(G/M)
V
(A)
E
M
(T)
L
(S/T)
S
0 0
Adult 2
G/Q
CD)
L S
R
(F)
L N G
L
m
Y
(F/N)
N V
E
(D)
M
(V)
T
(P)
W
Adult 3 Q Y L R L T A L
Y
(H)
G
A
W
D M
T
OS)
w
OS)
Meta. Q W S/T S/R V T A V H
G
OS)
A Q Y K w
These comparisons all confirmed the grouping pattern indicated by the 
phylogenetic tree. FheCLl was found to fall into the Adult 1 group, while FheCL2 fell 
into the Adult 3 group.
The pre-procathepsin LI and L2 amino acid sequences were also aligned with 
several related cathepsin Ls from other species. Details of the sequences used are given 
in Section 2.3.4). Comparison of the sequences based on amino acid identity and 
similarity (see Table 3.3) indicated the closest relationship was to the related parasitic 
trematode, Schistosoma mansoni. The next highest similarity was to the non-parasitic 
worm Caenorhabditis elegans, followed by the mammalian cathepsin Ls of mouse, rat 
and humans, and lastly the plant cysteine protease, papain. This indicates that the F.
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hepatica cathepsins LI and L2 are true eathepsin Ls and represent a monophyletic 
group of enzymes in the parasite.
Table 3.3: Similarity and identity of related eathepsin L sequences to F. hepatica CL1 and CL2.
Amino acid sequences were compared using ClustalW (http://npsa-pbil.ibcp.fr'). Similarity was 
calculated by adding the values for strongly and weakly similar residues to the identity. Accession 
numbers for all sequences are given in Table 22._____________________________________________
Sequence: Species: Length:
Identity to 
FheCLl:
Similarity to 
FheCLl:
Similarity to 
FheCL2:
Identity to 
FheCL2:
FheCLl
Fasciola
hepatica
326 100% 100% 92.63% 78.22%
FheCL2
Fasciola
hepatica
326 78.22% 92.63% 100% 100%
SmaCL2
Schistosoma
mansoni
317 44.65% 76.15% 42.51% 73.09%
CelCPLl
Caenorhabditis
elegans
337 40.47% 73.02% 40.76% 73.61%
MmuCL Mus musculus 334 41.47% 71.18% 41.06% 68.91%
RnoCL
Rattus
norvégiens
334 41.18% 70% 40.76% 68.91%
HsaCL Homo sapiens 333 42.86% 71.14% 39.65% 69.68%
CpaPap Carica papaya 345 32.77% 61.9% 32.77% 60.78%
The nucleotide sequences of the genes encoding F. hepatica pre-procathepsins 
LI and L2 were also compared to investigate if the same primers could be used to 
amplify both sequences. The 3’-ends of both sequences were found to match exactly, 
while the sequence encoding the start of the propeptide had two mismatches between 
FheCLl and FheCL2. However, these differences were silent and did not reflect any 
difference in amino acid sequence, therefore the same primers were used for 
amplification of both cDNAs.
3.2 Construction of pPIC9K.FheproCLl expression vector
Procathepsin LI encoding cDNA was successfully isolated from the 
pAAH5.FheCLl vector (Roche et al., 1997) containing the full pre-procathepsin
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sequence by PCR. With the restriction sites, His6-tag, spacer and restriction enzyme 
clamp sequences added by the PCR primers, the total length of the product was 
expected to be 980 bp. This was confirmed when run on a 1% agarose gel, with the 
band clearly appearing just below the 1 kb band of the DNA ladder (see Figure 3.3, lane 
1). After purification of the PCR product from the gel, it was double digested with 
SnaBI and Avrll and ligated with similarly treated pPIC9K vector. The ligation mix 
was then used to transform E. coli Top 10F’ cells.
Purified plasmid DNA from E. coli transformants was analysed by (a) PCR with 
the a-factor and 3’AOX primers (see Figure 3.3, lanes 2 and 3), as well as by (b) 
restriction digestion with PstI (see Figure 3.3, lanes 4 and 5). For the PCR with the a- 
factor and 3’AOX vector primers, a product of just over 1.1 kb was generated for 
positive colonies but not for negatives or the pPIC9K vector control. From analysis of 
the vector and insert sequences, PstI was expected to cut the vector in four locations but 
not to cut the insert. When separated on an agarose gel, the uppermost of the four bands 
(containing the insert) was retarded in the gel for positive transformants compared to 
pPIC9K control DNA.
Plasmid DNA from two colonies which were found to be positive for the 
FheproCLl insert were sequenced and one transformant selected for transformation into 
P. pastoris. The sequence confirmed that the FheproCLl cDNA was in frame with the 
yeast a-factor secretion signal sequence.
However, when the sequence was analysed, several differences were found 
compared to the original sequence deposited by our laboratory in the public database 
(GenBank sequence, U62288; Roche et al., 1997). While a number of these changes 
were silent with respect to the database sequence, some were reflected in the amino acid 
sequence of the protein: Gly95->Glu95, Tyrm ->Phe112, Gln116->His116, Ile127->Val127,
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Figure 3.3: 1% agarose gel showing construction of pPIC9K.FheproCLl expression vector. Lane 
M, 1 kb DNA ladder; lane 1, FheproCLl PCR product insert before ligation into pPIC9K; lanes 2 and 3, 
pPIC9K and pPIC9K.FheproCLl vectors amplified by PCR with a-factor and 3’AOX primers; lanes 4 
and 5, pPTC9K and pPIC9K.FheproCLl vectors restriction digested with Pstl.
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Ser -> Ala , Ser ->Ala . These changes in the sequence relative to the database 
are underlined in Figure 3.1.
On comparing the new sequence with others from F. hepatica and F. gigantica 
by alignment using ClustalX 1.81, it was found that the changes matched more closely 
with the related enzymes than the original sequence. It was therefore assumed that 
errors had been made in the original sequencing which have now been corrected by the 
better sequencing technologies available.
3.3 Transformation and screening of P. pastoris GS115 with 
pPIC9K.FheproCLl construct
P. pastoris GS115 spheroplasts were prepared and transformed with the 
pPIC9k.FheproCLl expression vector construct restriction-digested with Sail. 
Transformants were initially screened by growth on histidine-deficient plates; therefore 
only those showing the His+ phenotype, and having the construct integrated into their 
chromosomal DNA, showed growth. His+ transformants were grown on YPD plates 
containing varying concentrations of geneticin to isolate those clones with higher copy 
numbers of the construct integrated. Colonies were selected from the plates with the 
highest concentration of geneticin, and therefore the highest copy number, as these 
would potentially give higher levels of recombinant protein expression when induced 
with methanol.
One hundred of these high copy His+ colonies were replica plated onto minimal 
dextrose and minimal methanol plates to determine their Mut phenotype. Colonies 
which grew well on both media were determined to be Mut+, while those which grew 
poorly on minimal methanol medium were determined to be Muts phenotype. Greater
S “I-numbers of Mut phenotype colonies than Mut phenotype colonies were found. This 
was unexpected as linearization of the plasmid with Sail before transformation favours
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integration within the His4 gene producing Mut+ phenotype. It was decided that three 
His+ Muts colonies (labelled A 14, A22 and A3 8) would be selected for further 
expression studies.
3.4 Construction of pPIC9K.FheproCL2 expression vector
As with FheproCLl, the procathepsin L2 encoding cDNA was successfully 
cloned from the pAAH5.FheCL2 vector (Dowd et al., 1997) containing the full pre- 
procathepsin sequence by PCR. When run on an agarose gel, the expected 980 bp band 
was visualised (see Figure 3.4A). The purified, SnaBI/Avrll digested insert was ligated 
into pPIC9K vector and transformed into E. coli Top 10F’.
Purified plasmid DNA from E. coli transformants was screened by restriction 
digestion with the SnaBI/Avrll combination (see Figure 3.4B) and with PstI (see Figure 
3.4C). As with pPIC9K.FheproCLl, for the SnaBI/Avrll combination a 980 bp 
fragment was generated for positive colonies but not for negatives. Similarly, PstI was 
expected to cut the vector in four locations but not to cut the insert, with the uppermost 
of the four bands (containing the insert) running higher in an agarose gel for positive 
transformants compared to pPIC9K control DNA. Following this analysis, plasmid 
DNA from two colonies (labelled A3 and B l) which were found to be positive for an 
insert in both digests (see Figure 3.4) were selected for transformation into P. pastoris 
and sent for sequencing. The sequences were confirmed to match the database sequence 
and to be in frame with the yeast a-factor secretion signal sequence.
3.5 Transformation and screening of P. pastoris GS115 with 
pPIC9K.FheproCL2 construct
The two pPIC9K.FheproCL2 constructs were linearised with Sail and 
transformed into competent P. pastoris GS115 cells. His+ phenotype was confirmed by
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Figure 3.4: 1% agarose gels showing construction of pP!C9K.FheproCL2 expression vector. A,
procathepsin L2 PCRproduct before ligation into pPlC9K. Lane M, 1 kb DNA ladder; lane 7, FheproCL2 
PCR product. B, purified plasmid from selected E. coli transformants restriction digested with SnaBl and 
Avrll. Lane M, 1 kb DNA ladder; lanes 1 and 2, transformants A3 and B 1; lane 3, pPlC9K vector 
control. C, purified plasmid from selected E. coli transformants restriction digested with Pstl. Lane M,
1 kb DNA ladder; lanes 1 and2, transformants A3 and B1; lane 3, pPlC9K vector control.
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growth on histidine deficient medium and fifty colonies from each transformation were 
screened directly for expression by the colony blot rapid screening method. Two 
colonies (labelled A3.1 and B1.28) which were found to be strongly labelled with anti- 
His6 antibody and therefore showed potentially good expression levels were selected for 
further expression studies (see Figure 3.5).
91
Figure 3.5: Colony blot screening of P. pastoris pPIC9K.FhcproCL2 transformants for expression.
Colonies were transferred onto nitrocellulose membrane and grown on YNB/2% methanol plates. Bound 
protein after cell lysis was probed with mouse monoclonal anti-His6 antibody. Positive colonies show as 
a dark patch. The positive (transformed with pPIC9K.FheproCLl) and negative (transformed with 
pPlC9K) control colonies are marked with a ring, as are the two colonies chosen for further expression 
studies.
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Chapter 4: Expression and characterisation of wildtype procathepsin LI
4.1 Expression of procathepsin LI
Pilot expression experiments were carried out with the three His+ Muts colonies 
of P. pastoris, labelled A14, A22 and A38, which were transformed with the 
pPIC9K.FheproCLl expression vector construct. These were induced for 6 days by 1% 
methanol in BMMY medium buffered to pH 6.0. Samples of the culture were taken 
daily and the supernatants were analysed by 12% SDS-PAGE. Cultures of P. pastoris 
transformed with pPIC9K alone and with the human serum albumin construct (provided 
by Invitrogen in the Multi-Copy Pichia Expression Kit) were induced as negative and 
positive controls respectively. All cultures showed high levels of secreted recombinant 
protein in two bands at 30 kDa and 37 kDa (see Figure 4.1). These bands both ran 
higher than native mature cathepsin LI or L2 (see Figure 4.3) but the 37 kDa band was 
close to the size expected for unprocessed procathepsin L I. As expression levels were 
approximately equal for each clone, one (A14) was selected and grown on YPD agar 
plates for stocks. To check for consistency of expression, three colonies from these 
plates, labelled A14A, A14B and A14C, were again induced for 6 days with 1% 
methanol in BMMY medium buffered to pH 6.0. Samples taken daily were analysed by 
12% SDS-PAGE and showed consistent levels of protein expression. Clone A14A was 
selected arbitrarily as the final expression clone and glycerol stocks prepared for future 
inoculations.
The effect of various environmental conditions on rFheproCLl production was 
examined. Firstly, three identical cultures were induced with 1% methanol in BMMY 
medium buffered to pH 6.0, 7.0 and 8.0 respectively. Samples of culture supernatant 
taken after 48 and 72 h of induction were analysed by 12% SDS-PAGE (see Figure 4.2). 
While all three cultures produced roughly equal amounts of protein at all three pHs, the
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Figure 4.1: SDS-PAGE analysis of F. hepatica procathepsin LI expression from P. pastoris.
Cultures of P. pastoris transformed with a cDNA encoding procathepsin LI were induced with 1% 
methanol in BMMY medium buffered to pH 6.0 at 30°C for 6 days. P. pastoris transformed with human 
serum albumin (HS A) and pPIC9K alone were induced as positive and negative controls respectively. 
Aliquots (10 (il) removed at 48 and 72 h after induction were analysed by 12% SDS-PAGE. The 37 and 
30 kDa components are indicated. Lanes 1 and 6, HSA secretion control; lanes 2 and 7, pPIC9K 
background control; lanes 3 and8, clone A14; lanes 4 and9, clone A22; lanes 5 and 10, clone A38.
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Figure 4.2: SDS-PAGE analysis of F. hepatica procathepsin LI expression from P. pastoris.
Cultures of P. pastoris transformed with a cDNA encoding procathepsin LI were induced with 1% 
methanol. Fermentations were carried out at 30°C in media buffered to pH 6.0,7.0, and 8.0. Aliquots 
(10 |LLl) removed at 48 and 72 h after induction were analyzed by 12% SDS-PAGE. The 37 and 30 kDa 
components are indicated. Adapted from Collins et al- (2004).
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proportion of recombinant protein produced in the 37 kDa form increased with 
increasing pH.
4.2 Immunoblot analysis of expression of procathepsin LI
Samples of the supernatant taken after 72 h of induction from the pH 8.0 
buffered culture were analysed by 12% SDS-PAGE and by immunoblotting alongside 
ES products prepared from adult F. hepatica (see Figure 4.3). The blots were probed 
with antisera prepared against native mature cathepsin LI and against recombinant 
propeptide of cathepsin LI (see Section 2.3.2). Both the 37 and 30 kDa bands were 
found to be immunoreactive with sera prepared against both native mature enzyme and 
recombinant propeptide. This suggested that the identity of the 37 kDa band as 
unprocessed procathepsin LI and indicated that the 30 kDa represented a semi­
processed form of the enzyme rather than fully mature cathepsin L I .
4.3 Effect of the cysteine protease inhibitor Z-Phe-Ala-diazomethylketone on 
procathepsin LI production
To determine if the processing of the 37 kDa band to the 30 kDa band was 
occurring in culture due to the activity of CL1 or yeast proteases, cultures were induced 
with 1% methanol in BMMY medium buffered to pH 8.0 in the presence or absence of
25 (iM of the potent cysteine protease inhibitor, Z-FA-CHN2. Samples were again 
analysed by 12% SDS-PAGE after 48 and 72 h of induction (see Figure 4.4A). As with 
increasing pH, a greater proportion of the 37 kDa band was produced in the presence of 
the inhibitor. Cathepsin L activity of the culture supernatants taken at various time 
points up to 72 h after induction was analysed with the fluorogenic substrate Z-FR- 
AMC (see Figure 4.4B). This indicated that cathepsin L activity was greatly reduced in
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Figure 4.3: SDS-PAGE and immunoblot analysis of F. hepatica procathcpsin LI expression from 
P. pastoris. Comparison of P. pastoris-expressed proeathepsin L with native F. hepatica-secreted mature 
cathepsin LI. Aliquots of adult F. hepatica ES products (lanes 1, 3, and 5) were compared with samples 
taken from P. pastoris medium after induction for 72 h at pH 8.0 (lanes 2, 4, and 6). Lane M, molecular 
size markers; panel a, Coomassie Blue-stained 12% SDS-PAGE gel; panel b, samples probed with 
antiserum prepared in rabbits against mature portion of cathepsin L 1; panel c, samples probed with 
antiserum prepared in rabbits against recombinant propeptide portion of procathcpsin LI. Note, the anti­
propeptide serum reacts with the 37 and 30 kDa P. postora-expressed components (indicated with 
arrows) but not with parasite-produced mature cathepsin LI or cathepsin L2 (indicated by an asterisk). 
Control preimmunized rabbit serum was not reactive with any proteins (not shown). Adapted from 
Collins etal. (2004).
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Figure 4.4: Production of procathepsin LI by transformed P. pastoris in the presence and absence 
of Z-Phe-Ala-diazomctliylketone. A, transformed P. pastoris were cultured at 30°C and pH 8.0 in the 
presence (+) or absence (-) of the cysteine protease inhibitor Z-FA-C1 IN, (25 |iM). Aliquots of culture 
supernatant, removed after 48 and 72 h, were analyzed by SDS-PAGE. The 37 and 30 kDa bands are 
indicated. B, recombinant yeast cultured in the presence (dotted line) and absence {solid line) of 25 |iM 
Z-FA-CHN,. Cathepsin L activity in the culture supernatant was measured with the fluorogenic substrate 
Z-FR-AMC. Activity units are presented as nmol of AMC released m in1 ml-1. Adapted from Collins 
et ai. (2004).
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the culture containing the inhibitor, while protein production remained largely 
unaffected.
4.4 Effect of pH and temperature on procathepsin LI production
Production of protein at low pH was investigated by the induction of cultures by 
1% methanol in BMMY medium buffered at pH 4.5, 6.0 and 8.0. Samples were 
compared by 12% SDS-PAGE (see Figure 4.5 A). Reduction in pH favoured an almost 
complete elimination of the 37 kDa band, with an increased production of a lower band, 
possibly representing the mature enzyme, with decreasing medium pH.
Effect of culture temperature was investigated by induction of cultures by 1% 
methanol in BMMY medium buffered to pH 8.0 in the presence and absence of Z-FA- 
CHN2, with growth at 20 and 25°C instead of the normal 30°C. Samples were analysed 
by 12% SDS-PAGE (see Figure 4.5B). Lowering of induction temperature reduced the 
production of breakdown products, particularly in the presence of inhibitor. Reduction 
in temperature also affected the appearance and clarity of the culture supernatant.
While cultures induced at 30°C were a yellow-brown colour and quite turbid, cultures 
induced at 25 or 20°C were clearer and more yellow in colour.
4.5 N-terminal sequencing of procathepsin LI components
The 37 and 30 kDa components were purified from yeast culture supernatant by 
Ni-NTA agarose affinity chromatography, transferred to PVDF membrane and 
subjected to //-terminal sequencing (see Section 2.3.29). For the 37 kDa band, a 
sequence of Glu-Ala-Glu-Ala-Tyr was determined, corresponding to 5 amino acids 
positioned one residue from the end of the yeast a-factor secretory signal sequence.
This indicated that the 37 kDa band represented recombinant procathepsin LI plus the 
last 6 amino acids (Glu-Ala-Glu-Ala-Tyr-Val) of the yeast a-factor secretory signal
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Figure 4.5: Effect of medium pH and temperature on procathepsin Lt production. A, transformed 
P. pastoris were cultured at 30°C in media buffered to pH 4.5, 6.0, and 8.0. Aliquots of culturc 
supernatant, removed after 72 h, were analysed by 12% SDS-PAGE. The 37 and 30 kDa bands are 
indicated. B, transformed P. pastoris were cultured in media buffered to pH 8.0 at 20 and 25°C in the 
presence (+) or absence (-) of the cysteine protease inhibitor Z-FA-CI1N2 (25 |iM). Aliquots of culture 
supernatant, removed after 24 h, were analysed by 12% SDS-PAGE. The 37 and 30 kDa bands are again 
indicated,
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sequence before the Ser'91 start of the propeptide (see Figure 4.6). For the 30 kDa band, 
a sequence of Leu-Asn-Gln-Phe-Thr was determined, indicating that this band
• • 38represented an intermediate processed form of cathepsin LI beginning at residue Leu' 
(see Figure 4.8; Collins et al., 2004). Also, based on these two //-terminal sequences, 
the predicted average molecular weights for the 37 kDa and 30 kDa forms were 36.74 
and 29.62 kDa respectively, matching closely to the original estimates.
4.6 In vitro autoactivation of recombinant procathepsin LI
Processing of the rFheproCLl from the 37 kDa band to the 30 kDa band was 
further investigated by incubating purified rFheproCLl in 0.1 M sodium citrate buffer, 
pH 5.0, containing 1 mM DTT and 2 mM EDTA at 37°C. Samples were taken at 
various time points up to 2 h and analysed by 12% SDS-PAGE (see Figure 4.6). Over 
the course of the incubation, the 37 kDa procathepsin L was processed to the 30 kDa 
intermediate form and then through various intermediates to a single protein migrating 
at 24.5 kDa. The samples were also assayed for cathepsin L activity with the 
fluorogenic substrate Z-FR-AMC and showed a gradual 5-fold increase in the activity of 
rFheproCLl (Collins et al., 2004). The 24.5 kDa product was subjected to TV-terminal 
sequencing. This revealed a mixture of two sequences, Asn-Arg-Ala-Val-Pro and Arg- 
Ala-Val-Pro-Asp, corresponding to the sequence just 2 and 1 amino acids from the 
native mature protein processing site respectively (see Figure 4.6).
A control experiment compared processing of purified rFheproCLl when 
incubated in PBS, pH 7.3 with the previous low pH conditions. The incubation was 
carried out for 24 h, with samples taken at various time points and analysed by 12% 
SDS-PAGE (see Figure 4.7). While the samples at low pH processed as before, the 
samples in PBS remained unprocessed, with only some breakdown of the lower
101
Time
(min): 0 10 20 30 40 60 90 120
EDTA. Samples removed at various time points were analyzed by SDS-PAGE. The predominant proteins 
of 37,30, and 24.5 kDa were subjected to TV-terminal sequencing. The schematic indicates the amino acid 
sequences surrounding the intermolecular processing sites (arrowed) that generated these components and 
their location within the propeptide of procathepsin L I . The box indicates the conserved motif 
CL^RffiAT). Adapted from Collins et al. (2004).
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Figure 4.7: Control incubation of procathepsin LI in PBS. Purified procathepsin LI was incubatcd at 
37°C for 24 h in either 0 .1 M sodium acetate buffer, pi 1 4.5 (A ) or PBS, pl 1 7.3 (B), both containing 
2 mM DTT and 2.5 mM EDTA. Samples removed at various time points were analysed by SDS-PAGE. 
Processing of the 30 kDa band did not occur at the higher pl 1, although the lower intermediates were 
broken down.
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intermediates and mature protein. This also demonstrates the stability of the zymogen 
form of the enzyme. Extension of the incubation time to 24 h also allowed complete 
processing of the multiform rFheproCLl to the mature form in the low pH buffer.
4.7 Alignment of cathepsin L propeptides: identification of G.XNXFXD motif
The cleavage point between Gly"39 and Leu'38 which gave rise to the 30 kDa 
intermediate form corresponded closely to the Gly"42-Xaa-Asn-Xaa-Phe-Xaa-Asp"36 
(papain numbering) motif which was previously found to be pivotal in the 
intermolecular processing of papain expressed in the yeast S. cerevisiae (Vemet et al., 
1995). Therefore, an amino acid sequence alignment was performed with ClustalX 1.81 
of the region around this motif in selected plant, helminth parasite and mammal 
cathepsin L sequences (see Figure 4.8, also Table 2.2 for sequence details). The 
GAN AT AD motif was found to be completely conserved between papain and all the 
helminth parasite sequences, with the F. hepatica CL1 sequence of Gly-Leu-Asn-Gln- 
Phe-Thr-Asp conserved completely with the F. hepatica CL2, and F. gigantica CL1 
sequences. Furthermore, on examining the alignment prepared for the generation of the 
phylogenetic tree of Fasciola spp. Cathepsin Ls (see Figure 3.2), this sequence was also 
completely conserved in all but 2 of the Adult 1 group F. hepatica and F. gigantica 
sequences, with FheCL6 and FgiCL4 possessing a leucine in place of the phenylalanine. 
It was also noted that the Gly’42-Leu‘41 (papain numbering) bond was preserved in all 
helminth parasite sequences checked, as well as in papain and C. elegans CPL1. This 
bond was not conserved in the mammalian sequences checked, with Glu"42-Met'41 or 
Ala'42-Met'41 (papain numbering) replacing it.
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Figure 4.8: Comparison of the GXNXFAI) motif between papain and cathepsin L proteases of 
helminths and mammals. The GA'MYFJfD motif scqucnce of papain is identical to that of F. hepatica 
cathepsin LI and cathepsin L2 and to the cathepsin Ls of related the trcmatodes F. gigantica and 
S. mansoni (identical residues highlighted in black). The arrow indicates the position of the 
intermolecular cleavage site, between the G ly42-Leu•" bond (papain numbering), that generates the 
intermediate 30 kDa component of the F. hepatica procalhepsin L when it is expressed in P. pastoris. The 
Gly42 is substituted for Glu in the rat and mouse cathepsin L sequences, and for Ala in the human 
cathepsin L sequence (highlighted in gray, papain numbering). Accession numbers for all sequences are 
given in Table 2.2. Adapted from Collins et al. (2004).
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4.8 Inhibition of rFheproCLl activity by recombinant propeptide and Z-Phe- 
Ala-diazom ethy lketone
Purified rFheproCLl was mixed with a range of concentrations between 0 and 5 
|aM of recombinant cathepsin LI propeptide or Z-FA-CHN2 and assayed for activity 
against the fluorogenic substrate Z-FR-AMC. Inhibition titre curves of fluorescence 
versus inhibitor concentration were prepared and compared (see Figure 4.9A). The 
recombinant propeptide was found to be a potent inhibitor of rFheproCLl, with greater 
inhibition at a lower concentration than that achieved with equal concentrations of Z- 
FA-CHN2.
Effect of pH on inhibitor binding was investigated by preincubating 2 h 
activated rFheproCLl with either 0, 1 or 0.1 j-iM recombinant propeptide or 0, 1.5 or 
0.15 [iM Z-FA-CHN2 in 0.1M sodium citrate buffers, pH between 3.0 and 7.0, 
containing 2.5 mM EDTA, 2 mM DTT for 30 min at room temperature. These samples 
were then assayed as before and percentage inhibition values calculated (see Figure 
4.9B). At the higher concentrations, inhibition of greater than 95% was achieved at all 
pH values for both inhibitors. At the lower concentrations, however, inhibition was 
significantly lower. This was particularly noticeable for the recombinant propeptide, 
which showed a large drop in inhibition for pH 6.0 and 8.0 buffers.
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Figure 4.9: Inhibition of recombinant procathepsin LI activity. A, purified rFheproCLl was mixed 
with between 0 and 5 |iM of recombinant cathepsin LI propeptide {dotted line) or Z-FA-CHN2 {solid 
line) and assayed with the fluorogenic substrate Z-FR-AMC. B, 2 h activated rFheproCLl was 
preincubalcd with two concentrations of each of the inhibitors in 0 .1 M sodium citratc buffers with pH 
between 3.0 and 7.0. Results are presented as percentage inhibition for each inhibitor concentration 
compared with uninhibited enzyme; black bars represent 1 (iM propeptide, grey represents 0.1 (iM 
propeptide, diagonal lines represent 1.5 |iM  Z-FA-CIIN2 and white represents 0.15 (xM Z-FA-CHN2.
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Chapter 5: Expression and characterisation of wildtype procathepsin L2
5.1 Expression of wildtype procathepsin L2
Pilot expression studies were carried out with the two P. pastoris colonies, labelled 
A3.1 and B1.28, which were transformed with the pPIC9K.FheproCL2 expression 
vector construct and previously selected for expression by the colony blot method (see 
Figure 3.5). These were induced for 3 days by 1% methanol in BMMY medium 
buffered to pH 6.0, with samples taken daily and analysed by 12% SDS-PAGE. A 
culture of P. pastoris transformed with the pPIC9K.FheproCL2 construct was also 
induced and sampled as a positive expression control. Unlike the production of 
rFheproCLl, rFheproCL2 was produced almost entirely in the 37 kDa procathepsin 
form, with only small amounts produced as the intermediate 30 kDa or mature cathepsin 
forms (see Figure 5.1 A).
Cathepsin L activity of the supernatant samples was determined with the 
fluorogenic substrate Z-FR-AMC, using the rFheproCLl supernatants as a control (see 
Figure 5.IB). Although activity was found for the rFheproCL2 supernatants, it was 
between 10- and 14-fold lower than for the equivalent rFheproCLl cultures after 48 h of 
methanol induction. However, this was consistent with both the much lower levels of 
intermediate and fully processed protein found in the rFheproCL2 supernatants, as well 
as the lower activity levels for native FheCL2 versus native FheCLl (Dowd et al.,
1994).
As protein levels produced were visibly higher for the A3.1 P. pastoris clone, 
this was selected as the final expression clone. This was grown on YPD agar plates and 
glycerol stocks prepared for future inoculations.
The effect of environmental pH on rFheproCL2 production was examined by inducing 
three identical cultures with 1% methanol in BMMY medium buffered to pH 4.5, 6.0
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Figure 5.1: SDS-PAGE analysis of F. Iieputica procathcpsin L2 expression from P. pastoris.
A, Cultures of two P. pastoris clones (A3.1 and B 1.28) transformed with a cDNA encoding procalhepsin 
L2 were induced with 1% methanol in BMMY medium buffered to pi 1 6.0 at 30°C. P. pastoris 
transformed with procathcpsin LI was induccd as a positive control. Aliquots (10 (il) removed at 24,48 
and 72 h after induction were analysed by 12% SDS-PAGE. The 37 and 30 kDa components are 
indicated. B, cathepsin L activity in each culture supernatant was measured with the fluorogenic substrate 
Z-FR-AMC. Solid line, FheproCL I clone A 14A control; dashed line, FheproCL2 clone A3.1; dotted line, 
FheproCL2 clone B 1.28. Activity units are presented as nmol of AMC released min'1 ml'1.
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Figure 5.2: Effect of medium pH on procathepsin L2 production. Transformed P. pastoris were 
cultured at 30°C in media buffered to pH 4.5, 6.0, and 8.0. Aliquots of culture supernatant, removed after 
72 h, were analysed by 12% SDS-PAGE. The 37 and 30 kDa bands arc indicated.
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and 8.0 respectively. Samples of culture supernatant taken after 48 and 72 h of 
induction were analysed by 12% SDS-PAGE (see Figure 5.2). Production levels of 
protein remained largely unaffected, with roughly equal levels for each medium pH. As 
for production of rFheproCLl (see Figure 4.6A), the low level of processing which 
occurred was reduced at increased pH and increased at lower pH. Unlike for production 
of rFheproCLl, however, the majority of the protein remained in the 37 kDa 
procathepsin form in all cultures. The rFheproCL2 protein was purified from yeast 
culture supernatant by Ni-NTA agarose affinity chromatography for further studies.
5.2 In vitro autoactivation of recombinant procathepsin L2
As only very limited amounts of processed protein with low activity levels were 
found in rFheproCL2 supernatants, in vitro autoactivation of rFheproCL2 was 
investigated using a similar protocol to that used previously. Purified rFheproCL2 was 
incubated in 0.1 M sodium acetate buffer, pH 4.5, containing 1 mM DTT and 2 mM 
EDTA at 37°C. Samples were taken at various time points up to 2 h and analysed by 
12% SDS-PAGE (see Figure 5.3A). As for rFheCLl (see Figure 4.8), the 37 kDa 
procathepsin L2 was processed through intermediates to the fully mature form 
migrating at approximately 24-25 kDa. A similar incubation was performed with 
samples taken at time points up to 3 h and analysed for cathepsin L activity with the 
fluorogenic substrate Z-FR-AMC (see Figure 5.3B). This showed an approximately 5- 
fold increase in activity, similar to that found for activated rFheproCLl.
A control experiment compared processing of purified rFheproCL2 when 
incubated in PBS, pH 7.3 with processing when incubated in 0.1 M sodium acetate, pH 
4.5. The incubation was carried out for 24 h, with samples taken at various time points 
and analysed by 12% SDS-PAGE (see Figure 5.4). As for rFheproCLl, the low pH 
samples processed as expected, while the samples in PBS remained unprocessed, with
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Figure 5.3: Autocataiytic processing of procathepsin L2 at pH 4.5. A, Purified procathepsin L2 
(5.0 fig) was incubatcd at 37°C for 2 h in 0.1 M sodium acctate buffer, pi 14.5, containing 2 mM DTP and 
2.5 mM EDTA. Samples removed at various time points were analyzed by SDS-PAGB. A pattern of 
predominant proteins o f 37, 30, and 24-25 kDa was found similar to that for the autocataiytic processing 
of rFheproCLl. B, cathepsin L activity of samples taken at time points up to 3 h was measured with the 
fluorogenic substrate Z-FR-AMC. Activity units arc presented as nmol of AMC released min-' ml'1.
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Figure 5.4: Control incubation of procathepsin 12  in PBS. Purified procathepsin L2 was incubated at 
37°C for 24 h  in either 0 .1 M sodium acetate buffer,pH 4.5 (A) or PBS, pH 7.3 (B), both containing 
2 mM DTT and 2.5 mM BDT'A. Samp Ics removed at various time points were analysed by SDS-PAGE. 
Processing of the 30 kDa band did notoccur at the higher pH.
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the small amount of lower intermediates and mature protein being broken down 
completely by 24 h. This again demonstrated the stability of the zymogen form of the 
enzyme. Extension of the incubation time to 24 h also allowed complete processing of 
rFheproCL2 to the mature active form in the lower pH buffer.
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Chanter 6: Preparation, expression and analysis of inactive mutants
6.1 Expression of inactive procathepsin LI mutants
The inactive mutant procathepsin LI construct (pPIC9K.[Gly26]FheproCLl) was 
prepared from the pPIC9K.FheproCLl template in our laboratory by Dr. Colin Stack 
(Collins et al., 2004) by the method of gene SOEing (Ho et al., 1989). This mutant was 
produced by the substitution of the active site cysteine at position 26, with a glycine. As 
this cysteine residue is crucial to the cleavage of substrate peptide bonds, its 
replacement with glycine renders the protein inactive.
After transformation of the pPIC9K.[Gly26]FheproCLl construct into P. pastoris 
GS115 and screening of transformants, a number of colonies were analysed by SDS-
• 96PAGE for production of [Gly JFheproCLl. Two colonies, labelled 2.1 and 5.1 were 
selected for pilot expression studies. When supernatants were analysed by 12% SDS- 
PAGE, it was noted that the protein produced by one clone, labelled 5.1, exhibited 
slower migration than either wildtype rFheproCLl or the other mutant, produced by 
clone 2.1 (see Figure 6.1). The cDNA of both clones was sequenced and the 5.1 clone 
was shown to have an additional mutation to Cys26->Gly26 located within the propeptide 
and that was not found in the protein produced by the 2.1 clone. This mutation 
substituted a pro line in place of a leucine at position -12 in the propeptide, therefore this 
clone was labelled [Pro'12Gly26]FheproCLl.
Effect of pH on production was examined by inducing cultures of both mutants 
along with wild-type CL1 as a control by 1% methanol in BMMY medium buffered to 
pH 6.0 and 8.0. Samples of supernatant were taken at various time points and analysed 
by 12% SDS-PAGE (see Figure 6.1). Both mutants were unaffected by medium pH, 
with r[Gly26]FheproCLl appearing as a single strong band co-migrating with the 37 kDa
• 19 96procathepsin L component of wildtype rFheproCLl and the r [Pro' Gly JFheproCLl
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Figure 6.1: Expression of procathepsin LI inactive mutants by P. pastoris. P. pastoris cells 
transformed with either wild-type procathepsin LI or the procathepsin LI clones that had the active site 
Cys26 replaced by Gly were cultured at 25°C in media buffered to p il 6.0 (A) and 8.0 (B), After 24 h and 
48 h of induction with 1% (v/v) methanol, samples of culture supernatant were analysed by 12% SDS- 
PAGE. The 30-kDa intermediate form of procathepsin L was observed only in the wild-type culture. 
Mutant clone 5.1, which was later found to contain an additional mutation from L eu12 to Pro ran slightly 
higher than the wild-type or single mutant procathepsin L 1. Lanes I and 4, rFheproCL 1 wild-type; lanes 
2 and 5, r[Gly26]FheproCLl inactive mutant; lanes 3 and 6, r[ProuGly26JFheproCLl double mutant.
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appearing as a single strong band migrating slightly higher in the gel. No other bands or 
breakdown products were formed and the production of both mutants was almost 4-fold 
greater than that of the combined 37 and 30 kDa components of rFheproCLl.
The two mutant proteins were purified from yeast culture supernatant by Ni- 
NTA agarose affinity chromatography and subjected to iV-terminal sequencing. In both 
cases, a sequence of Glu-Ala-Glu-Ala-Tyr was determined, corresponding to 5 amino 
acids positioned one residue from the end of the yeast a-factor secretory signal 
sequence and matching results for the 37 kDa component of the wild-type. This 
indicated that the both bands represented recombinant inactive mutant procathepsin LI 
plus the last 6 amino acids (Glu-Ala-Glu-Ala-Tyr-Val) of the yeast a-factor secretory 
signal sequence before the Ser'91 start of the propeptide (see Figure 6.5). As expected, 
both mutant proteins lacked activity against the fluorogenic substrate Z-FR-AMC.
6.2 In vitro processing of inactive procathepsin LI mutants
In order to investigate processing of procathepsin LI to its mature form, both 
mutant proteins were incubated at pH 4.5 alongside wildtype rFheproCLl as a control in 
a similar manner to previous incubations (see Section 4.6) As in these previous 
incubations, purified wildtype rFheproCLl was autocatalytically processed through 
various intermediates to a mature form. However, neither of the inactive mutant 
enzymes were capable of processing to lower molecular size forms (see Figure 6.2).
This was to be expected due to lack of proteolytic activity present in the mutant 
enzymes.
Further investigations were performed with the incubation of exogenously added 
wildtype rFheproCLl which had been activated for 2 h mixed with each of the two 
mutant enzymes. Addition of activated wild-type rFheproCLl to purified 
r[Gly26]FheproCLl mutant at pH 5.0 resulted in the progressive appearance of a minor
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Figure 6.2: Incubation of procatHcpsin LI inactive mutants at pH 4.5. Purified rFheproCLI, 
r[Gly26]FheproCLI and [Pro-l2Gly26]FheproCL1 were incubated at 37°C for 2 h in 0.1 M sodium acetate 
buffer, pH 4.5, containing 2 mM DTT and 2.5 mM EDTA. Samples removed at various time points were 
analysed by SDS-PAGE. While autoactivation of rFheproCLI occurred as before, the inactive mutants 
remained unaffected by the incubation.
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band at ~35 kDa over an incubation period of 4 h and a second major band at -25 kDa 
that co-migrated with fully active cathepsin LI, with the intensity of this band 
increasing over the incubation time (see Figure 6.3A). In parallel experiments with 
purified r[Pro‘12Gly26]FheproCLl, no significant processing of the double mutant 
occurred, although the major band progressively shifted to a lower position in the gel 
over time to co-migrate with the 37 kDa procathepsin form of rFheproCLl (see Figure 
6.3B).
Effect of pH on exogenous processing of the mutants was investigated by 
repeating the above incubations for 2 h in 0.1 M sodium acetate buffers at pH 3.0, 4.0 
and 5.0. Similar results were found at all pH values, with the double mutant again 
showing only a small shift in position with no significant intermolecular processing (see 
Figure 6.3C). Experiments in which activated rFheproCLl was added to heat-denatured 
r[Gly26]FheproCLl showed that the mutant was sensitive to complete degradation by 
active cathepsin LI, confirming that the expressed mutant was correctly folded (see 
Figure 6.4).
6.3 A^-terminal sequencing of exogenously processed forms of inactive mutant 
procathepin LI
Reaction mixes containing exogenously added activated wildtype rFheproCLl 
and each of the inactive mutants were incubated as before (see Section 6.2), analysed by 
SDS-PAGE and transferred to PVDF membrane. The membrane was then sent for N- 
terminal sequencing of the exogenously processed forms of each mutant enzyme. 
Attempts were made to obtain the //-terminal amino acid sequence for the -35 kDa 
intermediate form of [Gly26]FheproCLl, but were unsuccessful. For the fully processed 
-25 kDa form, a sequence of His-Gly-Val-Pro-Tyr (with less than 10 % Gly-Val-Pro-
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Figure 6.3: Incubation oi' procathepsin LI inactive mutants with exogenously added active 
catlicpsin LI. Purified r[GlyJh|FheproCLl (5 |ng) (A) or r|Pro’,JGly2<,]FheproCLl (5 |Ag) (B) were 
incubated for up to 4 h in 0 .1 M sodium acetate buffer, pi I 5.0, containing 2 mM DTI' and 2.5 mM EDTA 
at 37°C in the presence of 0.5 jig of 2 h activated rFheproCLl (act). Note that the double mutant remains 
unprocessed. C, parallel experiments were carried out as above but replacing the buffer with 0.1 M 
sodium acetate, pl 1 3.0,4.0 and 5.0, and an incubation time of 2 h. Processing of the r[GlyM]FheproCLl 
mutant occurred at all pH values, while the double mutant remained unprocessed. Lanes I and 5, no 
incubation; lanes 2 a nd6, pl 1 3.0; lanes 3 and 7, pH 4.0; lanes 4 a nd8, pl 1 5,0.
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Figure 6.4: tuterinolecutar processing of r|Gly“ |FiicproCLl inactive mutant by exogenously 
added active catliepsiu LI. A, purified r[Gly26]FheproCL 1 (5 Jig) was incubated for up to 3 h in 0,1 M 
sodium citrate buffer, pi I 5.0, containing 2 niM DTI' and 2.5 mM EDTA at 37°C in the presence of 
0.5 (.ig o f2  h activated rFheproCL 1. The position of the mature wild-type cathepsin LI at 24.5 kDa 
(2.5 (ig loading) is indicated in the lane labelled wt with the arrow. B, parallel experiments were carried 
out as above but in this case purified r[Gly26]FheproCL 1 was unfolded by heating at 95°C for 3 min prior 
to the addition of activated wild-type CL I. Adapted from Collins et ah (2004).
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Tyr-Glu), indicating a cleavage site located 10 amino acids prior to the //-terminus of 
mature cathepsin LI (see Figure 6.5).
//-terminal analysis of the double mutant r[Pro'12Gly26]FheproCLl reactions 
revealed several sequences, with high levels of Val-Xaa-Asp, Asn-Asp and Leu-Xaa 
found. These sequences match positions found at the end of the yeast a-factor secretion 
signal sequence and the early residues of the propeptide (see Figure 6.5). These data 
showed that while the exogenously added wildtype cathepsin LI was capable of 
degrading the r[Pro' Gly JFheproCLl sequentially from the //-terminus, it was 
incapable of processing the protein into a mature form.
6.4 Construction of pPIC9K. [Gly26]FheproCL2 inactive mutant expression 
vector
The cDNA encoding the inactive mutant form of FheproCL2, in which the 
active site cysteine (Cys ) residue was replaced with a glycine residue, was produced as 
a synthetic gene in the pPCR-Script plasmid by Geneart GmbH, Regensburg, Germany. 
The gene was successfully amplified from the 03-702¥pPCR-Script plasmid by PCR as 
for both the wild-type cathepsins LI and L2. When run on a 1% agarose gel, the 
expected 980 bp band was visualised (see Figure 6.6A). The purified product was first 
ligated into the pGEM-T Easy vector and transformed into E. coli Top 10F’. 
Transformants were screened by the colony pick PCR method and one transformant 
containing the correct sized insert was selected for digestion and insertion into the 
pPIC9K expression vector (see Figure 6.6B). The purified, SnaBI/Avrll digested insert 
was ligated into pPIC9K vector and retransformed into E. coli Top 10F’.
Purified plasmid DNA from E. coli transformants was screened by colony pick 
PCR with the standard cathepsin L primers (see Figure 6.6C). Plasmid DNA from two 
colonies (labelled C5 and C9) which were found to be positive for an insert were
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EAEA^y^TDDLWHQWKRMYNKE YN GADDQHRRN
IWEKNVKHIQEHNLRHDLGLVTYTLGLNFQTDM
TFEEFKAKYLTEMSRASDILS^VPYEANNRAV
Figure 6.5: Amino acid sequence of the propeptide of F. Iicpalicii cathepsin LI with cleavage sites 
that lead to activation indicated. The downward solid arrow indicates the cleavage site observed when 
native mature cathepsin LI is secreted in vitro by adult F. hepatica. The first downward open arrow 
indicates the site of cleavage within the GAN.VFAT) motif (boxed) that gives rise to the 30 kDa 
intermediate component when procathepsin LI is expressed in P. pastoris, and the second and third 
downward open arrows show the sites of cleavage when this is further activated in vitro at pH 5.0 (see 
Figure 4.8). The upward solid arrows show the sites of cleavage of r[Gly!6]FheproCLl mutant by 
exogenously added mature cathepsin LI. The upward open arrows show the probable sites of cleavage of 
r[P ro12Gly26]FheproCLl double mutant by exogenously added mature cathepsin LI. The final residues of 
the yeast a-factor secretion signal sequence are marked in italics. Adapted from Collins et ak (2004).
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Figure 6.6: 1 % agarose gels showing construction of pPlC9K.[GlyJ6|FheproCL2 expression vector.
A, inactive mutant procathepsin L2 PCR product before ligation into pGEM-T. Lane M, 100 bp DN A 
ladder; lane 1, [GIy26]FheproCL2 PCR product. B, colony pick PCR of selected £. call pGEM-T. 
[Gly26]FheproCL2 transformants with 5’AOX and 3’AOX primers. Lane M, 100 bp DNA ladder; 
asterisk, transformant selcctcd for digestion and ligation into pPIC9K. C, colony pick PCR of selected 
E. colipPIC9K. [Gly26]FheproCL2 transformants with 5’AOX and 3’AOXprimers. Lane M, 100 bp 
DNA ladder; clones C5 and C9, used for transformation of P. pastoris, are indicated.
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selected for transformation into P. pastoris and sent for sequencing. The sequences 
were confirmed to match the database sequence (with the exception of the active site 
Cys26->Gly26 mutation) and to be in frame with the yeast a-factor secretion signal 
sequence.
6.5 Transformation and screening of P. pastoris GS115 with 
pPIC9K.[Gly26]FheproCL2 construct
The two pPIC9K.[Gly26]FheproCL2 constructs were linearised with Sail and 
transformed into competent P. pastoris GS115 cells. His+ phenotype was confirmed by 
growth on histidine deficient medium and between 16 and 20 colonies from each 
transformation were screened directly for expression by the colony blot rapid screening 
method. All colonies showed low expression of a His6-tagged protein. One colony, 
labelled C5.8, which showed slightly stronger labelling with anti-His6 antibody was 
selected for pilot expression studies (see Figure 6.7). No colonies showed antibody 
labelling as strongly as the rFheproCLl control.
6.6 Expression of inactive mutant procathepsin L2
The P. pastoris GS115 clone C5.8 which was transformed with the 
pPIC9K.[Gly26]FheproCL2 expression vector construct was induced for 6 days by 1% 
methanol in BMMY medium buffered to pH 6.0, with samples taken daily and analysed 
by 12% SDS-PAGE. Cultures of the wild-type procathepsins LI and L2 as well as the 
double mutant inactive procathepsin LI were also induced as controls and to gauge 
comparative expression levels (see Figure 6.8). Although the inactive procathepsin L2 
was produced with a predominant 37 kDa band as for rFheproCL2 and the procathepsin 
LI mutants, it was produced in several fold lower quantities. The protein was purified 
from culture supernatant by Ni-NTA agarose affinity chromatography. Purified protein
125
Figure 6.7: Colony blot screening of P. pastoris pPIC9K.|Gly16]FheproCL2 transformants for 
expression. Colonics were transferred onto nitrocellulose membrane and grown on YNB/2% methanol 
plates. Bound protein after cell lysis was probed with mouse monoclonal anti-His antibody. Positive 
colonies show as a dark patch. The positive control colony, transformed with pPIC9K.FheproCLl, and 
the colony chosen for pilot expression studies (C5.8) arc marked with a ring.
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Figure 6.8: Expression of proeathepsin L2 inactive mutant by P. pastoris, compared with previous 
recombinants. P. pastoris cells transformed with either the proeathepsin L2 clone that had the active site 
Cys26 replaced by Gly or the previous recombinants were cultured at 30°C in media buffered to pH 6.0. 
After 6 days of induction with 1% (v/v) methanol, samples of culture supernatant were analysed by 12% 
SDS-PAGE. Lane I, rFheproCLI wild-type; lane 2, r[ Pro-l2Gly RFheproCLI inactive mutant; lane 3, 
rFheproCL2 wild-type; lane 4, r[Gly2fi]FheproCL2 inactive mutant.
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was transferred to PVDF membrane and sent for //-terminal sequence analysis. A 
sequence of Glu-Ala-Glu-Ala-Tyr-Val was determined, matching with the last 6 amino 
acid residues of the yeast a-factor secretory signal sequence before the Ser'91 start of the 
propeptide. As expected, the mutant protein lacked activity against the fluorogenic 
substrate Z-FR-AMC.
6.7 Determination of the 3D structure of F. hepatica procathepsins LI and L2
In collaboration with Dr. Colin Stack in our laboratory, 30 mg of purified 
inactive mutant r[Gly26]FheproCLl was produced and sent to Dr. Linda Brinen of the 
Fasciola Structural Biology Laboratory at UCSF, San Francisco, USA for 
determination of the 3D structure of the protein by X-Ray crystallography. The 
structure is still being completed, but a preliminary model has been produced (see 
Figure 6.10) whose general structure compares well with the crystal structure of human 
cathepsin L (Coulombe et al., 1996).
Due to the low levels of production of r[Gly26]FheproCL2 from transformed P. 
pastoris cultures, a large scale culture, induction and purification of the inactive mutant 
protein was performed. This culture was started with 7.7 L of BMGY medium for the 
initial growth stage and resuspended in 1.55 L BMMY buffered to pH 6.0 containing 
1% methanol for induction of protein expression (see Section 2.3.22). The 
r[Gly26]FheproCL2 protein was then purified in a large scale process by Ni-NTA 
affinity chromatography and concentrated approximately 20-fold with a centrifuge 
concentrator. However, when the concentrated protein preparation was analysed by 
SDS-PAGE it was found that much degradation had occurred over the course of the 
process (see Figure 6.9), likely due to the longer times involved for the processing of 
such a large volume of culture supernatant. Also, only a relatively small quantity of 
protein was produced for the culture volume used; only 8 mg of protein was obtained
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from the 1.55 L induction culture, compared to 110 mg of rFheproCLl produced from a 
previous 400 ml induction culture. Further optimisation of the induction and 
purification process of this protein, including re-transformation of P. pastoris in order to 
identify higher copy number integrants with greater levels of protein production, would 
be required before more experimentation could be performed and the 3D structure of 
procathepsin L2 determined. This work is ongoing in our laboratory.
129
Figure 6.9: SDS-PAGE analysis of purified inactive mutant procathepsin L2. P. pctstoris cells 
transformed with the procathepsin L2 clone that had the active site Cys26 replaced by Gly were cultured at 
30°C in media buffered to pH 6.0 in a large scale culture. After 3 days of induction with 1% (v/v) 
methanol, the protein was purified from the culture medium by Ni-NTA affinity chromatography and 20X 
concentrated with a centrifuge concentrator. The concentrated r[Gly“ ]FheproCL2 inactive mutant was 
analysed by 12% SDS-PAGE and found to have been partially degraded during the preparation process. 
Lane M, molecular size markers; lane 1, concentrated purified r[Gly26]FheproCL2.
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Figure 6.10: Collaboration with the Fasciola Structural Biology Laboratory, UCSF on the 
determination of the 3D structure of F. hepatica procathepsin LI. Purified r[Gly26]FheproCLl 
prepared in our laboratory was successfully crystallised by Dr. Linda Brinen and her team (pictured top 
left) in the Fasciola Structural Biology Laboratory, UCSF, San Francisco, USA. An example of the 
crystals formed is presented in the bottom left. While the determination of the 3D structure of 
procathepsin LI is still being elucidated by X-ray crystallography, a preliminary model (right) has been 
prepared whose general structure matches well with that of human procathepsin L.
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Chapter 7: Comparison of recombinant cathepsin LI and L2
7.1 Secretion of cathepsin L proteases by F. hepatica parasites
Adult F. hepatica maintained in vitro secrete two major proteases previously 
characterised as 27.5 kDa cathepsin LI and 29 kDa cathepsin L2 in the laboratory 
(Smith et al., 1993a; Dowd et al., 1994). Immunoblotting of adult F. hepatica ES 
products demonstrated that both enzymes are reactive with sera prepared against 
purified native mature cathepsin L I . Neither reacts with sera prepared specifically 
against a recombinant cathepsin LI propeptide (see Figure 7.1, also Figure 4.2B;
Collins et al., 2004).
Immunofluorescence and immunoelectron microscopy experiments were carried 
out by Dr. Aaron Maule’s laboratory at Queen’s University Belfast, UK, using anti­
propeptide and anti-mature cathepsin LI antisera from our laboratory (Collins et al., 
2004). Confocal laser immunocytochemistry using the anti-mature cathepsin LI 
antiserum localised the protease to the gastrodermal epithelial cells throughout the gut 
of adult F. hepatica (see Figure 7.2B). Labelling was found to be more dense toward 
the apical end of these gastrodermal cells, suggesting that the enzyme is stored in 
secretory vesicles within the cells (see Figure 7.2C). This was confirmed by electron 
microscopy (see Figure 7.2D-F), with the densely-stained secretory vesicles showing 
strong immunoreactivity with both anti-mature and anti-propeptide sera. The reactivity 
of the vesicles with anti-mature and anti-propeptide antibodies indicates that the enzyme 
is stored in these vesicles in its inactive procathepsin form.
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Figure 7.1: SDS-PAGE and immunoblot analysis of /•.’ hepatica ES products. ES products obtained 
from medium in which F. hepatica were cultured were analysed by SDS-PAGE and immunoblotting. 
Lane M, molecular size markers; lane 1, Coomassie Blue-stained 12% SDS-PAGE gel ofES products; 
lane 2, ES products probed with antiscrum prepared in rabbits against native mature cathcpsin LI Jane 3, 
ES products probed with antiserum prepared in rabbits against recombinant propeptide of procathepsin 
LI; lane 4, ES products probed with normal rabbit serum. Arrows indicate position of major secreted and 
fully processed cathepsin LI and cathepsin L2. Adapted from Collins et al. (2004).
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Figure 7.2: Immunolocalization of procathepsin LI in F. hepatica gastrodermal epithelial cclls.
A, schematic representation of gastrodermal epithelial cells in F. hepatica (after Smyth and Halton, 1983). 
g, Golgi; gl, gut lamellae; n, nuclei; sb, secretory bodies. B, confocal scanning laser m icrograph showing 
immunoreactivity for mature cathepsin LI within the gastrodermis of adult F. hepatica; the nuclei 
(arrows) of the gastrodermal cells are clearly visible; gl, gut lamellae; hi, gut lumen. C, confocal scanning 
laser micrograph showing immunoreactivity for mature cathepsin LI within the gastrodermal cells of 
adult F. hepatica; the nuclei (arrows) of the gastrodermal cells are clearly visible. Immunoreactivity 
appeals as a punctuate pattern at the apical end of the cells where the secretoiy vesicles are located; gm, 
gut muscle; lu, gut lumen. D, electron micrograph showing non-reactivity of secretory bodies (a/row.s) 
within the epithelial cells of the gastrodermis with control preimmunized rabbit serum; gl, gut lamellae. E, 
electron micrograph showing the localization F. hepatica procathepsin L ! to secretory bodies of the 
gastrodermal epithelial cells with antiserum prepared against the recombinant propeptide of procathepsin 
LI; gl, gut lamellae. F, electron micrograph showing the localization of F, hepatica cathepsin LI to 
secretory bodies of the gastrodermal epithelial cells with antiserum prepared against purified mature 
portion of cathepsin LI. Note that the labeling is confined to the contents of the secretory bodies. Adapted 
from Collins et aL (2004).
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7.2 Analysis of mRNA production and intercellular expression by P. pastoris 
transformants
Total RNA was extracted from P. pastoris cells transformed with each of the 
recombinant proteins (with the exception of r[Gly26]FheproCLl) after they had been 
induced for 4 days by 1% methanol in BMMY medium buffered to pH 6.0. The RNA 
was quantified and a RT-PCR reaction prepared with 1 (a.g template to synthesise first 
strand eDNA. This cDNA should correspond to the total polyA+ mRNA produced by 
the cells. PCR was used to probe the cDNA for the presence of the cathepsin L gene 
transcripts and the reaction products visualised on a 1% agarose gel (see Figure 7.3A). 
All transformants showed a clear band at -980 bp with roughly the same intensity.
Samples of the same cultures were taken after 3 days of induction and cell 
lysates were prepared. These lysates were analysed directly by 12% SDS-PAGE and by 
immunoblotting (see Figure 7.3B). In the latter case, the lysates were probed with 
mouse monoclonal anti-His6 antibody to locate His6-tagged recombinants. SDS-PAGE 
analysis showed many bands in all supernatants; however, bands representing the 
recombinant proteins could not be discerned from background proteins generated by P. 
pastoris. In the immunoblot analysis, both the 37 and 30 kDa bands reacted with the 
anti-His6 antibody in the rFheproCLl lysate (see Figure 7.3B, Lane 7); bands of 
approximately 37 kDa were reactive for each of the other lysates (see Figure 7.3B, 
Lanes 8 to 10). No anti-His6 reactive bands were present in the non-induced control 
(see Figure 7.3B, Lane 6). These reactive bands present in induced P. pastoris cell 
lysates correspond to those present in culture supernatants.
7.3 Gelatin-substrate activity of recombinant cathepsins LI and L2
The effect of pH on the activity of the two active recombinants, rFheproCLl and 
rFheproCL2, was first investigated by gelatin gel zymography. Samples of the fully
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Figure 7.3: Analysis of mRNA production and intercellular expression by P. pastoris. A, tolal RNA 
was extracted from P. pastoris cells transfoiTned with the various recombinants and induced for 4 days by 
1% methanol in BMMY medium buffered to pH 6.0. First strand cDNA was synthesised for each sample 
by RT-PCR using 1 (ig template. The cDNA was analysed by PCR with the FheCLIF and FheCLlR 
primers (see Table 2,1) and visualised on a 1% agarose gel. Lane M, 1 kb DNA ladder; lane 1, 
rFheproCLl ; lane 2, r[Pro l2Gly26]FheproCLl ; lane 3, rFheproCL2; lane 4, r[Gly2(,]FheproCL2. B, 
similar cultures were induccd for 3 days and cell lysates analysed. Pane! a, 12% SDS-PAGE gel of cell 
lysates; panel b, immunoblot of cell lysates probed with mouse monoclonal anti-His antibody; lane M, 
molecular size  markers; lanes I and 6, non-induced control; lanes 2 and 7, rFheproCÎLl ; lanes 3 and 8, 
r[P ro12Gly26]FheproCL 1 ; lanes 4 and 9, rFhcproCL2; lanes 5 and 10, r[Gly26]FheproCL2.
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mature enzymes, prepared by activation for 24 h, were analysed by 10% GS-PAGE with 
an overnight incubation in 0.1 M sodium acetate buffers, pH 4.0, 5.0, 6.0, 7.0 and 7.75 
in the presence of 1 mM DTT (see Figure 7.4). Of immediate note was the difference in 
separation between the two proteins. Under the non-reducing conditions of the gelatin 
substrate gel, the migration of mature cathepsin LI was very much slower than that of 
mature cathepsin L2, with the former running about 1/3 of the way into the gel and the 
latter running almost all the way to the bottom. It was also noted that mature cathepsin 
LI migrated as two distinct bands, normally unresolved on 12% SDS-PAGE gels. 
Mature cathepsin LI showed strongest gelatinolytic activity at pH 4.0, with a decrease 
in activity with increasing pH. Mature cathepsin L2 showed strongest activity at pH 
5.0, with good activity at all other pH values, including at the higher pHs of 7.0 and 
7.75 where CL1 activity had greatly reduced.
7.4 Determination of pH optima of recombinant cathepsins LI and L2
Next, pH activity profiles were generated by assaying the mature enzymes for 
activity against the fluorogenic substrate Z-FR-AMC in buffers at a range of pH values 
(see Figure 7.5). For both enzymes, a major peak of activity was found at pH 7.0, with 
a steady decrease in activity at higher pH values. In the case of mature cathepsin LI, a 
possible second peak was observed around pH 4.5. This peak may also be present to a 
lesser extent for mature cathepsin L2, although there was a clearer steady drop in 
activity below pH 7.0.
7.5 Substrate preference of recombinant wild-type cathepsins LI and L2
Substrate preferences of the two mature recombinant enzymes were investigated 
by assaying them for activity against a variety of fluorogenic substrates, with particular 
emphasis on the P2 position amino acid residues (see Figure 7.6). Both enzymes
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Figure 7.4: Gelatine gel zymography of recombinant wild-type cathepsins Lt and L2. Samples of 
24 h activated recombinants were analysed by 10% GS-PAGE with overnight incubations at 37°C in 
0.1 M sodium acetate buffers, pH 4.0, 5.0, 6.0, 7.0 and 7.75, containing 50 mM NaCl and 1 mM DTT. 
Lanes 1, mature recombinant cathepsin L I ; lanes 2, mature recombinant cathepsin L2.
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Figure 7.5: Activity profiles for recombinant proteins at varying pH values. 24 h activated 
recombinant cathepsin LI (A) and cathepsin L2 (B) were assayed tor activity against the fluorogenic 
substrate Z-FR-AMC in a range of buffers. Doited line, 0.1 M sodium acetate buffers, pH 3.0 to 6.0; solid 
line, 0.1 M sodium phosphate buffers, pll 5.5 to 8.0; dashed line, 0.1 M tris/HCI buffers, pH 7.5 to 10.5.
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Figure 7.6: Substrate preference of recombinant wild-type cathepsins LI and L2. Mature 
recombinant cathepsins LI (black bars) and L2 (white bars) were assayed for activity against a variety of 
fluorogenic substrates: Boc-VLK-AMC, Z-LR-AMC, Z-FR-AMC, Z-PR-AMC, Boc-VPR-AMC, 
Tos-GPR-AMC, Boc-AGPR-AMC, Tos-GPK-AMC, Z-R-AMC and Z-RR-AMC. Cathepsin L2 is noted 
to have a much greater preference for proline in the P2 position than cathepsin L I .
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showed strongest activity for substrates with leucine in the P2 position, particularly 
when coupled with arginine in the Pi position, as in the case of Z-LR-AMC. The next 
highest activity was against Z-FR-AMC, an activity characteristic of cathepsin L 
proteases. For peptides that included a proline in the P2 position, a clear difference was 
seen between the two enzymes. While mature cathepsin LI showed little or no activity 
against these substrates, mature cathepsin L2 showed good activity, ranging from 
between 20% and nearly 50% of the activity found against the most preferred substrate, 
Z-LR-AMC. Neither enzyme was active against the substrates Z-R-AMC or Z-RR- 
AMC as expected, again a characteristic feature of cathepsin L activity.
7.6 Collagen digestion by recombinant wild-type cathepsins LI and L2
Activity of recombinant cathepsins LI and L2 against interstitial materials was 
investigated by analysing their digestion of collagen as a representative structural 
protein. Collagen Types II and VI were incubated overnight in PBS, pH 7.3, with fully 
mature recombinant cathepsin LI or L2 (previously activated for 24 h). Samples of the 
collagen Type II mixes were analysed by 12% SDS-PAGE (see Figure 7.7) and 
displayed a marked difference in collagenolytic activity between the two enzymes. 
Mature cathepsin LI showed little activity against collagen Type II, while mature 
cathepsin L2 completely digested the collagen over the course of 24 h. In the case of 
collagen Type VI, samples were analysed by both 12% SDS-PAGE and on semi-native 
gels (see Figure 7.8). Both the enzymes showed similar patterns of degradation of this 
collagen, although mature cathepsin L2 progressed much further in this process over the 
course of 24 h.
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Figure 7.7: Digestion of collagen Type II by mature recombinant cathepsins LI and 12. Samples of 
collagen Type II (bovine nasal septum; 15 |_ig) were incubated with 0.5 |0,g mature recombinant enzyme or 
collagenase in PBS, pH 7.3, overnight at 37°C. Samples taken at various time points were analysed by 
12% SDS-PAGE. Lane M, molecular size markers; lane 1, collagen Type II in PBS as negative control; 
lanes 2, 5 and 8, collagen Type II digested with collagenase blend; lanes 3, 6 and 9, collagen Type II 
digested with mature cathepsin LI; lanes 4, 7 and 10, collagen Type II digested with mature cathepsin 
L2.
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Figure 7.8: Digestion of collagcn Type VI by mature recombinant cathcpsins LI and L2. Samples of 
collagen Type VI (basement membrane; 15 |ig) were incubated with 0.5 |ig mature recombinant enzyme 
or collagenase in PBS, pH 7.3, overnight at 37°C. Samples were analysed by 12% SDS-PAGE (A) and on 
semi-nalivc gels (B). Lane M, molecular size markers; lane I, collagen Type VI in PBS as negative 
control; lane 2, collagen Type VI digested with collagenase blend; lane 3, collagen Type VI digested with 
mature cathepsin LI Ja n e  4, collagen Type VI digested with mature cathepsin L2.
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7.7 Exogenous processing of inactive mutant cathepsin L is by activated wild- 
type cathepsins LI and L2
To further investigate the blocking of exogenous processing by the Leu'12->Pro' 
12 in the double mutant procathepsin LI, both mutant proteins were “cross-processed” 
by addition of 24 h activated rFheproCL2 in parallel with incubation with activated 
rFheproCLl as in previous experiments (see Figure 7.9). In this case it was found that 
rFheproCL2, which has a  high substrate preference for proline in the P2 position not 
present in cathepsin LI, was capable of processing the double mutant to a -25 kDa form 
co-migrating with that of the single mutant [Gly26]FheproCLl. It was also noted that an 
equal concentration of activated rFheproCL2 was capable of more fully processing 
[Gly26]FheproCLl over the course of the 3 h incubation than activated rFheproCLl.
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Figure 7.9: Exogenous processing of procathcpsin LI inactive mutants by active cathepsins L l and
L2. Purified r|GIy26]FheproCLl and r[Pro l2Gly26]FheproCLl were incubated for 3 h in 0.1 M sodium 
acetate buffer, pH 4.5, containing 2 mM DTT and 2.5 mM EDTA at 37°C in the presence of either 24 h 
activated rFheproCL I (A) or rFhcproCL2 (B). Mature CL2, which has a high substrate preference for 
proline in the P2 position, is capable of processing the rlPro i:Gly26]FheproCLI double mutant which 
remains unprocessed by mature cathepsin L 1.
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Chapter 8: Discussion
8.1 F. hepatica procathepsin LI and L2 and related cysteine proteases
Comparison of the two major F. hepatica cysteine proteases, cathepsins LI and 
L2, at the amino acid sequence level indicates a very close relationship between the two. 
The similarity of the amino acid sequences is very high at 92.63%, with the identity also 
high at 78.22% (see Section 3.1; also Table 3.3). Clearly, a significant commonality in 
function of the two enzymes within the parasite is likely. This high level of sequence 
identity is also responsible for cross reactivity of the enzymes with antiserum prepared 
against each other (see Figures 4.3 and 7.1).
A phylogenetic analysis of cathepsin L sequences from both F. hepatica and F. 
gigantica indicated that the sequences fall into 4 distinct clades. Of particular 
importance was that while three of these clades contained only sequences of cDNAs 
obtained from adult parasites, the fourth only contained sequences derived from 
metacercarial or newly excysted juvenile stage flukes (see Figure 3.2). It is therefore 
clear that there are stage-specific cathepsin Ls produced in both F. hepatica and F. 
gigantica. These data are supported by a previous phylogenetic analysis performed by 
Irving et al. (2003) in which the Fasciola sequences could be similarly divided into 4 
clades. However, the addition of further cathepsin L cDNA sequences to the analysis 
retains this division of three adult and one metacercarial group. Only 2 largely 
incomplete sequences and one complete sequence out of 31 total cDNAs did not fit 
easily into the groupings; in the former case, the data is insufficient to allow a reliable 
alignment; in the latter, the sequence may represent an intermediate between two of the 
adult groups.
Analysis of amino acid sequence alignments of the cathepsin L sequences within 
each group showed some characteristic features. Firstly, while the majority of the
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propeptide sequence matched closely for all enzymes, the C-terminal portion from 
residue -21 up to and including the 5th amino acid of the mature region showed distinct 
variation between groups (see Table 3.1). Most notably here, the Metacercarial Group 
proteins were unique in possessing an aspartate residue at position 1 of the mature 
region, contrasting with the alanine found in all three adult groups. This feature was 
also common to both F. hepatica and F. gigantica and may represent a characteristic 
signature of such early stage cathepsin Ls. Secondly, residues which have been 
implicated in subsite interactions by Turk et al. (1998) also display the grouping 
patterns between the different clades (see Figure 3.2). Three of these residues, at 
positions 70, 162, and 164, form part of the S2 pocket and are key to the determination 
of substrate specificity in cathepsin L (Smooker et al., 2000). These three residues are 
quite similar in Adult Groups 1 and 2, both of which contain Leu70 and Asn162 while 
Adult Group 1 contains Ala164 in contrast to Adult Group 2’s Gly164. Adult Group 3 and 
the Metacercarial group share Thr162 and Ala164, while Adult Group 3 contains Tyr70 in 
place of the Trp70 present in the Metacercarial Group. As can be seen here, the least 
variation is found between groups at position 163 while the greatest is at position 69. 
This later position is of significance as variation here directly specificity of the S2 
pocket; Smooker et al. (2000) demonstrated that mutation at this location from leucine 
to tyrosine in F. hepatica cathepsin L5 enhanced its activity against the substrate Tos- 
GPR-AMC 10-fold. This increased preference for proline in the P2 position has been 
shown previously (Dowd et al., 1994) and confirmed in this project (see Section 8.7) to 
be found in F. hepatica cathepsin L2 (an Adult Group 3 protease) but not in cathepsin 
LI (an Adult Group 1 protease). As cathepsin L5 belongs to Adult Group 2, it is 
possible that the Adult Group 1 and Group 2 proteases share substrate preferences to a 
certain degree, and mutation of Leu7 0 Tyr70 of FheCLl may also introduce the ability 
to cleave proteins with proline in the P2 position as has been shown for FheCL5. It is
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also likely that all members of the Adult Group 3 may share this broader substrate 
preference of FheCL2. The presence of Trp70 in the Metacercarial Group may allow an 
even broader range of residues to bind in the S2 pocket, allowing cleavage of a wider 
variety of proteins by the NEJ. Irving et al. (2003) demonstrate that it is the divergence 
between the Metacercarial Group and the 3 Adult Groups which would have occurred 
earliest, followed by the divergence of Adult Groups 1 and 2 from Group 3, and finally 
the divergence of Adult Group 1 from Group 2. This data would support the idea that 
the Fasciola cathepsin Ls started with a broad specificity and have steadily evolved 
tighter specificities over time; the groups would also reflect an increasing specificity of 
function as the parasite evolved alongside new host species.
Alignment of F. hepatica pre-procathepsin LI and L2 sequences with selected 
helminth and mammalian cathepsin Ls, along with papain, demonstrate that the proteins 
have closest links with the parasitic helminth, S. mansoni, followed by the free living 
nematode, C. elegans. They also match quite closely with the mammalian cathepsin Ls. 
These observations follow the pattern expected as the helminth cathepsin L lineages 
eventually gave rise to the mammalian cathepsins L, S and K (Dalton et al., 2004a).
The Fasciola enzymes are clearly true cathepsin Ls and represent a monophyletic group 
of enzymes in the parasite.
8.2 Expression of wildtype procathepsins LI and L2
In order to study the functional similarities and differences between F. hepatica 
cathepsins LI and L2 the recombinant proenzymes were expressed in the 
methylotrophic yeast, Pichia pastoris. Both enzymes had been previously expressed in 
our laboratory from full length pre-proenzyme sequences cloned into Saccharomyces 
cerevisiae (Roche et al., 1997; Dowd et al., 1997). However, it was decided to transfer 
these cDNAs into the P. pastoris system due to the benefits potentially achievable over
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the previous system; P. pastoris is capable of producing very high quantities of 
recombinant protein in a secreted form; it can be grown to very high levels of biomass, 
up to 50% of the total culture volume, without losses in recombinant production; finally, 
the organism secretes very low quantities of background native yeast proteins, reducing 
the need for multiple purification steps to obtain pure recombinant protein (Cereghino 
and Cregg, 2000; Brady et al., 2001; Aoki et al., 2003). With the presence of the yeast 
a-factor signal sequence within the chosen pPIC9K vector, only the cDNAs 
representing the proenzymes of FheCLl and FheCL2 were amplified from the original 
S. cerevisiae vectors and transferred to the new system, rather than the full pre­
proenzyme sequences. The incorporation of a C-terminal His6-tag sequence to each 
cDNA also allowed for a simple one-step purification of the secreted recombinant 
proteins from the yeast medium by Ni-NTA affinity chromatography.
After the construction of the pPIC9K.FheproCLl expression vector and its 
transformation into E. coli cells, samples of plasmid DNA from two clones confirmed to 
contain the FheproCLl cDNA insert were sequenced and both found to be correctly in 
frame with the a-factor signal sequence. However, when the sequence was compared 
by alignment with the original pre-procathepsin LI sequence deposited by our 
laboratory in the public database (GenBank sequence, U62288; Roche et al., 1997), 
several differences were found between the two. While a number of these changes were 
silent with respect to the database sequence, six were reflected in the amino acid 
sequence (see Section 3.2; also Figure 3.1). On replacement of the database sequence 
with the new sequence in the sequence analysis of F. hepatica and F. gigantica 
cathepsin Ls, the residue changes matched more closely with the related enzymes than 
the original sequence. As both clones also showed the same changes relative to the 
database in several parallel sequencing runs, it was assumed that the new sequence 
reflects a more accurate picture of the enzyme; errors may have been made in the
149
original sequencing procedure which have now been corrected with the better 
sequencing technologies available at this time.
Once three P. pastoris colonies transformed with the pPIC9K.FheproCLl were 
selected, pilot expression studies were carried out, with yeast cells induced for 6 days by 
1% methanol in BMMY medium buffered to pH 6.0, followed by SDS-PAGE analysis 
of the culture supernatants. All three cultures produced similar levels of recombinant 
proteins which migrated as two major bands of 37 and 30 kDa (see Figure 4.1). A final 
expression clone was selected from these three and the induction repeated, this time 
with the BMMY medium buffered at pH 6.0, 7.0, or 8.0. Again, two major proteins 
were secreted into the medium at 37 and 30 kDa (see Figure 4.2). Both components 
migrate higher than either the mature cathepsin LI or cathepsin L2 secreted by the adult 
F. hepatica parasites when the supernatants were compared with adult parasite 
excretory-secretory (ES) products on 12% SDS-PAGE (see Figure 4.3). However, 
immunoblotting experiments in which both the recombinant supernatant and adult ES 
products were probed with polyclonal antisera prepared against the propeptide portion 
and the mature portion of procathepsin LI showed that both react with the 37 and 30 
kDa components expressed in P. pastoris, confirming that both components are indeed 
two forms of procathepsin L. By contrast to this, the fully processed native enzymes 
secreted by the adult parasite only showed reactivity to the antiserum prepared against 
the mature portion of procathepsin LI, with no reactivity with the anti-propeptide 
antiserum (see Figure 4.3).
After purification of the two rFheproCLl components from yeast medium, TV- 
terminal sequencing analysis of each band revealed that the 37 kDa protein represented 
the full procathepsin LI (plus the last 6 amino acids of the yeast a-factor secretory 
signal sequence) while the 30 kDa component represented an intermediate form 
• • • • beginning at residue Leu’ of the propeptide. These results also confirmed that the
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molecular weights of the two components as previously estimated from the SDS-PAGE 
gel matched closely to the predicted average molecular weights of 36.74 and 29.62 kDa 
respectively. It could be assumed, therefore, that no post-translational modifications of 
the enzyme had occurred which may have caused the proteins to migrate more slowly 
within the gel; this was as expected due to the lack of glycosylation sites identified in 
the FheproCLl sequence.
The partial processing of the rFheproCLl to the intermediate form represented 
by the 30 kDa band was also clearly effected by the pH of the BMMY medium in which 
recombinant protein expression was induced; while the amount of recombinant protein 
produced in medium buffered to pH 6.0, 7.0, and 8.0 increased over the course of the 
induction to roughly the same levels, the relative ratio of the 37 and 30 kDa forms 
showed dependence on medium pH (see Figure 4.2). As medium pH increased, the 
proportion of unprocessed rFheproCLl represented by the 37 kDa band also increased. 
A pH profile of activity for the recombinant cathepsin LI (see Section 8.7) showed that 
it was similar to that of the native mature enzyme (Dowd et al., 1994; Dowd et al., 
2000); the enzyme is active over a pH range of 4.0 to 8.5, with a major peak of activity 
between pH 6.5 and 7.0. Therefore, the increase in the pH of the yeast medium beyond 
the pH optimum for FheCLl activity (i.e. to pH 8.0) reduced the level of processing of 
the rFheproCLl to the intermediate 30 kDa form, indicating some level of autocatalytic 
involvement in this processing.
In order to further address this issue, yeast cells transformed with 
pPIC9K.FheproCLl were induced at pH 8.0 in the presence and absence of the potent 
cathepsin L-specific inhibitor, Z-Phe-Ala-diazomethylketone (see Figure 4.4). The 
inhibitor was added twice daily at a concentration of 25 |o.M, a concentration which is 
250-fold greater than its K( for cathepsin L (Dowd et al., 1994; Higgins and Cregg, 
1998). The proportion of the full length rFheproCLl produced represented by the 37
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kDa band was considerably greater than that in uninhibited cultures, although the 
partially processed 30 kDa intermediate form was still evident. These data support the 
idea that rFheproCLl secreted from P. pastoris autoprocesses to an intermediate active 
form and that this autoprocessing is prevented by the inhibition of cathepsin L activity 
by the potent inhibitor Z-FA-CHN2.
The cathepsin L proteases of F. hepatica are active within the gut of the 
organism, where the environmental pH is estimated to be quite low, around pH 5.5 or 
slightly lower (Halton, 1997). As FheCLl maintains activity at this lower pH range and 
the previous inductions showed greater levels of processing from the full 37 kDa form 
of rFheproCLl to the 30 kDa intermediate form at pH 6.0 than at pH 7.0 or 8.0, a 
further induction of yeast cells at the lower pH of 4.5 as well as at pH 6.0 and 8.0 was 
carried out (see Figure 4.5A). In this case, reduction of medium pH to 4.5 caused 
almost complete elimination of the full 37 kDa component, indicating almost complete 
processing of the recombinant procathepsin LI to the 30 kDa intermediate form at low 
pH. It was also noted that a third, lower band was visible at pH 6.0 and pH 4.5. This 
band was more intense in the pH 4.5 sample and may represent either a further 
intermediate or the fully processed mature enzyme. These data confirmed the overall 
pattern of increasing levels of autoprocessing of rFheproCLl with decreasing pH.
Reductions in the temperature at which the yeast cultures were induced to 25°C 
and 20°C instead of the normal 30°C showed no effect on processing of the 
recombinant enzyme, although the clarity of the cultures was increased and the levels of 
background proteins and degradative products present decreased with decreasing 
temperature, especially in the presence of the Z-FA-CHN2 inhibitor (see Figure 4.5B). 
However, lower quantities of recombinant protein were produced at the lower 
temperatures.
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In order to further characterise and compare the recombinant F. hepatica 
cathepsin LI to the native enzyme, activity of the enzyme against the fluorogenic 
substrate Z-FR-AMC in the presence of varying levels of either the cysteine protease 
inhibitor Z-FA-CHN2 or a recombinant form of the FheCLl propeptide was assayed. 
Greater levels of inhibition occurred with the recombinant propeptide at lower 
concentrations than with Z-FA-CHN2 and at varying pH values (see Figure 4.9), 
confirming the high specificity of the propeptide for cathepsin LI.
The cDNA encoding procathepsin L2 was transferred to the P. pastoris 
expression system in a similar manner to procathepsin LI and confirmed to match the 
expected sequence (see Figure 3.4). Expression was induced in two 
pPIC9K.FheproCL2 transformed yeast clones in parallel with the pPIC9K.FheproCLl 
clone by 1% methanol in medium buffered to pH 6.0. Unlike rFheproCLl, rFheproCL2 
was produced almost entirely in the full length procathepsin L2 form migrating at 37 
kDa in SDS-PAGE (see Figure 5.1 A). Very little of the protein (only faint minor 
bands) was processed to lower forms such as the 30 kDa intermediate of rFheproCLl. 
Assays of supernatant samples against the fluorogenic substrate Z-FR-AMC showed 
much lower activity for rFheproCL2 supernatants compared with those containing 
rFheproCL2 (see Figure 5.IB). However, as the enzyme was almost entirely in the 
zymogen form and the activity of native cathepsin L2 against Z-FR-AMC is lower than 
that of cathepsin LI (Dowd et al., 1994), these results were consistent. Yeast cultures 
induced in medium buffered at pH 4.5, 6.0 and 8.0 produced roughly equal amounts of 
rFheproCL2, although with a slight increase in the level of processing observed with 
decreasing pH (see Figure 5.2). While this observation matches the pattern seen for the 
production of recombinant procathepsin LI at these pH values, it should be noted that 
the level of processing is still far lower for rFheproCL2 and the vast majority of the 
protein remains in the 37 kDa procathepsin form at all three pH values. This difference
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suggests that the recombinant wildtype procathepsin L2 is more stable in yeast medium. 
It is tempting to speculate that, as cathepsin LI is a member of the Adult Group 1 
Fasciola cathepsin Ls while cathepsin L2 is a member of the Adult Group 3 (see 
Section 8.1), differences in the propeptide sequences between these two groups may 
account for different stabilities of the zymogen forms and/or differential processing of 
the two recombinant enzymes in yeast medium. However, it is also possible that these 
observed differences are due to the effect of components of the yeast proteome during 
trafficking of the recombinants for secretion from the yeast cell.
8.3 Processing of wildtype procathepsins LI and L2
To further examine this intermolecular processing at pH values lower than 6.0, 
the 37 kDa and 30 kDa rFheproCLl components were purified from a pH 8.0 yeast 
culture supernatant by Ni-NTA affinity chromatography and dialysed against PBS, pH 
7.3. Samples of this purified protein preparation were then reduced to pH 5.0 by 
addition of 0.1 M sodium citrate buffer containing 1 mM DTT and 1.25 mM EDTA and 
incubated at 37°C for 2 h. Samples taken at various time points during the course of the 
incubation were analysed by SDS-PAGE. Over the course of the incubation, the 37 kDa 
procathepsin LI was processed to the 30 kDa intermediate form and then through 
various further intermediates to eventually give rise to a single peptide migrating at 24.5 
kDa (see Figure 4.6). This corresponded with a 5-fold increase in the enzyme’s activity 
against the fluorogenic substrate Z-FR-AMC.
iV-terminal sequencing analysis of the 24.5 kDa band revealed sequences of 
NRAVP and RAYPD, corresponding to the sequence starting just 2 and 1 amino acid 
residues from the start, respectively, and indicated that the 24.5 kDa band represented 
the fully mature cathepsin LI enzyme (see Figure 4.6). These results were compared 
with a control experiment in which the pH was not reduced, with the 0.1 M sodium
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citrate buffer replaced by PBS, pH 7.3. Here, the 37 kDa procathepsin LI was not 
processed at all, even to the 30 kDa intermediate form (see Figure 4.7). There was 
some breakdown of the 30 kDa intermediate form present in the preparation but no 
processing to the fully mature form. These data indicate not only the stability of the 
zymogen form of the enzyme at neutral pH but also the pH dependence of the 
autocatalytic processing of the proenzyme.
Similar experiments performed using purified recombinant procathepsin L2 
showed a pattern of autocatalytic processing to the mature active form of the enzyme 
closely matching that of procathepsin L I . Samples of purified protein were reduced to 
pH 4.5 by addition of 0.1 M sodium acetate buffer containing 1 mM DTT and 1.25 mM 
EDTA and incubated at 37°C for 2 h. Samples taken at various time points during the 
course of the incubation were analysed by SDS-PAGE. Over the course of the 
incubation, the 37 kDa procathepsin L2 was processed through various intermediates to 
eventually give rise to a single peptide migrating at 24.5 kDa (see Figure 5.3A), 
representing the fully mature active enzyme. This again corresponded with a 5-fold 
increase in the enzyme’s activity against the fluorogenic substrate Z-FR-AMC (see 
Figure 5.3B). A control experiment in which the pH was not reduced, with the 0.1 M 
sodium acetate buffer replaced by PBS, pH 7.3 showed no processing of the zymogen to 
the mature form under these conditions (see Figure 5.4); this again matches the 
observations for the processing of procathepsin L I .
o q  *3 o
The cleavage site between Gly' and Leu’ that generated the 30 kDa 
intermediate form of rFheCLl was of particular interest as it occurred within the Gly'42- 
Xaa-Asn-Xaa-Phe-Xaa-Asp’36 (papain numbering) motif which was previously found to 
play a pivotal role in the intermolecular processing of papain expressed in S. cerevisiae. 
Vernet et al. (1995) showed by random mutagenesis studies and by sequence 
comparisons of various papain-like cysteine proteases that the Gly'42 and Asp'36 (papain
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numbering) residues within this GJWSLYFZD motif were the most constrained and 
proposed that two cleavage sites between Gly’42-Leu'41 and between Ala'37-Asp'36 were 
of importance in proenzyme processing. The group considered the latter cleavage site 
» • • • to be more significant, as it was predicted to perturb the negative charge of the Asp’ 
residue (papain numbering), which is absolutely conserved in all non-cathepsin B-like 
cysteine proteases of helminth parasites, plants and mammals, including cathepsins L, S 
and K (Vernet et al., 1995; Tort et al., 1999). Studies of the crystal structure of human 
cathepsin L shows that this residue participates in an important salt bridge between the 
propeptide and the mature enzyme (Coulombe et al., 1996). In the case of both F. 
hepatica cathepsins LI and L2, the GANAF’ZD motif corresponds to the sequence Gly' 
-Leu-Asn-Gln-Phe-Thr-Asp" (FheCLl numbering), a sequence which is completely 
conserved in all F. hepatica and F. gigantica cathepsin L sequences with the exception 
of two members of the Adult Group 1 (see Section 8.1; also Figure 4.8); only FheCL6 
and FgiCL4 (see Table 2.2 for sequence details) differ, with Phe'35 replaced with Leu'35.
The Leu'41 (papain numbering) residue is also conserved in another helminth 
parasite cathepsin L sequence, that of S. mansoni CL2, as well as in that of the free- 
living helminth, C. elegans (see Figure 4.8). Thus, the Gly’42-Leu'41 (papain 
numbering) bond is preserved across these sequences and this implicates its importance 
in propeptide function in these helminths. However, these two residues are not 
conserved in mammalian sequences such as the cathepsin Ls of humans, mice and rats, 
where the glycine residue is replaced by either glutamate or alanine and the leucine 
residue is replaced by methionine (see Figure 4.8). This could suggest that these 
differences explain why an intermediate 30 kDa form of human cathepsin L was not 
observed in studies of its intermolecular processing (Menard et al., 1998). However, 
this is unlikely as McQueney et al. (1997) showed that a cleavage between Ala’42 and 
Met’41 (papain numbering) was involved in the intermolecular processing of an inactive
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mutant form of human procathepsin K by activated human cathepsin K. Therefore (as 
has been pointed out by Coulombe et al., (1996), while there may be a direct 
involvement of the final aspartate residue in the GZNZFZD motif in the pH-dependant 
processing of proforms of papain-like cysteine proteases, cleavage at other peptide 
bonds within this motif, such as is the case here in rFheproCLl, could influence the 
local charge state triggering processing through to the mature enzyme form.
8.4 Expression of inactive mutant procathepsin L is
In order to further study the intermolecular processing of the F. hepatica 
cathepsin Ls, an inactive mutant form of FheproCLl was prepared and expressed in the 
P. pastoris expression system. The activity of the enzyme was removed by replacement 
of the active site cysteine at position 26 with a glycine. Pilot expression studies of two 
transformed yeast colonies in medium buffered at pH 6.0 and 8.0 showed the 
recombinant protein secreted migrates as a single strong band in SDS-PAGE for both 
transformants and was unaffected by the pH of the medium. The inactive recombinant 
proteins were also produced in almost 4-fold greater quantities than the wildtype 
recombinant procathepsin LI in parallel inductions (see Figure 6.1). However, it was 
noted that while the protein produced by one clone co-migrated with the 37 kDa 
component of rFheproCLl, protein produced by the second clone migrated slightly 
higher in the gel (see Figure 6.1). Results of//-terminal sequencing analysis of the two 
proteins showed that both represented the complete procathepsin LI sequence (with the 
additional 6 amino acids of the yeast a-factor secretion signal sequence as found for the 
37 kDa component of rFheproCLl). However, sequencing of the cDNA of each clone 
indicated that the second, more slowly migrating mutant contained a mutation within 
the propeptide, resulting in the replacement of a leucine at position -12 with a proline.
It is presumably this mutation which leads to the protein’s slower migration, possibly by
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slightly altering the 3D structure of the propeptide. The double mutant r[Pro’ 
12Gly26]FheproCLl was included in further experiments to ascertain if this mutation 
within the propeptide would have any effect on exogenous processing of the protein.
As expected, neither inactive recombinant displayed activity when assayed against the 
fluorogenic substrate Z-FR-AMC.
Further insight into the differences and similarities of the F. hepatica cathepsin 
Ls could be obtained by the elucidation of the 3D structure of one or more of the 
enzymes. As the recombinant inactive procathepsin LI mutant, r[Gly26]FheproCLl, 
retains the full length propeptide, a large scale induction and purification of the protein 
was prepared in collaboration with Dr. Colin Stack in our laboratory. The purified 
protein was sent to Dr. Linda Brinen of the Fasciola Structural Biology Laboratory at 
UCSF, San Francisco, USA, for the determination of the 3D structure by X-Ray 
crystallography. A preliminary model (see Figure 6.10), demonstrates that the general 
structure compares well with that of the other cathepsin Ls and cathepsin L-like cysteine 
proteases; once completed, more detailed analysis of the protein structure will be 
possible.
A third inactive mutant, this time replacing the Cys26 of procathepsin L2 with 
Gly26, was prepared and expressed in the P. pastoris system. Although the protein is 
produced as a single band at around 37 kDa as expected for the full length procathepsin 
L2 form, it is produced in much lower quantities when compared with the previously 
prepared recombinant proteins in parallel expression cultures (see Figure 6.8). This is 
possibly due to integration of fewer copies of the cDNA into the P. pastoris genome, 
although analysis of the mRNA produced by the yeast during induction does not support 
this (see Section 8.7). The results of vV-terminal sequencing analysis of the expressed 
protein again confirmed that the band represented the full procathepsin L2 sequence, 
with the now expected addition of the last 6 amino acid residues of the yeast a-factor
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secretion signal sequence. Lack of activity of the protein was confirmed in assay 
against the fluorogenic substrate Z-FR-AMC. Attempts were made to produce the 
protein at a large enough scale and high purity for the determination of the crystal 
structure but were unsuccessful; the larger quantities of culture needed to produce this 
protein compared with the previous recombinants greatly increased the amount of 
downstream processing required, including the addition of a concentration step; the 
extra time and handling involved may have caused the partial degradation of the protein, 
reducing its suitability for X-Ray crystallography. However, further work is ongoing in 
the laboratory to obtain clones which express r[Gly26]FheproCL2 in higher quantities 
more comparable with the other recombinants.
8.5 Exogenous processing of inactive mutant procathepsin Lis
When incubated in parallel with rFheproCLl at pH 5.0, neither the inactive 
mutant r[Gly26]FheproCLl nor the double mutant r[Pro'12Gly26]FheproCLl processed to 
lower molecular size forms (see Figure 6.2). Experiments were performed in which 
each of the purified inactive recombinant proteins were mixed with activated mature 
rFheCLl. In the case of r[Gly26]FheproCLl, addition of activated rFheCLl at pH 5.0 
resulted in the progressive appearance of a minor band at around 35 kDa along with a 
major band at around 25 kDa that co-migrates with fully active cathepsin LI (see Figure 
6.3 A) over a 4 h incubation period. In contrast to this, similarly prepared double mutant 
r[Pro‘l2Gly26]FheproCLl showed no substantial processing, only slightly shifting over 
the course of the incubation to more closely match the migration of the 37 kDa 
component of wildtype procathepsin LI (see Figure 6.3B). These patterns were 
unaffected by lowering the pH of the incubation mix to 4.0 or 3.0 (see Figure 6.3C). 
Furthermore, experiments in which activated wildtype cathepsin LI was added to heat- 
denatured mutant procathepsin LI showed that the latter was sensitive to complete
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degradation by active cathepsin LI and confirms that the expressed mutant is correctly 
folded (see Figure 6.4).
//-terminal sequencing of the components produced shed further light on the 
exogenous processing of the inactive mutants. While no result was obtainable for the 
~35 kDa component arising from r[Gly JFheproCLl, the lower ~25 kDa component 
had a sequence of HGYPY (with less than 10% GVPYE), placing the cleavage site 10 
amino acid residues prior to the //-terminus of mature cathepsin L I. In the case of the 
double mutant r[Pro'12Gly26]FheproCLl, a mixture of several sequences was found 
corresponding to the early residues of the propeptide (see Figure 6.5). This data 
indicates that while the exogenously added wildtype cathepsin LI was incapable of 
processing the double mutant, it was capable of sequentially degrading the mutant from 
the //-terminus, removing the remains of the yeast a-factor secretion signal sequence as 
well as the first few residues of the propeptide. A low preference for proline in the P2 
position may be responsible for this lack of cleavage (see Section 8.7).
An overview of the cleavage sites observed in all the processing experiments 
involving both autoactivation of wildtype procathepsin LI and the intermolecular 
processing of the inactive mutants by exogenously added active cathepsin LI, along 
with those previously determined for the native mature cathepsin LI secreted by F. 
hepatica parasites in vitro is shown in Figure 6.5. It is clear from these data that 
autoactivation and intermolecular activation occur by cleavages at different sites and 
thus processing of procathepsin LI to an active enzyme may be achieved by more than 
one pathway. It should be noted that the location of the Leu->Pro mutation at position - 
12 in the double mutant is in close proximity to the cleavage point (Ser'n -His'10) which 
occurs when the single mutant r[Gly26]FheproCLl is exogenously processed by active
wildtype cathepsin L I . Further to this, the portion of the propeptide immediately prior
* 12 * • • • • to and including Leu' corresponds in alignments to the location in human procathepsin
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L of a short two-stranded antiparallel P-sheet formed with the mature region (between 
Lys'14-Phe' 12 and Phe112-Asp114, human cathepsin L numbering), stabilising the 
propeptide as it leaves the active site cleft (Coulombe et al., 1996). This region of the 
propeptide may therefore be a target for intermolecular processing.
Also of particular note is the absence of a cleavage site within the GA’N.A’F.A’D 
motif that would generate the 30 kDa intermediate component by exogenous activation 
of r[Gly26]FheproCLl. As has been demonstrated already (see Section 8.3), this 
cleavage site is dominant in yeast-expressed rFheproCLl and the strict conservation of 
the motif suggests an important role in the processing of the procathepsin Ls of F. 
hepatica. Vemet et al. (1995) demonstrated the importance of this motif in papain 
processing by using various mutations within the GANJiFZD sequence; certain residue 
replacements prevented correct folding of the enzyme, preventing activity, while others 
prevented full processing of the enzyme, leaving inactive or partially active 
intermediates. The remaining portion of the propeptide towards its C-terminal which is 
further processed from the 30 kDa form to the mature form in rFheproCLl is less 
structured and more easily accessible to proteases, as shown by the crystal structures of 
human procathepsin L (Coulombe et al., 1996) and cathepsin B (Turk et 1996; 
Podobnik et al., 1997). This can also be seen in the collective data which shows that 
papain (Vemet et al., 1995), cathepsin L (Coulombe et al., 1996), cathepsin B (Turk et 
al., 1996; Podobnik et al., 1997), cathepsin S (Quraishi and Storer, 1998), and cathepsin 
K (McQueney et al., 1997) can all be activated to mature enzymes either by cis- or 
trans-cleavage at various bonds within this region of the propeptide. Also, the 
cathepsin B of the related helminth parasite S. mansoni can be similarly activated (Lipps 
et al., 1996; Sajid and McKerrow, 2002). However, the sites of cleavage of the wild- 
type and mutant procathepsin LI differed suggesting that prior cleavage within the 
GJH\LZFZD motif of the wild-type enzyme may have altered the accessibility of the
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C-terminus to protease action. Also clear is that additional amino acid residues are left 
by both processing pathways at the //-terminus of the mature enzyme, unlike in the 
mature cathepsin LI present in adult F. hepatica ES products which is fully processed 
to the characteristic //-terminal residue. It is therefore possible that an additional 
protease, such as an exopeptidase, may be required to remove these additional amino 
acids.
8.6 Secretion of cathepsin L proteases by F. hepatica parasites
The two major cysteine proteases of F. hepatica, cathepsins LI and L2, are 
secreted when the adult parasite is maintained in vitro and were previously characterised 
in our laboratory (Smith et al., 1993a; Dowd et al., 1994). //-terminal sequencing of 
both these enzymes indicated that they were secreted as fully mature cathepsin L 
enzymes. Immunoblotting experiments in which adult F. hepatica ES products were 
probed with antisera prepared against purified mature cathepsin LI and recombinant 
CL1 propeptide demonstrated that while both react strongly with the anti-mature 
antiserum, neither enzyme reacts with the anti-propeptide antiserum (see Figure 7.1; see 
also Figure 4.3). Comparison of the amino acid sequences of the two enzymes show a 
high level of identity of 78.22% (see Section 8.1), explaining their cross-reactivity with 
antiserum prepared against either enzyme seen here and in other studies (Roche et al., 
1997; Dowd et al., 1994). Together, these data confirm that the enzymes are secreted in 
a fully processed form.
F. hepatica cathepsins LI and L2 belong to a phylogenetic lineage which 
includes the mammalian cathepsin Ls and have substrate specificities that are typical to 
this group; both have a preference for positively charged residue side chains, such as 
arginine, in the Pi position and bulkier hydrophobic side chains, such as phenylalanine 
and leucine, in the P2 position, as evidenced by their characteristic breakdown of the
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fluorogenic substrate Z-FR-AMC (Coulombe et al., 1996; Dowd et al., 1994).
However, they differ from their mammalian counterparts in their ability to exhibit 
activity over a wide pH range, between pH 4.0 and 8.5, and remain stable at neutral pH. 
While human cathepsin L loses all activity after just 20 min of incubation at pH 7 and 
37°C, the F. hepatica cathepsin Ls retain most of their activity after 24 h in the same 
conditions (Dowd et al., 2000). It has been suggested that this enhanced stability is 
important in the digestion of host proteins within the parasite gut and in the migration of 
the parasite through host tissues such as the intestine and liver (Dalton et al., 2003).
With the obvious importance of the cathepsin L proteases to F. hepatica, it is of 
great interest to examine how and where the enzymes are produced and secreted by the 
parasite before their appearance in the ES products. Previous immunolocalisation and 
in situ hybridisation studies have shown that the F. hepatica cathepsin L proteases are 
synthesised within the gastrodermis that lines the parasite gut (Smith et al., 1993a; 
Dalton et al., 2003). The gastrodermis is composed of epithelial cells that are columnar 
in shape and contain large numbers of dense vesicles, referred to as secretory vesicles, 
situated at the apical end (see Figure 7.2A). Despite being secretory in function, these 
vesicles have long been described as similar to lysosomes and have been suspected for 
almost thirty years to contain proteases of some form (Halton, 1967; Robinson and 
Threadgold, 1975; Halton, 1997). As part of this study, immunofluorescence and 
immunelectron microscopy experiments were carried out by Dr. Aaron Maule’s 
laboratory at Queen’s University, Belfast, UK, using the anti-propeptide and anti- 
mature cathepsin LI antisera from our laboratory (Collins et al., 2004). Confocal laser 
immunocytochemistry using the native mature cathepsin L antiserum demonstrated that 
the proteases are located to the gastrodermal epithelial cells through the gut of adult F. 
hepatica (see Figure 7.2B). This labelling appeared punctate and was more dense 
towards the apical end of the gastrodermal cells, suggesting that the enzymes are
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associated with the secretory vesicles (see Figure 7.2C). Further experiments using 
immunoelectron microscopy revealed that the cathepsin L proteases are indeed stored 
within the secretory vesicles (see Figure 7.2D-F). Also, the secretory vesicles were 
strongly immunoreactive with both the antiserum prepared against the recombinant 
cathepsin LI propeptide (see Figure 7.2E) and the anti-mature cathepsin L antiserum 
(see Figure 7.2F). This dual labelling demonstrates that the enzymes are present in the 
secretory vesicles in the inactive procathepsin L zymogen form.
The above observations provide important insights into the regulation of 
cysteine protease activity within the gastrodermis of F. hepatica. Firstly, these 
observations are in agreement with those of Halton and co-workers (Halton, 1967; 
Halton, 1997), as it appears that the function of the secretory vesicles is to package 
proteolytic enzymes for delivery into the gut lumen. Secondly, it makes good sense for 
the enzymes to be accumulated in the secretory vesicles in the inactive precursor form 
rather than as active mature enzyme given the high abundance of the vesicles in the 
epithelial cells and the accompanying possibility of protease leakage into the cytoplasm. 
Finally, in combination with the data on the in vitro processing of these two enzymes 
discussed above (see Sections 8.2 and 8.3), these observations suggest that the 
processing and activation of the procathepsins LI and L2 takes place following the 
secretion of the zymogen into the gut lumen.
Electron microscopy has shown that the contents of the secretory vesicles are 
extruded into the gut lumen where they mix with the ingested blood and tissue meal 
between the long extruding lamellae (Robinson and Threadgold, 1975; Halton, 1997). 
Briefly, the epithelial cells lining the gastrodermis go through a cyclical pattern of 
changes between a secretory phase, where the Golgi-apparatus is active and there are 
large numbers of secretory vesicles, and an absorptive phase, characterised by more 
numerous surface lamellae and the release of the contents of the secretory vesicles into
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the gut (Robinson and Threadgold, 1975; Halton, 1997; see also Figure 8.1). Across the 
surface of the gastrodermis, both processes occur simultaneously, within adjacent cells 
at different points in the cycle at any one time (Halton, 1997). As the pH of the gut is 
estimated to be around 5.5 or slightly lower (Halton, 1997) and the in vitro activations 
of both FheproCLl and FheproCL2 to the mature form occur best around pH 4.0-5.5 
(see Sections 8.2 and 8.3), it seems likely that this is the location of enzyme activation. 
The enzymes could immediately begin functioning in protein catabolism on activation 
as it would be in direct contact with the bloodmeal within the gut.
F. hepatica, like other helminth parasites, has a blind-ending gut and removal of 
undigested products and accumulated waste, such as haematin, occurs by the simple 
voiding of the gut contents approximately every 3 h (Halton, 1997). Active mature 
cathepsins LI and L2 would therefore be regularly liberated from the gut of the parasite 
into the surrounding intestinal or hepatic tissues allowing them to perform their other 
external functions, such as tissue degradation facilitating the movement of the parasite 
through host tissues (Halton, 1997; Fairweather et al., 1999). The enhanced stability of 
these enzymes would allow for high concentrations over long periods needed to digest 
native matrix proteins such as collagens (see Figures 7.7 and 7.8).
The pattern of storage, secretion, and activation of the F. hepatica procathepsins 
contrasts quite dramatically with the pattern found with the mammalian procathepsin 
Ls, which are trafficked through the Golgi apparatus to acidic lysosomes in which the 
processing to the mature active enzyme form occurs (Coulombe et al., 1996; Menard et 
al., 1998). However, there are some examples which show similarity to the situation in
F. hepatica', low levels of procathepsin L are known to be secreted from normal cells, 
playing a role in extracellular processing (Ishidoh and Kominami, 1998); high levels of 
secretion have been correlated with the metastatic activity of transformed cells (Lorenzo
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Figure 8.1: Schematic diagram of the gut cell in Fasciola hepatica. A, epithelial cell of the
gastrodermis in the secretory phase, with active Golgi apparatus and numerous secretory vesicles towards 
the apical end containing the cathepsin Ls. B, epithelial cell in the absorptive phase, with an increase in 
the number of surface lamellae and the release of the contents of the secretory vesicles into the gut lumen. 
Adapted from Halton (1997).
B
surface lamellae
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et al., 2000; Guillaume-Rousselet et al., 2002). Similarly, the eathepsin-L like cysteine 
protease, cathepsin K, is secreted in humans by osteoclasts and has a function in bone 
resorption (Shi et al., 1995; Drake et al., 1996; McQueney et al., 1997). In this case, 
osteoclasts adhere to the bone surface and form an extracellular compartment, known as 
an absorption pit, between the cell and bone into which cathepsin K is secreted. The pH 
within this pit is slightly acidic and is considered to be important for both the 
dissolution of the bone and the activation of procathepsin K to the active mature form 
(Shi et al., 1995; Drake et al., 1996). Further comparisons can be made with 
mammalian cathepsins B, K, and L, which have been shown to be secreted into the 
extracellular lumen of thyroid follicles and play a role in the proteolytic processing of 
covalently cross-linked soluble thyroglobulin to liberate the thyroid hormone thyroxine 
(T4) (Tepel et al., 2000; Friedrichs et al., 2003).
8.7 Comparison of recombinant wildtype cathepsins LI and L2
Comparison of the levels of expression of each of the recombinants produced in 
parallel cultures (see Figure 6.8) indicates that, with the exception of the inactive mutant 
procathepsin L2, roughly equal quantities of protein are produced for each of the 
wildtype recombinants, rFheproCLl and rFheproCL2, while larger amounts are 
produced for the inactive mutant procathepsin Lis. Analysis of the mRNA produced 
during parallel induction experiments, however, shows no discernible difference in 
levels of specific recombinant mRNA as a proportion of the total poly A+ mRNA 
produced (see Figure 7.3A); it is possible, therefore, that sequence differences between 
the recombinant transcripts may affect levels of translation and/or secretion of the 
proteins. Analysis of cell lysates from the same parallel cultures indicate that some 
protein is retained within the cells, although the level is small and is only detectable by 
immunoblot with a mouse monoclonal anti-His6 antibody (see Figure 7.3B). The bands
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visualised for each recombinant on immunoblot match those which occur for the 
secreted proteins present in yeast medium supernatant. This observation indicates that 
some processing of the two wildtype procathepsin Ls may occur during trafficking 
within the cells before secretion into the medium.
The effect of pH on the activity of active mature rFheCLl and rFheCL2 was 
investigated by two methods; determination of the pH optima of the enzymes in assay 
against the characteristic fluorogenic substrate Z-FR-AMC and migration and activity in 
gelatine substrate gels (GS-PAGE). The pH profile of activity for the recombinant 
mature cathepsin LI showed that it was similar to that of the native mature enzyme 
(Dowd et al., 1994; Dowd et al., 2000); active rFheCLl was active over the pH range of 
3.5 to 8.5 with highest levels of activity at pH 6.5-7.0 (see Figure 7.5). Interestingly, a 
second peak of activity was found at a pH of 4.5, in the region of pH values at which the 
zymogen form has been shown to autoactivate. It is possible, therefore, that a small 
amounts of processed active CL1 are responsible for accelerated processing of 
procathepsin Ls. However, this second peak was not found to occur for active 
rFheCL2, and may only have a small effect. Overall, rFheCL2 displayed a clearer 
pattern of activity, with a clear peak of activity at pH 7.0. Gelatinolytic activity was 
visible across a wide pH range for both enzymes, with highest activity occurring in gels 
incubated at pH 4.0 and 5.0 for rFheCLl and rFheCL2 respectively. It should be noted 
also that rFheCL2 retained strong gelatinolytic activity at the higher pH values of 7.0 
and 7.75, where little activity was detected for rFheCLl at pH 7.0 and none was found 
at pH 7.75 (see Figure 7.4). Also observed was a major difference in the migration of 
the two proteins; while mature CL2 migrated as a single band almost all the way to the 
bottom of the gel, mature CL1 migrated much more slowly, only about 1/3 of the way 
into the gel, in two bands. Clearly, as the GS-PAGE gels are effectively run under 
native conditions and separation is based on charge rather than size, there is a difference
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in the overall charge of the two mature proteins. Also, while both enzymes were 
activated in parallel over the course of 24 h to form only one band visible on SDS- 
PAGE each, CL2 may be more efficiently producing its mature form while CL1 is 
retaining one or two amino acids of the propeptide at the //-terminal, leaving a mixture 
of two mature forms of almost identical size (making them visually inseparable on SDS- 
PAGE) with slightly differing charges (making them separately visible on GS-PAGE). 
The differences between the amino acid sequences of each enzyme immediately prior to 
the TV-terminal of the mature peptide are possibly responsible for this differential 
cleavage.
Substrate preference of the two recombinant enzymes was investigated by 
comparison of their activity in assays against various fluorogenic peptide substrates (see 
Figure 7.6). Strong activity of both enzymes against Z-FR-AMC and no activity against 
Z-R-AMC and Z-RR-AMC provided the characteristic cathepsin L activity expected. In 
agreement with previous analyses (Dowd et al., 1994), the activity of cathepsin L2 
against Z-FR-AMC was approximately half that of CL1. Unlike human cathepsin L 
(Lecaille et al., 2002), high levels of activity were found for both F. hepatica cathepsin 
Ls against substrates with leucine in the P2 position, with the higher activity against Z- 
LR-AMC for both enzymes than for any other substrate tested. However, this 
additional preference for leucine in the P2 position has also been shown in the cathepsin 
Ls of another helminth parasite, S. mansoni (Brady et al., 2000). Of particular note was 
the difference in preference between the two enzymes against substrates with proline in 
the P2 position; while CL1 showed very low levels of activity against these substrates, 
CL2 showed between 2- and 10-fold more activity against them, particularly when 
coupled with glycine in the P3 position, such as in Tos-GPR-AMC and Boc-AGPR- 
AMC. This data is in agreement with previous results obtained in our laboratory (Dowd 
et al., 1994).
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This greater preference for proline in the P2 position is also found in human
• • 67cathepsin K. Lecaille et al. (2002) have shown that replacement in cathepsin K of Tyr
• * 67(human cathepsin K numbering) with Leu as found in human cathepsin L alongside a
70S 70Smutation of Leu ->Ala altered its pattern of substrate preferences to more closely 
match those of cathepsin L; most notably, the mutations removed cathepsin K’s 
preference for proline in the P2 position and greatly enhanced its preference for 
phenylalanine here. The Tyr6 7 Leu67 (human cathepsin K numbering) corresponds to 
the presence of Tyr70 in FheCL2 and Leu70 in FheCLl which causes a similar alteration 
in substrate specificity (see Section 8.1). However, FheCL2 still retains a high 
preference for both leucine in the P2 position (found in human cathepsin K but to a 
lesser extent in human cathepsin L) and phenylalanine (found in human cathepsin L but 
not human cathepsin K) here. These data suggest that FheCL2 may possess a cathepsin 
K-like activity in addition to its cathepsin L activity, rather than in place of it.
Cathepsin K is known to have a collagenolytic activity (Kafienah et al., 1998; Hou et 
al., 2001; Hou et al., 2003). Collagens contain numerous proline residues, so the 
preference of F. hepatica cathepsin LI for proline in the P2 position may indicate a 
function in collagen degradation similar to that of human cathepsin K. Collagenolytic 
activity of both recombinant F. hepatica cathepsin Ls was assayed against collagens 
Type II (from bovine nasal septum) and VI (from basement membranes) (see Figures
7.7 and 7.8). In both cases, active mature cathepsin L2 demonstrated greater 
collagenolytic activity over the course of 24 h compared to cathepsin LI; cathepsin L2 
breakdown of both collagen types was comparable to that of a commercial collagenase 
blend. The greater ability of F. hepatica cathepsin L2 to cleave collagen suggests it 
may have a more prominent function in aiding the migration of the parasite through the 
host tissues of the intestine and the liver compared to cathepsin LI.
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• • 12 12As has been discussed above (see Section 8.5), a mutation of Leu’ ->Pro‘
within the propeptide of one of the F. hepatica inactive procathepsin LI mutants 
prevented its intermolecular processing to lower molecular size forms by exogenously 
added active recombinant cathepsin LI, with cleavage only of the first few amino acid 
residues achieved. The substrate preference assay results above demonstrate that while 
both FheCLl and FheCL2 can cleave substrates with leucine in the P2 position, only 
FheCL2 possesses any substantial ability to cleave substrates with proline here. 
Intermolecular processing experiments involving the double mutant r[Pro’ 
12Gly26]FheproCLl were repeated to include incubation with exogenously added active 
mature rFheCL2 in parallel with active mature rFheCLl (see Figure 7.9). Unlike 
cathepsin LI, cathepsin L2 was capable of processing the proline containing mutant 
cathepsin LI to the mature form over the course of a 3 h incubation. Cathepsin L2 was 
also capable of more fully processing the single mutant r[Gly26]FheproCLl over the 
course of these parallel experiments than cathepsin L I. Both these results further 
demonstrate in practical terms the broader substrate specificity of cathepsin L2, as well 
as the possible key role of position -12 for the intermolecular processing of cathepsin
The large family of cathepsin Ls found in the Fasciola spp. is in contrast to the 
small numbers of cathepsin Fs so far discovered for the trematodes P. westermani and
C. sinensis (see Figure 1.3; also Dalton et al., 2005). The cathepsin Fs of both P. 
westermani and C. sinensis have similar functions, namely the facilitation of migration 
through the host and acquisition of nutrients by the hydrolysis of haemoglobin and 
collagens (Park, H. et al., 2001; Park, S. Y. et al., 2001; Park, H. et al., 2002; Shin et al., 
2005). However, the P. westermani and C. sinensis cathepsin Fs are much more closely 
related to each other than to members of the Fasciola cathepsin L clade, indicating a 
corresponding greater conservation of these functions between the enzymes (Park et al.,
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2002; Kang et al., 2004). While the cathepsin Fs of these species have not greatly 
diversified over time, the cathepsin Ls of the Fasciola spp. have evolved into distinct 
groups with increasing levels of specificity and therefore of functional capability. In the 
case of the Schistosoma spp., both cathepsin Ls and a cathepsin F have been identified 
(Day et al., 1995; Dalton et al., 1996; Brindley et al., 1997; Brady et al., 2000), although 
again there is no large diverse group of cathepsin L-like proteases as found for the 
Fasciola spp. Therefore, the cathepsin L-like cysteine proteases of the Fasciola spp. 
have evolved separately from those of the other major trematode parasite species.
The differing substrate specificities found here for F. hepatica cathepsins LI and 
L2 demonstrate some of this evolved diversity of function. Cathepsin L2, belonging to 
the evolutionarily older Adult Group 3 enzyme (see Section 8.1; also Irving et al.,
2003), possesses a wider substrate specificity with a greater ability to accept proline 
residues in the S2 subsite. This allows it to more efficiently cleave collagens and 
indicates a greater role for cathepsin L2 in facilitating the migration of the parasite 
through host tissues than for cathepsin L I . Cathepsin LI, as an evolutionarily younger 
Adult Group 1 enzyme (see Section 8.1; also Irving et al., 2003), is more specific in its 
substrate preferences, indicating a development for more specialised functions within 
the parasite. Cathepsin LI may therefore have greater involvement in processes such as 
cleavage of immunoglobulins and immunomodulation by suppression of the host ThI 
response, as has been seen in experiments with bacterial co-infections in laboratory 
animals (Brady et al., 1999; O’Neill et al., 2000; O’Neill et al., 2001). This 
specialisation and diversity of function within the Fasciola cathepsin L family has not 
been observed in the other trematode parasite species.
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8.8 Summary and conclusions
Given the importance of cathepsin L proteases in the virulence of F. hepatica 
and other helminth pathogens it is important to understand the mechanisms of their 
synthesis, processing and activation.
A large number of nucleotide and protein sequences have been deposited in the 
online databases representing cathepsin Ls of both F. hepatica and F. gigantica. In this 
project, these enzymes have been shown to form four major clades in phylogenetic 
analyses; 3 Adult Groups and 1 Metacercarial Group. There are distinct features of the 
propeptides of each group and the residues responsible for S2 subsite specificity (Turk et 
al., 1998; Smooker et al., 2000) also fall into the four clades, indicating diversity of 
function among the Fasciola cathepsin Ls. A pattern of evolving specialisation of these 
enzymes can be seen.
Although recombinant versions of the two F. hepatica cathepsin Ls studied here 
have been produced previously in Saccharomyces cerevisiae (Dowd et al., 1997; Roche 
et al., 1997), it was decided to transfer the genes to vectors suitable for the Pichia 
pastoris yeast expression system. This system can provide larger quantities of secreted 
recombinant from high concentrations of biomass and can allow easier, one-step 
purification due to its low levels of background native protein secretion (Cereghino and 
Cregg, 2000; Brady et al., 2001; Aoki et al., 2003). The larger quantities of protein 
have been used for various characterisation studies and for collaborative work with 
other laboratories.
As has been noted already, the propeptides of several members of the papain 
superfamily have been shown to contain autocatalytic cleavage sites (Ishidoh and 
Kominami, 1994; Menard et al., 1998; Quraishi and Storer, 2001), most notably the 
well conserved GANATZD motif (Vernet et al., 1995). In this study, the transport and
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processing of Fasciola hepatica cathepsin LI and L2 both in vivo and in vitro was 
investigated using the recombinant proenzymes.
Intermolecular processing was studied by generating inactive procathepsin L 
mutants, where the catalytic cysteine residue at position 26 was substituted with a 
glycine, which was incapable of autoactivation. The results show that P. pastoris- 
expressed cathepsins LI and L2 can autoactivate in low pH conditions to an active 
intermediate form by an initial cleavage within the conserved heptapeptide (Gly-Xaa- 
Asn-Xaa-Phe-Xaa-Asp), as previously described for papain (Vernet et al., 1995).
Further activation of the enzyme occurs by cleavage in the vicinity of the yV-terminus. In 
contrast, intermolecular processing of the mutant inactive procathepsin Ls to a mature 
product by exogenous mature cathepsin L did not involve the formation of the above
intermediate but was initiated by a direct cleavage close to the V-terminus.
■ • • • • 12Further to this, a second cathepsin LI inactive mutant, in which Leu’ of the
propeptide Was replaced with Pro'12 in addition to the Cys26->Gly26 mutation was 
generated serendipitously and shed further light on the processing and substrate 
specificity of the two enzymes. Exogenous processing studies show that this mutation 
prevents proper processing of the mutant by cathepsin LI, but not by cathepsin L2, 
indicating variations in specificity, and therefore function, between the two enzymes.
It has been previously shown in our laboratory that the cathepsins LI and L2 are 
secreted by F. hepatica and therefore function extracellularly, (Smith et al., 1993a; 
Dalton et al., 2003) in a similar manner to the mammalian cathepsin Ls involved in the 
processing of the hormone thyroglobulin (Tepel et al., 2000; Friedrichs et al., 2003). In 
this project, antibodies against both the mature and propeptide regions of the F. 
hepatica cathepsin Ls were employed in confocal laser and electron 
immunocytochemistry studies to show that the enzymes are stored in secretory vesicles 
of the gastrodermal epithelial cells in their inactive proenzyme forms. It is suggested
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that the inactive zymogens are released from the secretory vesicles into the gut, where 
they are processed to the mature active form by autocatalytic means at the low pH of the 
gut environment.
Differences in substrate specificity were further examined by investigating the 
activity of the recombinant cathepsins LI and L2 against various fluorogenic substrates. 
These showed a marked difference, with cathepsin L2 displaying the ability to cleave a 
larger range of substrates, particularly those containing proline in the P2 position. This 
ability is a feature of human cathepsin K, which is known to have collagenolytic 
activity. The recombinant enzymes were compared in their ability to cleave native 
structural proteins, with collagens used as examples of such proteins. While cathepsin 
LI does show some collagenolytic activity, cathepsin L2 is far more efficient, more 
comparable to a commercial collagenase. It is therefore suggested that cathepsin L2 
possesses a cathepsin K-like activity in addition to, but not in place of, its cathepsin L 
activity and may play an important role in migration of the parasite through host tissues.
The data obtained in this study provides a mechanism by which F. hepatica 
synthesizes and secretes two fully activated proteases that are essential to its existence 
as a parasite, and demonstrates differences in function between divergent groups of 
cathepsin Ls which have evolved in F. hepatica.
8.9 Related collaborative work
The production of large quantities of purified recombinant F. hepatica 
cathepsins LI and L2 has allowed several collaborative studies both within and outside 
of our laboratory. As well as the immunolocalisation and in situ hybridisation studies 
performed as part of this project, work has been performed in collaboration with Dr. 
Aaron Maule and his laboratory in Queen’s University, Belfast, UK, to investigate the 
role of F. hepatica cathepsin Ls in the processing of neuropeptides within the nervous
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system of the parasite. Work is ongoing to elucidate the 3D structures of both cathepsin 
LI and L2 by X-Ray crystallography in collaboration with Dr. Linda Brinen of the 
Fasciola Structural Biology Laboratory at UCSF, San Francisco, USA. Recombinant 
FheproCLl has been used in the analysis of a novel multi-domain member of the 
cystatin superfamily recently identified in the laboratory of Dr. Nathalie Moiré of the 
Université François Rabelais, Tours, France (Khaznadji et al., 2005, in press). The 
recombinant enzymes are also being used in ongoing experimental vaccine trials with 
Dr. Grace Mulcahy of the Department of Veterinary Microbiology and Parasitology at 
University College Dublin and Dr. Sandra O’Neill of the School of Nursing, Dublin 
City University. Mutation studies on the F. hepatica cathepsin Ls in regard to their 
substrate specificity are also being conducted by Prof. John P. Dalton and Dr. Colin 
Stack at the Institute for the Biotechnology of Infectious Diseases, University of 
Technology, Sydney, Australia.
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Abstract
Fasciola hepatica secretes cathepsin L proteases that facilitate the penetration of the parasite through the tissues of its host, and also 
participate in functions such as feeding and immune evasion. The major proteases, cathepsin LI (FheCLi) and cathepsin L2 (FheCL2) are 
members of a lineage that gave rise to the human cathepsin Ls, Ks and Ss, but while they exhibit similarities in their substrate specificities to 
these enzymes they differ in having a wider pH range for activity and an enhanced stability at neutral pH. There are presently 13 Fasciola 
cathepsin L cDNAs deposited in the public databases representing a gene family of at least seven distinct members, although the temporal 
and spatial expression of each of these members in the developmental stage of F. hepatica remains unclear. Immunolocalisadon and in situ 
hybridisation studies, using antibody and DNA probes, respectively, show that the vast majority of cathepsin L gene expression is carried out 
in the epithelial cells lining the parasite gut. Within these cells the enzyme is packaged into secretory vesicles that release their contents into 
the gut lumen for the purpose of degrading ingested host tissue and blood. Liver flukes also express a novel multi-domain cystadn that may be 
involved in the regulation of cathepsin L activity. Vaccine trials in both sheep and cattle with purified native FheCLi and FheCL2 have 
shown that these enzymes can induce protection, ranging from 33 to 79%, to experimental challenge with metacercariae of F. hepatica, and 
very potent anti-embryonation/hatch rate effects that would block parasite transmission. In this article we review the vaccine trials carried out 
over the past 8 years, the role of antibody and T cell responses in mediating protection and discuss the prospects of the cathepsin Ls in the 
development of first generation recombinant liver fluke vaccines.
© 2003 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.
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1. Introduction
The trematode parasites Fasciola hepatica (temperate) 
and Fasciola gigantica (tropical) are the causative agents of 
liver fluke disease (fasciolosis) in cattle and sheep. Infection
* Corresponding author. Tel.: +353-1-7005407; fax: +353-1-7005412. 
E-mail address: john.dalton@dcu.ie (J.P. Dalton).
causes world-wide economic losses of approximately 
US$2,000 million annually to the agricultural sector 
(Spithill et al., 1999a). Fasciolosis is also an emerging 
pathogen of humans particularly in the South American 
countries Bolivia, Peru and Equador, in Egypt and Iran 
(O’Neill et al., 1998; Mas-Coma et al., 1999; Rokni et al., 
2002). It is estimated that 2.4 million people are infected 
with liver fluke world-wide (Mas-Coma et al., 1999).
0020-7519/$30.00 © 2003 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved, 
doi: 10.1016/S0020-7519(03)00171-1
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Fasciolosis is acquired following the ingestion of 
vegetation or water contaminated with the encysted 
infectious liver fluke larvae, known as metacercariae. 
Metacercariae excyst in the intestines, burrow through the 
intestinal wall and migrate into the liver tissue where they 
spend about 8 - 1 2  weeks feeding on host tissue and blood 
and consequently causing extensive haemorrhaging and 
perforations. This acute stage of disease can result in death 
in highly infected sheep, but death is rarely seen in cattle. 
After this period the parasites move into the bile ducts 
where they complete their growth and maturation. The 
hermaphroditic adult liver flukes puncture the wall of the 
bile duct and feed on blood that provides the nutrient for 
the production of enormous numbers of eggs that are carried 
into the intestine with the bile fluids and are passed onto 
pasture with the faeces. An aquatic larval stage hatches from 
the eggs and infects an intermediate mud-snail host, such as 
Lymnaea truncatula. After several developmental and 
multiplication stages within the snail the parasites emerge 
and become encysted on vegetation and thus continue the 
cycle (Andrews, 1999).
A number of chemicals are commercially available for 
the treatment of animal fasciolosis, including closantal, 
clorsulon, rafoxanide, nitroxynil and triclabendazole (see 
Fairweather and Boray, 1999). Following dosing, the 
therapeutic concentration of these drugs in the blood is 
reached for approximately 1 - 2  days and hence only current 
parasitic infections are cleared. Animals on contaminated 
pastures are then susceptible to re-infection. Triclaben­
dazole requires particular mention since this is the only drug 
effective against early stage parasites, i.e. the stages that 
migrate through the liver and induce acute fasciolosis. The 
drug was launched in Ireland in 1983 under the brand name 
Fasinex (Ciba-Geigy, now Novartis Animal Health) and has 
enjoyed substantial commercial success. However, in 1995 
an anonymous letter to the Irish Farmer’s Journal (Anon., 
1995) reported the presence of triclabendazole-resistant 
liver flukes on a farm in Co. Sligo, an area where fasciolosis 
is endemic. If verified this provides an example of how 
quickly (within 1 2  years) drug resistance to anthelminthics 
can appear in the field. Triclabendazole resistance has now 
been reported in Australia (Overend and Bowen, 1995; 
Fairweather and Boray, 1999), Scotland (Mitchell et al.,
1998) and the Netherlands (Moll et al., 2000; Gaasenbeek 
et al., 2 0 0 1 ).
Apart from the appearance of drug resistant parasites, 
other pressures in the form of EU regulations, consumer 
concerns for ‘greener’ food and for animal welfare, and 
environmental issues regarding the passage of chemical 
residues onto pastures and into waterways will make the 
control of helminth diseases, including fasciolosis, with 
chemical drugs unsustainable. The future of liver fluke 
control will almost certainly depend on the development of 
a protective vaccine; the challenge will be to develop and 
commercialise such a product that will give a benefit that is 
visible to farmers (i.e. enhanced performance of animals,
reduced deaths, etc.) at a competitive price (i.e. at a cost as 
low as drug treatments). It must be remembered, however, 
that vaccines provide ‘protection’ against infection and 
thereby have an advantage over drugs (particularly those 
that are effective against the adult liver fluke stages alone) 
that only provide a ‘treatment’. Moreover, vaccines are 
considered safe and environmentally friendly.
Recent advances in molecular biology (proteomics and 
genomics) have made it relatively easy to identify and 
isolate potential vaccine components but in the case of liver 
flukes there is still a dearth of vaccine candidates that have 
been tried and tested in the target species, i.e. sheep and 
cattle. Research on a number of molecules including 
cathepsin Ls, glutathione 5-transferase (GST), leucine 
aminpeptidase (LAP) and fatty acid binding proteins 
(FABP), however, has demonstrated the feasibility of 
inducing protective responses in laboratory and large animal 
models (reviewed by Spithill and Dalton, 1998; Spithill 
et al., 1999a). This article will review the work of our 
laboratory and others on liver fluke cathepsin L  proteases 
and update the progress towards a vaccine.
2. Biochemical characteristics of cathepsin Ls
Fasciola hepatica cathepsin L proteases were the first of 
this class of enzyme to be described in helminths (Smith 
et al., 1993). It is now known that this enzyme class is 
expressed by all parasitic worms and in many cases they are 
secreted and hence are pivotal in the host-parasite inter­
play. However, they appear to be particularly prominent in 
trematodes as compared to nematodes where cathepsin 
B-like enzymes tend to be expressed in greater amounts 
(Tort et al., 1999).
Enzyme activity attributable to cysteine proteases was 
detected in our laboratory in extracts of F. hepatica 
parasites and ES products over a decade ago (Dalton and 
Heffeman, 1989). However, a more recent characterisation 
of these extracts using synthetic peptide substrates, such as 
Z-Phe-Arg-NHMec, demonstrated that the dominant 
activity was cathepsin L-like. Two distinct cathepsin L 
proteases have been purified in our laboratory from culture 
medium in which adult F. hepatica parasites were incubated 
and shown to be the predominant proteolytic activity 
secreted by the worms (Smith et al., 1993; Dowd et al., 
1994). Subsequently, transcripts encoding these two major 
cathepsin L-like proteases, termed FheCLi and FheCL2, 
have been isolated from cDNA libraries by immunoscreen- 
ing with anti-sera prepared against the native enzymes 
(Dowd et al., 1997; Roche et al., 1997). These transcripts 
encode zymogens with structures that are similar to those of 
vertebrate cathepsin Ls in that they consist of a hydrophobic 
signal peptide (1 2 - 2 0  residues), a pro-segment ( 1 0 0  
residues) and a mature enzyme (200 residues) (see Fig. 1). 
Unlike mammalian cathepsin Ls, FheCLi and FheCL2 do 
not possess potential N-glycosylation sites in their mature
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Fig. 1. Activation of Ni-NTA-agarose purified P. pa.vtom-expressed 
recombinant FheCLi at pH 5.5. Purified recombinant FheCLi resolves as 
two bands of 38 (upper) and 34 kDa (lower, arrowed) that represent the full 
pre-pro-mature and a truncated pro-mature form of the enzyme, 
respectively. While this preparation exhibits cathespin L activity it can 
be further activated to the fully processed mature enzyme (last lane on 
right) by incubating it for a period of 1—2 h in 0.1 M sodium acetate, pH 
5.5. The positions of the major proteins resolved in the gel with respect to 
the cathepsin L pro-enzyme are shown schematically and were determined 
by N-terminal sequencing.
enzyme portion and clectrophoretic/immunoblot analyses 
suggest that they are not glycosylated.
The substrate specificity of the cathepsin Ls was 
examined using synthetic fluorogenic peptide substrates 
that are classically used to characterise mammalian 
cathepsin Ls, Ss, Ks (Z-Phe-Arg-NHMec), cathepsin B 
(Z-Arg-Arg-NHMec) and cathepsin H (Z-Arg-NHMec) 
(Barrett and Kirschke, 1981). Both enzymes demonstrated 
high catalytic efficiency (kc.JK m) for Z-Phe-Arg-NHMec, 
but showed little or no activity against the latter two 
substrates. This substrate specificity is consistent with their
grouping with the non-cathepsin B proteases; however, 
FheCL2 could also cleave substrates that contained proline 
in the P2 position, and the substrate Z-Gly-Pro-Arg is used 
to distinguish between FheCLi and FheCL2 activities 
(Dowd et al., 1994, 1997).
The F. hepatica cathepsin L-like proteases are active over 
a wide pH range (pH 3.0-8 .0), and stability studies 
demonstrated that FheCLi retains 100% of its activity 
when incubated at 37 °C for 24 h. In contrast, human 
cathepsin L is irreversibly inactivated above pH 7.0, a 
property that is thought to protect cells against uncontrolled 
proteolysis in the event of accidental leakage from the 
lysosomes (Dowd et al., 2000). The stability of the liver fluke 
enzymes may reflect the fact that the parasite employs them 
to generate a migratory path through a large tissue mass, the 
liver, on its way to the bile ducts.
3. The cathepsin L gene family
Early studies by Heussler and Dobbelaere (1994) 
indicated that F. hepatica expressed several cathepsin L 
genes, but since this report the number of cathespin L cDNA 
entries into the public databases has gradually grown so that 
at writing there are 13 known F. hepatica cathepsin genes. 
The number of F. gigantica cathepsin L entries in 
the databases has also grown mainly due to the efforts of 
Grams et al. (2001) and Yamasaki et al. (2002), and 
unsurprisingly many of these genes appear to be homo- 
logues of the F. hepatica genes. The family as it stands is 
presented in Fig. 2; some of the encoded polypeptides
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Fig. 2. Dendrogram of F. hepatica and F. gigantica cathepsin L gene family. Relationship of the cathepsin L cDNAs (public database accession numbers at end 
of branches). FheCLi and FheCL2 are highlighted in bold. Sequences isolated from cDNA from newly excysted juveniles are italicised. Samples were 
analysed using 1,000 bootstrap replicates (numbers represent values obtained).
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differ in only a few amino acids and may represent alleles 
rather than distinct genes. Nevertheless, it is clear that at 
least seven different cathepsin L genes are expressed by 
these trematodes. Phylogenetic studies of this gene family 
revealed that they belong to a clade that includes the 
mammalian cathepsin Ls, cathepsin Ss and cathepsin Ks 
(the parasite enzymes show 40-55%  similarity with the 
mammalian homologues) (Tort et al., 1999) Of particular 
note is that the newly excysted juvenile (NEJ)-specific 
cathepsin L cDNAs (two from F. hepatica and one from 
F. gigantica) cluster together in the dendrogram shown in 
Fig. 2, which may suggest that cathepsin L expression in 
NEJ is limited to two genes whereas in the adult stages 
many more genes are expressed.
It is difficult to assess the temporal expression and 
localisation of each of the cathepsin L gene products 
because their close nucleic acid/amino acid sequences 
similarities preclude the development of specific PCR/anti- 
body reagents. However, in situ hybridisation studies by 
Grams et al. (2001) with F. gigantica and by us with 
F. hepatica (Fig. 3) are consistent with immunolocalisation 
studies (Smith et al., 1993) and show that the vast majority 
of cathepsin L pro teases are expressed in the cells lining the 
parasite’s guts. It is possible that more than FheCLl and 
FheCL2 proteases are secreted by the parasite, which would 
agree with the 2-D electrophoresis analysis by Wijffels et al. 
(1994) and Jefferies et al. (2001) that shows the presence of 
multiple cathepsin L proteases in adult F. hepatica ES 
products. The structure of one of the F. gigantica genes was 
recently determined by Yamasaki et al. (2002), and consists 
of four exons and three introns of similar size and
arrangement to those found in crustacean and mammalian 
cathepsin Ls.
4. Regulation of cathepsin L activity
Enzymatic assays have shown that cathepsin L activity is 
expressed in the infective stage of the parasite, the NEJ, in 
the immature developmental stages that migrate through the 
liver parenchyma and in adults that reside in the bile ducts 
(Carmona et al., 1993; Smith et al., 1993). A proteomics 
approach to characterising NEJ proteins confirmed the 
presence of cathepsin L proteases in this stage (Tkalcevic 
et al., 1995) and now full-length F. hepatica and F. gigantica 
NEJ-specific cathepsin L sequences are available in the 
public databases (Fig. 2).
As mentioned above the proteases are synthesised in the 
epithelial cells that line the parasite gut (Fig. 3). Within 
these cells the proteases are packaged into secreted vesicles 
in high concentration ready for secretion. During trafficking 
to these secretory vesicles the activity (and stability) of the 
cathespin Ls is controlled by the presence of the pro-peptide 
on the protein (as has been demonstrated for mammalian 
cathepsin Ls) (Roche et al., 1997). It remains unclear 
whether the proteases are activated before they reach the 
vesicles or following their secretion by the NEJ and by the 
adult.
It is possible that other mechanisms exist to protect the 
parasite’s cells from unwanted protease activity. Recently, 
Khaznadji, Collins, Dalton and M oire (unpublished) 
discovered a novel molecule that contains five cystatin
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Fig. 3. Localisation of cathepsin L proteases by in situ hydridisation. Light micrographs showing the expression of cathepsin L protease in transverse sections 
(20 \iM) of adult F. hepatica. In situ hybridisation was performed using digoxigenin-labelled DNA probes to cathepsin L protease gene. Specific sense 
[5/-tgtggctcctgttgggcattc-3/] and anti-sense [S'-ggattcggtttccaatcc-S7] primers were designed to amplify a region of 195 bp (incl uding primers) from F. hepatica 
cathepsin L genes. Each probe (sense strand and anti-sense strand) was generated using asymmetrical PCR and digoxigenin-labelled di-nucleotide 
triphosphates (dNTPs) (Roche Diagnostics); cryostat sections were stained following overnight hybridisation at 50 °C. Gene expression can be seen as a dark 
red/brown chromogen formed by substrate cleavage by alkaline phosphatase conjugated to anti-digoxigenin antibodies bound to the probes. All sections were 
treated in the same way except that A and C  were exposed to the sense strand probes (negative controls) whereas B and D were exposed to the anti-sense strand 
probes. Asterisks indicate gut lumen and arrows indicate positive staining/cathepsin L expression. (A) Low power micrograph showing unstained gut. Mag. 
X 20. (B) Low power micrograph showing positive staining in four gut. Mag. X 20. (C) High power micrograph showing several unstained gut. Mag. X 40. 
(D) High power micrograph showing strong positive staining in 2 gut. Mag. X 40.
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1
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Onchocystatin, Nippocystatin «6 Bin-CPl-l(2)
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—  Fam ily 3
Human high molecular weight kininogen
Fascìola /¡epatica high molecular weight multi-domain cystatin
Functional cystatin iloniain  
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tV Disulfide bridge 
I  Hradykinin peptide
Fig. 4. The novel multi-domain /■'. hepatica cystatin. The Nematode cystatins-like Onchocystatin from Onchocerca volvulus, Nippocystatin from 
Nippostrongylus brasiliensis and Bm-CPI-1 from Brugia malayi are related to the cystatin family 2 of the cystatin superfamily (seeMaizels et al„ 2001). The 
F. hepatica multi-domain cystatin, however, is structurally related to the kininogen family (or cystatin family 3) but may be the first-described member of a 
new cystatin family.
domains, two of which are potent inhibitors of cathepsin L 
(the structure of the other three cystatin domains appears to 
be degenerate, Fig. 4). This multi-domain cystatin is 
expressed in NEJ and adult flukes but its expression is 
greater in the former stage. The cathepsin L protease may be 
required in large amounts by the NEJ to allow them quickly 
to invade the host intestinal wall following excystment, and 
a corresponding cystatin inhibitor may be necessary to 
protect the parasite from its own proteolytic activity during 
its storage or after secretion.
5. Functions of the cathepsin Ls
Cathepsin Ls that are secreted into the gut lumen 
following ingestion of host blood and liver tissue perform 
the task of digesting host tissues. The breakdown products 
of this endoproteolysis are then absorbed into the epithelial 
cells where they may undergo further degradation by 
dipeptidyl peptidases and aminopeptidases to amino acids 
that are then used in the anabolism of parasite proteins, or in 
the case of adults, in the production of eggs (Tort et al.,
1999).
Because liver flukes possess a blind-ending intestine, 
the contents of the gut must be emptied by frequent
regurgitation (approximately every 3 h). Accordingly, the 
protease must reach the outside tissue where they may carry 
out additional important functions for the parasite, including 
the excavation of a migratory tract. In this context, we have 
demonstrated that liver fluke cathepsin Ls can efficiently 
cleave interstitial matrix proteins such as fibronectin, 
laminin and native collagen (Berasain et al., 1997). We 
have also shown that the parasite cathepsin Ls can cleave 
immunoglobulins precisely in the hinge region (thus 
separating the Fab from the Fc regions) and prevent the 
antibody-mediated attachment of eosinophils to the parasite 
surface and hence may aid in protecting the parasite from 
immune attack (Carmona et al., 1993; Smith et al., 1993; 
Berasain et al., 1997).
More recently, however, we have proposed that the 
secreted cathepsin Ls may be involved in suppression and/or 
modulation of T hl immune responses and induction of non- 
protective host Th2 responses. An analysis of cytokine 
production by antigen-stimulated spleen cells of F. hepatica- 
infected mice showed that these are predominantly of the 
Th2 type, i.e. production of interleukin (IL)-4, IL-5 and 
IL-10, but little or no IFN- 7  (O’Neill et al., 2000). This is 
consistent with immunological observations in cattle which 
show that in the early stages of infections mixed Thl/Th2 
responses are observed but as infection progresses, a Th2
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Tabie 1
Summary of vaccine (rials with F. hepatica cathepsin L proteases
Antigen Host Dose Protection (%) Reduction in 
viable eggs (%)
FheCLl“ Cattle 10-200 figX 3 38.2-69.4 ND
FheCLla Cattle 200 (j,g X 3 43 40-65
FheCLl +  haem fraction'1 Cattle 200 M-g X 3 52 80
FheCLl +  haem fraction11 Cattle 200 p,g X 3 72.4 98
FheCLl +  FheCLl” Cattle 200 |xg X 3 54 55
FheCLlc Sheep 100 p,g X 2 34 71
FheCL2' Sheep 100 (igX 2 33 81
FheCL2 +  FheCL2c Sheep 100 ^g each X 2 60 ND
FheCL2 +  FheCL2 +  LAPC Sheep 100 |xg each X 2 79 ND
FheCL proteases1' Sheep 120 +  90 (JLg 0 69.4
ND, not determined. 
u Dalton et ah (1996). 
b Mulcahy et al. (1998). 
c Piacenza et al, (1999).
11 Wjjffels et al. (1994).
response predominates (Mulcahy et al., 1999). However, at 
high levels of infection in mice (approximately 15 
metacercariae) a marked suppression of T hl responses 
was observed (O’Neill et al„ 2000). Moreover, when mice 
were concurrently infected with F. hepatica and Bordetella 
pertussis , the Thl-specific response to the bacterial 
pathogen (assessed by measuring IFN-7 ) was suppressed. 
This suppression led to a delay in the clearance of the 
bacterium in the co-infected mice as compared to mice 
infected with B. pertussis alone (Brady et al., 1999). Liver 
fluke infection also suppressed the Thl responses to a 
B. pertussis whole cell vaccine (WCV) suggesting that the 
parasite may secrete Thl suppressive factors. Subsequently, 
O’Neill et al. (2001) demonstrated that injection of purified 
cathepsin L just prior to vaccination with B. pertussis WCV 
blocked the production of EFN- 7  by WCV-stimulated spleen 
cells. It is possible, therefore, that secreted cathepsin Ls play 
some immunomodulatory/immunosuppressive function by 
blocking the development of protective Thl responses in the 
host and thus aiding the progression of non-protective Th2 
responses that would favour the longevity of the parasite.
6. Vaccine trials with cathepsin L proteases
The involvement in biological roles that are essential to 
the parasite’s survival in the host makes the F. hepatica 
cathepsin L proteases likely targets at which novel vaccines 
could be directed. Native FheCLl and FheCL2 proteases 
could be purified from the ES products of adult worms by a 
series o f conventional gel permeation and ion exchange 
chromatography steps and produced in sufficient quantities 
to allow experimental vaccine trials in cattle. In our first 
vaccine trial a dose-ranging experiment demonstrated that 
significant protection against liver fluke infection (average 
54%) could be obtained and that doses of as little as 10 |xg of 
protein, given on three occasions, could induce protective
responses (Dalton et al., 1996). Subsequent trials, performed 
with 2 0 0  (jLg per dose, confirmed the protective nature of the 
cathepsin L proteases (Tabie I). When the cathepsin L 
proteases were administered in conjunction with other liver 
fluke antigens, such as a haem-binding protein, protection 
levels of 73% were achieved (Dalton et al., 1996, Table 1). 
A further vaccine trial in cattle showed that a combination 
of FheCLl and FheCL2 elicited 53% protection against 
challenge, and trials in sheep induced protection levels from 
33 to 60% (Mulcahy et al., 1998; Piacenza et al., 1999, 
Table 1). When FheCLl and FheCL2 were combined with 
F. hepatica leucine aminopeptidase (LAP) protection levels 
were 79% in sheep (Piacenza et al., 1999).
Additional beneficial aspects of the protection induced 
by the cathepsin L vaccines were observed. First, in all 
vaccine trials the proportion of liver flukes that did not 
develop to maturity was greater in vaccinates than in non­
vaccinated controls. Consequently, the damage to the host’s 
liver during acute infection was significantly reduced. 
Secondly, vaccination of both sheep and cattle also elicited 
a highly significant reduction (50-98% ) of the parasite’s 
ability to produce eggs, and those eggs that were synthesised 
showed reduced ‘hatch rates’ (Dalton et al., 1996; Mulcahy 
et al., 1998; Table I). The implications of these findings are 
that by reducing the parasite burden of the host and, at the 
same time, blocking the synthesis of viable eggs by those 
parasites that do survive in vaccinated animals, the vaccine 
would have a profound effect on pasture contamination and 
hence disease transmission.
7. What is the mechanism behind protection?
Studies examining the immune responses of cattle that 
were given either experimental or natural infections of 
F. hepatica metacercariae showed that animals generate 
IgG l antibodies and little or no IgG2 antibodies
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(Mulcahy et al., 1999; Hoyle et al., 2002). These 
observations suggest that the immune responses to liver 
fluke antigens are highly polarised to a Th2 type. On the 
other hand, antibody responses to the cathepsin L-based 
vaccines include high titres of both IgG l and IgG2 
indicating that protection is associated with the induction 
of a T hl responses or a mixed Thl/Th2 response (Mulcahy 
et al., 1998, 1999).
A recent analysis of the cathepsin L-specific IgGl 
antibody responses in infected cattle revealed that these 
antibodies do not appear in the serum until 4 or 5 weeks 
post-infection. Moreover, animals given a second infection 
4 weeks after the primary infection did not exhibit any 
boosting of immune responses to the cathepsin L proteases 
(Hoyle et al., 2002; Fig. 5). It is clear, therefore, that 
cathepsin Ls are not highly immunogenic in the early stages 
of infection such that, at this stage, they may be considered 
‘hidden antigens’. This may be an important strategy used 
by the parasite to prevent antibodies being generated to 
critical molecules. Accordingly, vaccinating animals with 
cathepsin Ls would elicit a high titre of anti-cathepsin L 
antibodies that would upset this evasion strategy and, 
therefore, would be detrimental to the early migratory stages 
of the parasite. Indeed, when animals are vaccinated with 
cathepsin L a positive correlation was observed between 
protection and antibody titres (Mulcahy et al., 1998; Fig. 6 ).
The effects of the vaccine on egg production and ‘hatch 
rate’ may be mediated by antibodies that inhibit parasite 
feeding by blocking cathepsin L activity, thereby preventing 
the acquisition of amino acids for the synthesis of egg 
proteins. Additionally and/or alternatively, since cathepsin 
Ls have been immunolocalised to the reproductive 
organs of the mature parasite (Spithill et al., 1999a; 
Wijffels et al., 1994) and may play a role in egg production,
Days
Fig. 5. IgGl antibody response of experimental-infected cattle to FheCLl. 
Cattle were experimentally infected with metacercariae of F. hepatica 
either once (solid arrow) or twice (4 weeks apart, dotted arrows). Serum 
was collected weekly and assayed by ELISA for IgGl antibodies to purified 
FheCLl (IgG2 antibodies were either very low or undetectable). Antibody 
responses to FheCLl in both experimental groups were observed 4 -5  
weeks after the primary infection.
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Fig. 6 . Immune responses of FheCLl-vaccinated and non-vaccinated 
control cattle. Relationship between antibody titres and numbers of liver 
fluke recovered from livers of non-vaccinated animals and cattle vaccinated 
with cathepsinL proteases. In vaccinated animals, high total antibody titres 
(diamonds) correlate with lower fluke burdens (these antibodies consist of 
both IgGl and IgG2). In contrast, in non-vaccinated control animals 
(circles) high antibody titres correlate with higher infections (these 
antibodies consist predominantly of IgGl, see text).
vaccine-induced antibodies may inhibit the enzyme and 
thereby have a direct effect on female reproductive 
structures.
While antibodies seem to be central to the protective 
effects of the cathepsin L vaccine, it is clear that the 
generation of a Thl or Thl/Th2 type immune response is 
also critical. The induction of this type of response was 
dependant on the adjuvant employed in our studies i.e. 
Freund’s Complete/Incomplete Adjuvant. However, it also 
seems likely that by blocking cathepsin L activity the 
vaccine prevents the parasite from suppressing the Thl 
response of the host and from inducing the development of 
Th2 responses that are typical of natural infections.
8. Functional expression of cathepsin L proteases
While FheCLl and FheCL2 could be purified from liver 
fluke ES products in quantities that allowed the detailed 
analysis of their biochemical and physico-chemical proper­
ties, and their assessment as vaccine candidates, it is 
obvious that for their future commercialisation a method of 
recombinant production is necessary. The production of 
cathepsin L proteases in a fully functional form requires 
expression of the pro-mature form of the enzyme since the 
pro-peptide region is required for correct folding of the 
molecule. Prokaryotic systems of expression, e.g. E. coli, 
are not suitable for the production of functionally active 
cathepsin proteases, although these systems have been 
employed to express non-active proteins, such as 
F. gigantica cathepsin L (Yamasaki et al., 2002), which 
were subsequently re-folded to active form. Unfortunately, 
re-folding methodologies are complex, cumbersome and 
expensive, and serve to obviate their application in 
commercial production schemes.
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Yeast systems have proved more successful for the 
functional expression of many parasite proteases including 
the F. hepatica cathepsin Ls (Dalton et al., in press). We 
have reported that the yeast Saccharomyces cerevisiae, 
transformed with a full-length FheCLl or FheCL2 cDNA, 
expressed and secreted functional enzyme into the culture 
medium from which homogeneous enzyme could be 
obtained by conventional purification techniques such as 
gel filtration and ion exchange chromatography (Dowd et al., 
1997; Roche et al., 1997). While the functional expression 
of mammalian cathepsin proteases in S. cerevisiae has also 
been reported, these have necessitated the use of an a-factor 
pre- or pre-pro-signals. However, functional expression of 
FheCLl and FheCL2 did not require such a fusion protein 
and N-terminal sequencing of expressed proteases revealed 
that they were processed in yeast to the mature enzyme by 
cleavage at the precise position as that observed for the 
native enzymes (Dowd et al., 1997; Roche et al., 1997). 
Notwithstanding these advances, the expression of cathe- 
spin L  protease was low (approximately 100 |xg/l) and 
hence still not suitable for large-scale production. More 
recently, however, we have employed the yeast Pichia 
pastoris for protease expression using vectors that include 
the yeast a-factor pre-pro-signals (Invitrogen). High-level 
expression of FheCLl has been achieved (800 mg/1) and the 
protease, which carries a His6 tag, can be isolated by a one- 
step affinity chromatography procedure on Ni-NTA-agarose 
(Fig. 1). The protease is expressed as a pro-enzyme together 
with a semi-processed form, both of which can be activated 
at low pH to fully active mature enzyme (Fig. 1). The 
physico-chemical properties (substrate specificity, pH 
optima, stability, etc.) and molecular size of cathespin L 
are similar to the native enzyme, and more importantly with 
respect to vaccines, no post-translational glycosylation 
occurs (unpublished data). These experiments demonstrate 
that liver fluke FheCLl and FheCL2 could be produced at a 
commercial level using yeast as the heterologous expression 
system.
9. Concluding remarks
In our laboratory the cathepsin L proteases of F. hepatica 
have given consistent positive results when used as vaccines 
against fasciolosis in cattle and sheep and therefore have 
excellent prospects for the development of first generation 
anti-fluke vaccines. Vaccinations in sheep with a purified 
fraction of cysteine proteases of adult F. hepatica carried 
out by Wijffels et al. (1994), however, did not provide any 
protection against a challenge infection, although a >70%  
reduction of faecal eggs counts (FEC) was observed 
(Table 1). In addition, vaccination trials in cattle with 
F. gigantica cathepsin Ls did not protect animals against 
this fluke species (Spithill et al., 1999a). The dis­
crepancies remain unresolved and may only be resolved if 
a comparative analysis of the immune responses to
the vaccines was carried out. There are differences in 
vaccine formulations, doses and/or route of administration 
between the trials (see Spithill et al., 1999a,b) that may have 
induced a variety of effector mechanisms to the vaccines. 
Each of these factors will need to be investigated system­
atically during the developmental stages of a commercial 
vaccine.
Besides the cathepsin L proteases there are several other 
molecules that are potential vaccine candidates including 
GST, FABP (Spithill and Dalton, 1998) and LAP (Piacenza 
et al., 1999). While trials with these antigens have given 
some very variable results, no detailed analysis of immune 
responses to the vaccines has been carried out to determine 
immunological factors that correlate with protection/no 
protection. It is therefore still feasible that these molecules 
could be realised as a basis for commercial vaccines, either 
alone or in combination with other candidates, if the precise 
conditions for inducing protection were elucidated.
The commercialisation of a vaccine will require a system 
for production and downstream processing that is not so 
costly as to reduce the final product’s competitiveness 
against current drug treatments. Both E. coli and yeast 
expression systems may be suitable for the production of 
vaccines for experimental trials, but before progressing into 
developmental phase the best/cheapest system for up-scale 
production/downstream processing will have to be con­
sidered for final commercialisation in an animal health 
market that already suffers from relatively low-valued/low 
profit-margin products (Dalton et al., in press). Never­
theless, the prospects for future vaccines are good, 
particularly considering the pressure on the industry to 
move away from chemical treatments.
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The secretion and activation of the major cathepsin  
LI cysteine protease involved in the virulence of the  
helm inth pathogen F ascio la  hepa tica  w as investigated. 
Only the fully processed and active m ature enzym e can 
be detected  in m edium  in w hich adult F. hepa tica  are 
cultured. However, im m unocytochem ical studies re­
vealed  that the inactive procathepsin LI is packaged in  
secretory vesicles o f ep ithelia l cells that line the para­
site gut. These observations suggest that processing and 
activation of procathepsin LI occurs follow ing secretion  
from these cells into th e acidic gut lumen. Expression of 
the 37-kDa procathepsin LI in P ich ia  p a sto r is  showed  
that an interm olecular processing event w ithin  a con­
served GXNXFXD m otif in  th e propeptide generates an 
active 30-kDa interm ediate form. Further activation of 
the enzym e was in itiated  by decreasing the pH to 5.0 and 
involved the progressive processing of the 37 and 30- 
kDa forms to other interm ediates and finally to a fully  
m ature 24.5 kDa cathepsin L w ith  an additional 1 or 2 
am ino acids. An active site m utant procathepsin  L, con­
structed by replacing the Cys26 w ith Gly26, failed  to au­
toprocess. However, [Gly26]procathepsin L w as pro­
cessed by exogenous wild-type cathepsin  L to a m ature 
enzym e plus 10 am ino acids attached to the N  term inus. 
This exogenous processing occurred w ithout the form a­
tion  of a 30-kDa interm ediate form. The resu lts indicate  
that activation of procathepsin LI by rem oval o f the 
propeptide can occur by different pathways, and that 
th is takes place w ith in  the parasite gut where th e pro­
tease functions in  food d igestion and from w here it is 
liberated as an active enzym e for additional extracorpo- 
real roles.
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Fasciola hepatica is a helminth parasite that causes liver 
fluke disease in cattle and sheep worldwide and has recently 
emerged as an important pathogen of humans (1). Cathepsin 
LI, a major cysteine protease secreted by the parasite plays a 
pivotal role in various aspects of its pathogenicity. For exam­
ple, the enzyme takes part in nutrient acquisition by catabo- 
lizing host proteins to absorbable peptides (2 ), facilitates the 
migration of the parasite through the host intestine and liver 
by cleaving interstitial matrix proteins such as fibronectin, 
laminin, and native collagen (3), and is implicated in the inac­
tivation of host immune defenses by cleaving immunoglobulins 
(4, 5). Further, cathepsin LI has recently been shown to sup­
press Thl immune responses in infected laboratory animals 
making them susceptible to concurrent bacterial infections (6 ,
7, 8 ). Accordingly, the protease has been recognized as an 
important target a t which parasite intervention strategies 
should be directed (9). In this regard, we have shown tha t the 
induction of anti-cathepsin L immune responses prior to a 
challenge infection of F. hepatica larvae elicits high levels of 
protection in cattle against disease (1 0 , 1 1 , 1 2 ).
Phylogenetic studies have shown tha t the F. hepatica cathep­
sin LI belongs to an enzyme lineage tha t eventually gave rise 
to the mammalian cathepsin Ls, Ks, and Ss (2). The isolation of 
a cDNA encoding F. hepatica cathepsin L revealed tha t the 
enzyme, like its mammalian homologs, is synthesized as an 
inactive preproenzyme consisting of a prepeptide, a propeptide 
and mature enzyme region (13). By analogy with the mamma­
lian proteases we assume that the prepeptide is removed fol­
lowing translocation into the endoplasmic reticulum and that 
the N-terminal propeptide extension is involved in several 
functions including intracellular targeting of the enzyme (14- 
16), correct folding of the mature enzyme by acting as an 
intramolecular chaperone (17-19) and prevention of uncon­
trolled proteolysis by binding to the enzyme substrate cleft in a 
reverse, non-productive direction (14). As has been demon­
strated for the propeptide of human cathepsin L and other 
papain-like cysteine proteases (14, 17, 19, 20) the free propep­
tide of the F. hepatica procathepsin L is a specific and potent 
inhibitor of the cognate mature enzyme at neutral pH but does 
not bind to the enzyme at pH 5.5-3.5 (21).
Human lysosomal procathepsin L is stable at high pH be­
cause the propeptide protects the protein from the denaturing 
effects of the alkali (15). Removal of the propeptide to generate 
the fully active mature enzyme occurs a t the lower lysosomal
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pH of 5.5 (14, 15, 22, 23). It has been widely reported that 
cleavage of the proregion of cysteine proteases can occur auto- 
catalytically in vitro under acidic conditions (15, 24, 25, 26). As 
the stability of the propeptide-protease complex is dependent 
on electrostatic interactions, reduction of the environmental 
pH, weakens the bond between the propeptide and the catalytic 
site. As a consequence, the proenzyme possibly adopts a looser 
conformation, in which the propeptide is bound less tightly 
into the active site making it more susceptible to proteolysis 
(16, 27).
The precise mechanism of proteolytic conversion from proen­
zyme to mature enzyme is still actively debated. The three- 
dimensional structure of procathepsin L (14) and procathepsin 
B (28, 29, 30) show tha t the N terminus of the mature enzyme 
is quite removed from the active site thus making it  difficult to 
visualize an autocatalytic cleavage event. Moreover, circular 
dichroism studies reveal tha t activation does not involve sig­
nificant conformational changes in the structure of procathep­
sin L (15) or procathepsin B (16). Therefore, the initial event in 
autocatalysis may involve an active proenzyme, possibly cre­
ated by the reduced pH, tha t cleaves another proenzyme in the 
vicinity of the N term inus and sets off a chain reaction (15, 16). 
However, more recent studies on procathepsin B and proca­
thepsin S identified autoproteolytic intermediates of processing 
when cystatin was included in in vitro activation reactions, 
which supported the view tha t the segment of the propeptide 
th a t binds the active site cleft is susceptible to cleavage (31). 
Accordingly, it was suggested that an initial slow intramolec­
u lar cleavage event within this segment of the propeptide trig­
gers a more rapid cascade of intermolecular cleavages a t the N 
term inus (31).
Earlier studies on the processing of yeast-expressed recom­
binant papain identified a conserved heptapeptide (Gly-Xaa- 
Asn-Xaa-Phe-Xaa-Asp) motif located between residues -4 2  
and —36 in the propeptide tha t may be a site of initial cleavage 
in the pH-dependent autoactivation of the enzyme (32). It was 
suggested th a t the lowering of the pH perturbed the negative 
charge of Asp- 3 6  resulting in a conformational change th a t 
switched on the processing events by allowing proteolysis to 
occur at the Ala~37/Asp 36 bond. Following this primary cleav­
age further removal of the remaining amino acids of the 
propeptide may result from the proteolytic activity of the in­
termediate species, resulting in fully active mature protease
(32).
Given the importance of cathepsin L proteases in the viru­
lence of F. hepatica and other helminth pathogens (2) it is 
important to understand the mechanisms of their synthesis, 
processing and activation. We have previously shown th a t ca­
thepsin LI is secreted by this parasite and therefore functions 
extracellularly (4, 33) similar to the mammalian cathepsin Ls 
involved in the processing of the hormone thyroglobulin (34- 
36). In the present study we have employed confocal laser and 
electron immunocytochemistry to show th a t the enzyme is 
stored in secretory vesicles of the gastrodermal epithelial cells 
in its inactive proenzyme form. We investigate the autoactiva­
tion oiF. hepatica cathepsin LI using the wild-type proenzyme 
expressed in Pichia pastoris. Intermolecular processing was 
studied by generating an inactive procathepsin L mutant, 
where the catalytic Cys residue at position 26 was substituted 
with a Gly, which was incapable of autoactivation. Our results 
show th a t P. pastoris-expressed cathepsin L can autoactivate 
a t low pH to an active intermediate form by an initial cleavage 
within the conserved heptapeptide (Gly-Xaa-Asn-Xaa-Phe- 
Xaa-Asp), as previously described for papain (32). Further ac­
tivation of the enzyme occurs by cleavage in the vicinity of the 
N terminus. In contrast, intermolecular processing of the mu­
tan t inactive procathepsin L to a mature product by exogenous 
m ature cathepsin L did not involve the formation of the above 
intermediate but was initiated by a direct cleavage close to 
the N terminus. These data provide a mechanism by which 
F. hepatica synthesizes and secretes a fully activated protease 
th a t is essential to its existence as a parasite.
EXPERIMENTAL PROCEDURES
M aterials—Z-Phe-Arg-NHMec' and Z-Phe-Ala-CHN2 were obtained 
from Bachera (St. Helens, UK). DTT and EDTA were obtained from 
Sigma (Dorset, Poole, UK). Prestained molecular weight markers and 
the Avrll and SnaBI restriction enzymes were obtained from New 
England Biolabs (UK) Ltd. (Hitchin, UK). Primers were obtained from 
Sigma-Genosys (Pampisford, UK). The pPIC9K vector and Pichia  
pastoris  strain GS115 were obtained from Invitrogen Corp. (San 
Diego, CA). Ni-NTA agarose and columns were obtained from Qiagen 
(Crawley, UK).
In  Vitro Cultivation o f  Parasites—Adult F. hepatica were obtained 
from infected cattle at a local abattoir and cultured in vitro in RPMI 
1640 containing 30 mM HEPES, 1% glucose and 25 mg/ml gentamycin 
as described by Dalton and Heffeman (37). The medium was collected 
after 6 h, cleared by centrifugation at 14,000 X g  for 30 min at 4 °C and 
stored at — 20 °C.
Preparation o f  Antipropeptide and  Antim ature Cathepsin L I  A n ti­
sera—Native mature cathepsin LI (nFheCLl) was purified from excre­
tory-secretory (ES) products of adult F, hepatica by gel permeation and 
ion exchange chromatography and antiserum prepared in rabbits as pre­
viously described (4, 38). Recombinant cathepsin LI propeptide was gen­
erated and purified as described by Roche et al. (21) and antiserum 
prepared by immunizing New Zealand White rabbits five times with 20 
fig  of protein formulated in Freund’s Complete and Incomplete Adjuvant.
Immunofluorescence and Immunoelectron Microscopy—Adult F. he­
patica  were recovered from infected cattle at a local abattoir, washed, 
and transported to the laboratory in mammal saline (0.9% NaCl) at 
37 °C. Parasites were rinsed in mammal saline and allowed to I'egur- 
gitate their gut contents before being flat-fixed in 4% paraformaldehyde 
(PFA) in PBS (pH 7.2) for 4 h. They were washed in antibody diluent 
(ABD: PBS with, 0.1% bovine serum albumin; 0.3% Triton X-100; 0.1% 
sodium azide) for 24 h before being incubated for 48 h at 4 °C in 
antiserum prepared against purified mature cathepsin LI (diluted 
1:3000) and subsequently washed in  ABD (24 h, 4 °C). Swine anti­
rabbit tetramethyl rhodamine isothiocyanate (TRITC; 1:100; Dako Ltd.) 
was used to visualize bound primary antibody before the worms were 
washed in ABD (24 h, 4 °C) and mounted on glass microscope slides in 
PBS/glycerol (1:9) containing 2.5% 2,4-diazabicylco 2.2.2 octane. Spec­
imens were viewed using a Leica TCS-NT confocal scanning laser 
microscope.
For electron microscopy worms were washed in mammal saline and 
fixed for 1 h in 2% double-distilled glutaraldehyde (GTA) (Agar Scien­
tific) in 0.1 M sodium cacodylate buffer (pH 7.2) containing 3% sucrose 
at 4 °C. Following thorough washing in buffer, specimens were dehy­
drated through graded ethanol to propylene oxide, infiltrated and em­
bedded in Agar 100 resin (Agar Scientific). Ultrathin sections (80-90  
nm) were cut on a Reichert Ultracut E ultramicrotome, collected on bare 
200-mesh nickel grids and dried at room temperature. For immunogold 
labeling sections were etched with 10% hydrogen peroxide for 5 min and 
rinsed thoroughly with 20 mM Tris-HCl buffer (pH 8.2) containing 0.1% 
bovine serum albumin and Tween 20 (1:40 dilution). Grids were incu­
bated in normal goat serum (1:20 dilution) for 30 min and then trans­
ferred to primary antibody diluted to 1:20,000  with 0 .1% bovine serum 
albumin/Tris-IICl buffer for 12-18 h. Grids were then washed in bovine 
serum albumin/Tris-HCl and transferred to a 20 ¡x\ drop of 10 nm 
gold-conjugated goat anti-rabbit IgG (Bio Cell International) for 2 h at 
room temperature. Following another buffer wash, grids were lightly 
fixed with 2% double-distilled GTA for 3 min, and finally washed with 
buffer and rinsed with distilled water. Grids were double stained with 
uranyl acetate (5 min) and lead citrate (3 min) and examined in a FEI 
(Philips) CM100 transmission electron microscope, operating at 100 keV.
Controls consisted of (i) incubation of whole-mounts/sections with 
secondary antibody in the absence of primary antibody and (ii) incuba­
tion with preimmune serum followed by the secondary antiserum.
1 The abbreviations used are: Z-Phe-Arg-NHMec, benzyloxycarbonyl-L- 
phenylalanyl-L-arginine 4-methylcoumarinyl-7-amide; Z-Phe-Ala-CHNa, 
benzyloxycarbonyl-L-phenylalanyl-L-alanine-diazomethylketone; DTT, di- 
thiothreitol; PBS, phosphate-buffered saline; NTA, nitrilotriacetic acid.
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Construction o f  Expression Vectors Encoding cDNA for Wild-type 
Procathepsin L I  (rFheproCLl) and  Gly2(i Procathepsin L l  (rmutFhepro- 
CL1) and  Transform ation into Pichia pastoris—The F. hepatica proca­
thepsin  L (FheproC Ll) w as am plified by PCR from the pAAH5 Saccha­
romyces cerevisiae expression vector into which th e  full-length cDNA 
had been previously cloned in  our laboratory (13). P rim ers w ere used 
(see p rim ers A and D below) to incorporate a  SnaBI restriction site  a t 
the  5 '-end of th e  gene and an  A vrll restriction  site and Hisfi tag  
sequence a t  the  3 '-end. The 980-bp fragm ent w as inserted into the  
A vrll/S naB l site of P, pastoris  expression vector pPIC9K (Invitrogen),
M utants were generated from th is constnict by a PCR-based site- 
directed mutagenesis method known as gene splicing by overlap extension 
(SOEing) (39) using the  pPIC9K-FheproCLl DNA as a tem plate. The 
construction of the  inactive FheproCLl m utan t involved changing the 
active site cysteine (Cys2G) residue to a  glycine in a two-step PCR process. 
The prim ers used were as follows: prim er A, 5'-GCGGCTACGTATCGA- 
ATGATGATTTGTGGCAT-3'; prim er B, 5 '-GAATGCCC AACCGGAGCC- 
AC-3'; prim er C, 5'-GTGGCTCCGGTTGGGCATTC-3'; prim er D, 5'-GC- 
GCCTAGGTCAGTGGTGGTG GTGGTGGTGGGCCC-3'.
The underlined  nucleotides indicate th e  replacem ents introduced. 
Each reaction used  one flanking prim er th a t  hybridized a t  one end of 
the  target sequence (prim er A or D) and one overlapping in te rn a l 
prim er th a t  hybridizes a t  th e  site of the  m utation  and contains the 
m ism atched base (prim er B or C), In  th e  firs t round of amplification two 
sections of the  cDNA w ere am plified using  p rim er combinations A +B 
and C+D. These two PCR products, w ith  an  overlap of 21 bp a t  one end 
of each fragm ent, w ere th en  combined in  a  second PCR to am plify the  
en tire  rm utF heproC L l cDNA. P rim ers for th is  reaction were the two 
outside prim ers used  in each of th e  two firs t round reactions (prim ers A 
and D). For all PCRs, high-fidelity Taq polym erase w as used (25 cycles 
a t  94 °C for 30 s, 55 °C for 1 min, and 72 °C for 2 min). The rm u tF h ep ­
roC L l cDNA w as th en  inserted  in to  th e  A vrll/S naB l site of expression 
vector pPIC9K. Both the  w ild-type (rFheproC L l) and m u tan t (rm u tF ­
heproC L l) plasm id in se rt w ere sequenced to verify the  presence of 
correct gene sequence and m utation.
The rFheC LI or rm u tF h eC L l plasm ids w ere linearized by digestion 
w ith  Sail and introduced to P. pastoris GSII5 cells by spheroplasting
(40). T ransform ants w ere selected for th e ir  ability to grow on histidine- 
deficient ag ar p lates and on ag ar p la tes containing m inim al m edia and 
m ethanol. Insertion  of rFheC L I or rm u tF heC L l in to  P. pastoris  w as 
confirmed by PCR using p rim ers specific to th e  yeas t genome (41).
Expression and  Purification o f  Procathepsin L I  a n d  Gly20 Procathep- 
sin  L I —Y east transfo rm an ts w ere cultured in  250 ml of BMGY broth, 
buffered to pH  6.0, in  1 lite r  of baffled flasks a t  30 °C un til an  ODfino of 
2 -6  w as reached. Cells w ere harvested  by centrifugation a t  2000 rpm  
for 5 min, and pro tein  expression induced by resuspending in  50 m l of 
BMMY broth, buffered a t  pH  6.0, 7.0, or 8.0, containing 1% m ethanol
(41). The cultu res w ere grown a t  30 °C w ith shaking a t  225 rpm  for 3 
days, 1 ml sam ples were removed daily and then  filter-sterilized m eth ­
anol w as added to m ain ta in  a  final concentration of 1%. To assess the 
effect of the  cathepsin L cysteine inhib ito r Z-Phe-Ala-diazomethyl- 
ketone (~CHN2) on th e  production of procathepsin L l by yeas t the  
inhib ito r w as added a t  the tim e of induction to a final concentration of 
25 fxM and th en  twice daily a t  th e  sam e concentration over the subse­
quen t 3 days.
Recom binant proteins w ere purified from yeast m edium  by affinity 
chrom atography using  Ni-NTA-agarose (QiagenX Briefly, a  column pre­
pared  w ith  1 m l o f resin  w as equilibra ted  by passing  through 10 ml of 
50 m M  sodium phosphate buffer, pH 8.0, containing 300 m M  N aCl and 
10 m M  imidazole. 10 m l of yeas t m edia su p e rn a tan t w as mixed w ith 40 
m l of th e  sam e buffer and applied to th e  column. The column w as 
w ashed w ith  15 m l of 50 m M  sodium phosphate buffer, pH 8.0, contain­
ing 300 m M  NaCl and 20 m M  im idazole, and bound protein  eluted using 
50 m M  sodium phosphate buffer, pH  7.0, containing 300 m M  NaCl and 
250 m M  imidazole. Purified recom binant pro teases were dialysed 
against PBS and stored a t  —20 °C. Sam ples of yeast m edium  su perna­
ta n ts  (10 fil) and purified pro teins ( ~ l - 5  fxg) w ere analyzed by 12% 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblot- 
ting  (see below).
Fluorometric Substrate A ssay  for Cathepsin L l  A ctivity— C athepsin  
L l activity w as determ ined by th e  fluorom etric sub stra te  assay de­
scribed by Dowd et al. (38). Y east cu ltu re  su p e rn a tan ts  o r purified 
recom binant pro tease w ere assayed in a  to tal volum e of 1 ml of sub ­
strate/buffer mix (2.5 m M  EDTA, 2 m M  DTT, 0.1 M sodium phosphate 
buffer, pH 6.0, and  10 ¿lm Z-Phe-Arg-NHMec). The reaction w as incu­
bated a l 37 °C and stopped a fte r  30 m in by the  addition of 200 jxl of 10% 
acetic acid. Fluorescence w as recorded a t  an excitation w avelength of 
370 nm  and an  em ission w avelength of 440 nm. The activity of the
sam ples were calculated from a  standard  curve of NIIM ec ranging from 
0 to 10 ¡j M ,  and presented  as nanom oles of NHMec m in-1 m l-1 .
In  Vitro Processing o f  Procathepsin L l  a n d  Gly36 Procathepsin L l — 
Purified recom binant procathepsin L l (~ 5  ¿¿g) w as incubated in acti­
vation buffer (0.1 m sodium  citra te  buffer, pH  5.0, 1 mM DTT, and 1.25 
mM EDTA) a t  37 °C. Sam ples were tak en  a t  various tim e points up to
2 h  and th e  proteolytic cleavage of th e  propeptide visualized by 12% 
SDS-PAGE. Aliquots w ere also assayed for enzyme activity w ith the 
specific su bstra te  Z-Phe-Arg-NHMec as described above.
Exogenous processing of Gly26 procathepsin L l w as carried out by 
m ixing 5 (ig of th e  purified m u tan t enzym e w ith 0.5 ^ g  of wild-type 
procathepsin L th a t had  been activated as described above. Processing 
of the  m u ta n t pro tein  over a period of 3 h a t 37 °C was analyzed by 12% 
SDS-PAGE. To confirm th a t  [Gly26]procathepsin L l was expressed as a 
correctly folded protein  a  sim ilar experim ent was performed in parallel 
w ith  m u tan t enzyme preparations th a t  h ad  been unfolded by heating  a t 
95 °C for 3 min.
Identification o f  Cleavage Products by N -term inal Sequencing—Fol­
lowing 12% SDS-PAGE, proteins w ere transferred  to polyvinylidene 
difluoride m em brane using  a  sem idry tran sfe r  cell a t 15V for 20 min. 
The m em brane was w ashed w ith  dH 20  and stained w ith 0.025% Coo- 
m assie B rillian t Blue R-250 in 40% m ethanol (40). Protein bands of 
in te re s t w ere subjected to N -term inal sequencing a t Genosphere Bio­
technologies (Paris, France).
Sequence Analysis—The F. hepatica cathepsin  L l  protein sequence 
w as aligned w ith several re lated  cathepsin sequences using ClustalX 
1.81. Protein sequences used included Caricapapaya , Fasciola hepatica 
cathepsin L l, F. hepatica  cathepsin L2, F. gigantica  cathepsin L l, 
Schistosom a m ansoni cathepsin L2, Caenorhabditis elegans CPL-1, 
mouse cathepsin L, r a t  cathepsin L, and hum an cathepsin L.2 Se­
quences w ere num bered according to th e  p apain  num bering used by 
V ernet et al. (32) w here th e  propeptide residues are recorded as a 
negative beginning from the cleavage site betw een propeptide and 
m atu re  enzyme.
SD S-PAG E and  Im m unoblotting—Protein  sam ples were separated 
by 12% SDS-PAGE and gels sta ined  w ith  a  0.1% w/v solution of Coo- 
m assie B rillian t Blue R-250 in  40% m ethanol/10%  acetic acid (42). 
Im m unoblots were p repared  by transferring  proteins to nitrocellulose 
m em branes, presoaked in  a tran sfe r buffer (50 mM Tris, 384 mM glycine, 
20% m ethanol), and th en  blocking these for 1 h  a t  room tem peratu re 
w ith 5% m ilk in  PBS/0.1% Tween 20. The nitrocellulose m em branes 
were probed w ith  polyclonal rabb it an tim atu re  cathepsin L l serum , 
rabb it anti-recom binant propeptide and preim m unized control rabbit 
serum  diluted 1/1,000 in 1% m ilk/PBS/0.1% Tween-20 for 45 min a t 
room tem peratu re . They w ere th en  washed th ree  tim es for 5 min each 
w ith  1% milk/PBS/0.1% Tween-20, followed by incubation for 45 m in a t 
room tem peratu re  w ith a  1/10,000 dilution of secondary antibody (goat 
an ti-rabb it IgG-peroxidase conjugate) prepared in 1% milk/PBS/0.1% 
Tween-20. Blots w ere w ashed as before and bound antibody visualized 
w ith 3,3'-diam inobenzidine (DAB, Sigma).
RESULTS AND DISCUSSION
Secretion o f Cathepsin L  Proteases by F. hepatica Parasites— 
When adult F, hepatica are maintained in vitro they secrete 
two major proteases that were previously characterized as 27,5 
cathepsin L l and 29 kDa cathepsin L2 in our laboratory (4, 38). 
N-terminal sequencing revealed a sequence AVPDK for both 
enzymes th a t correlated with the N terminus of fully processed 
m ature cathepsin L enzymes. In addition, immunoblotting ex­
periments demonstrated tha t while they are both reactive with 
sera prepared against purified mature cathepsin Ll, neither 
reacts with sera prepared specifically against a recombinant 
propeptide of cathepsin L l (Fig. 1, see also Fig. SB), Isolation of 
cDNAs encoding the two enzymes showed that they exhibit a 
high level of identity (77%) at the amino acid level that explains 
their cross-reactivity with antiserum prepared against either 
enzyme (13 , 38).
The two proteases are members of a phylogenetic lineage
2 Protein sequences and accession num bers from G enBank™  are as 
follows: Carica papaya  papain  (P00784), F. hepatica cathepsin L l 
(U62288), F. hepatica  cathepsin L2 (U62289), F. gigantica  cathepsin L l 
(AF112566), S. m ansoni cathepsin L2 (Z32529), C. elegans CPL-1 
(NP_507199), mouse cathepsin L (P06797), r a t  cathepsin L (KHRTL), 
and h u m an  cathepsin L (M20496).
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Fig. 1. SDS-PAGE an d  im m u n ob lo t a n a ly sis  o f  F. h e p a tic a  ex ­
creto ry -secreto ry  (ES) p rod u cts . ES products obtained from m e­
dium  in  which F. hepatica w ere cultured w as analyzed by SDS-PAGE 
and im m unoblotting. Lane M, m olecular size m arkers; lane J, Coomas- 
sie B lue-stained 12% SDS-PAGE gel of'ES products; lane 2, ES products 
probed with antiserum  prepared  in rabb its against native m atu re  ca­
thepsin  L l; lane 3, ES products probed w ith  an tiserum  prepared in  
rabb its against recom binant propeptide of procathepsin L l; lane 4, ES 
products probed with norm al rab b it serum . Arrow s indicate position of 
m ajor secreted and fully processed cathepsin L l  and cathepsin L2.
th a t includes the mammalian cathepsin Ls and have substrate 
specificities tha t are typical of this group, i.e. a preference for 
positively charged residues, such as arginine, in the P I position 
and hydrophobic residues, such as phenylalanine and leucine, 
in the P2 position (14). In contrast to mammalian cathepsin Ls, 
however, the enzymes exhibit activity over a wide pH range 
(4.0-8.5) and are remarkably stable at neutral pH; they retain 
most of their activity following a 24-h incubation a t pH 7,0 and 
37 °C whereas human cathepsin L is completely inactivated in 
less than 20 min under the same conditions (43). These en­
hanced stability properties were suggested to be important in 
host protein digestion in the parasite gut and in facilitating the 
migration of the parasite through the host intestine and liver
(33).
Immunolocalization and in situ hybridization studies previ­
ously carried out by our laboratories had shown that the ca­
thepsin L proteases are synthesized within the gastrodermis 
th a t lines the parasite gut (4, 33). The gastrodermis is com­
posed of epithelial cells tha t are columnar in shape and contain 
numerous dense vesicles situated at the apical end (see Fig. 
2A). Although secretory in function, these vesicles have been 
described as lysosomal-like and for almost thirty  years have 
been suspected to contain proteases (44-47). Confocal laser 
immunocytochemistry using antiserum prepared against the 
native mature cathepsin L localized this protease to the gas- 
trodermal epithelial cells (Fig. 2B) throughout the gut of adult 
F. hepatica. The pattern of immunoreactive labeling appeared 
punctate and was more dense toward the apical end of the 
gastrodermal cells indicating tha t the cathepsin L protease was 
associated with the secretory vesicles (Fig. 2C). Electron mi­
croscopy revealed that the enzyme is indeed stored in secretory 
vesicles within these cells (Fig. 2, D-F). The secretory vesicles 
were strongly immunoreactive with an antiserum prepared 
against the recombinant-expressed propeptide (Fig. 2E) and to 
the mature portion of cathepsin L l (Fig. 2F) indicating tha t the 
enzymes are present in these vesicles as the inactive proforms, 
procathepsin L. (The specificity of the sera for the propeptide 
and mature regions of the procathepsin L l is demonstrated in 
Fig. 3B.)
The above observations provide important insights into the 
regulation of protease activity within the gastrodermis of these 
parasites. First, in agreement with the observation by Halton 
and co-workers (44, 46, 47) it appears th a t the function of the 
vesicles is to package proteolytic enzymes for delivery into the 
gut lumen. Second, the accumulation of procathepsin L l, the
Fig. 2. Im m u n oloca liza tion  o f  p ro ca th ep sin  L l in  F. h e p a tic a  
gastrod erm al ep ith e lia l ce lls . A, schem atic representation  of gastro­
derm al epithelial cells i n i ’, hepatica  (after Sm yth and Halton, Ref. 46). 
g, Golgi; gl, gut lamellae; n, nuclei; sb, secretory bodies. B, confocal 
scanning laser m icrograph showing im m unoreactivity for m ature ca­
thepsin  L l w ithin  the gastroderm is of adu lt F. hepatica; the  nuclei 
(arrows) of the gastroderm al cells are clearly visible, gl, gut lamellae; 
lu, gut lum en. C, confocal scanning laser m icrograph showing im m u­
noreactivity for m ature cathepsin L l w ithin the gastroderm al cells of 
adu lt F. hepatica; the nuclei (arrows) of the  gastroderm al cells are 
clearly visible. Im m unoreactivity appears as a punctuate p a tte rn  a t the 
apical end of th e  cells where the  secretory vesicles are located, gm , gut 
muscle; lu , gut lum en. D, electron m icrograph showing non-reactivity of 
secretory bodies (arrows) w ith in  th e  epithelial cells of the gastroderm is 
w ith control preim m unized rabb it serum , gl, gut lam ellae. E, electron 
m icrograph showing the  localization F, hepatica  procathepsin L l to 
secretory bodies of the  gastroderm al epithelial cells w ith antiserum  
prepared  against the recom binant propeptide of procathepsin Ll. gl, 
gu t lam ellae. F, electron m icrograph showing the localization of F. he­
patica  cathepsin L l to secretory bodies of th e  gastroderm al epithelial 
cells w ith antiserum  prepared against purified mature portion of ca­
thepsin  L l, Note that the labeling is confined to the  contents of the 
secretory bodies.
inactive precursor, in the secretory vesicles rather than active 
mature protease makes good sense given the high abundance of 
these vesicles in the epithelial cells and hence the possibility of 
protease leakage into the cytoplasm (see Fig. 2A). Third, the 
data suggest tha t activation of the procathepsin L l takes place 
following secretion of the proteases into the gut lumen. Elec­
tron microscopy has shown tha t the contents of the secretory 
vesicles are extruded into the gut lumen where they mix with 
the ingested blood and tissue meal between the long extruding 
lamellae (Refs. 47 and 48; see Fig. 2A). Enzyme activation is 
likely to take place here as the pH is estimated to be —5.5 or 
slightly lower (47, 48). Once activated, the protease would be in 
direct contact with the bloodmeal and could immediately begin 
its function in protein catabolism. Since these helminth para-
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Fio. 3. SDS-PAGE an d  im m u n ob lo t a n a ly sis  o f  h e p a tic a  pro- 
c a th e p s in  L l ex p ressio n  from  P. p a s to r is .  A, cultures of P. pastoris 
transform ed w ith a  cDNA encoding procathepsin  L l were induced w ith 
1% m ethanol. Ferm entations were carried  out a t 30 “C in m edia buff­
ered to pH  6.0, 7.0, and  8.0. Aliquots (10 /j.1) removed a t  48 and 72 h 
after induction were analyzed by 12% SDS-PAGE. The 37 and 30 kDa 
com ponents are indicated. B, com parison of P. pasforts-expressed pro­
cathepsin  L w ith  native F, hepatica-secreted  m ature  cathepsin L l. 
Aliquots of adu lt F. hepatica ES products (lanes 1, 3, and 5) were 
com pared w ith  sam ples taken  from P. pastoris m edium after induction 
for 72 h  a t  pH  8.0 (lanes 2, 4, and 6). Lane M, m olecular size m arkers; 
panel a, Coomassie B lue-stained 12% SDS-PAGE gel; panel b, sam ples 
probed with an tiserum  prepared  in rabbits against m ature portion of 
cathepsin L l; panel c, sam ples probed w ith antiserum  prepared in 
rabb its against recom binant propeptide portion of procathepsin L l. 
Note, the  antipropeptide serum  reacts w ith  the  37 and 30 kD a P, 
pasioris-expressed components (indicated w ith arrows) b u t no t w ith 
parasite-produced m ature  cathepsin L l or cathepsin L2 (indicated by 
a n  asterisk). Control preim m unized rabb it serum  was not reactive with 
any proteins (not shown).
sites have a blind-ending gut, removal of undigested products 
and accumulated hematin is achieved by simply voiding the 
contents approximately every 3 h (46, 47). In this way active 
m ature cathepsin L would be regularly liberated from the 
parasite into the surrounding intestinal or liver tissues where 
it could perform its function in tissue degradation and thus aid 
the movement of the parasite through these tissues (47, 49).
The secretion of F. hepatica procathepsin contrasts with the 
intracellular trafficking of mammalian procathepsin L through 
the Golgi apparatus to acidic lysosomes where the enzyme is 
processed to the mature form by removal and degradation of 
the propeptide (14, 15). However, a low level of procathepsin L 
is also secreted from normal cells and is thought to play an 
extracellular processing function (50), while high levels of se­
cretion has been correlated with the metastatic activity of 
transformed cells (51, 52). A comparison may also be made with 
human cathepsin K, which is secreted by osteoclasts and func­
tions in bone resorption (25, 53, 54). Following adherence of 
osteoclasts to the bone surface an extracellular compartment 
known as an absorption pit is created between cell and bone 
into which cathepsin K is secreted. The pH within the pit is 
slightly acidic and is considered important not only for the 
dissolution of the bone but also for the activation of procathep­
sin K to its active proteolytic form (53, 54). Cathepsin B, L, and 
K have also been shown to be secreted into the extracellular 
lumen of thyroid follicles where they play a role in the proteo­
lytic processing of covalently cross-linked soluble thyroglobulin
to liberate the thyroid hormone thyroxine (T^) (34-36).
Expression and Processing of Wild-type Procathepsin L l—To 
study the mechanism by which the F. hepatica procathepsin L l 
is processed to an active mature enzyme the recombinant 
proenzyme was expressed in the yeast P. pastoris. The trans­
formed yeast cells were induced by 1% methanol in BMMY 
medium buffered at pH 6.0, 7.0, or 8.0 and then the recombi­
nant protein secreted into the medium analyzed by SDS-PAGE. 
Two major proteins migrating at 37 and 30 kDa were visualized 
(Fig. 3A). These components migrate higher than the mature 
cathepsin L l and cathepsin L2 secreted by the adult F. hepat­
ica parasites in 12% SDS-PAGE (Fig. 3B). Immunoblotting 
experiments showed that polyclonal antiserum prepared 
against the propeptide portion and against the mature portion 
of procathepsin L both reacted with the P. pastoris-expressed 
37 and 30 kDa components confirming tha t these are two forms 
of the procathepsin L. By contrast, the fully processed enzymes 
secreted by the parasite are reactive with antiserum prepared 
against the mature portion of the procathepsin L l but are not 
reactive with antiserum prepared against the propeptide por­
tion (Fig. 3B).
The 37 and 30 kDa components were purified from the pH
8.0 yeast medium by Ni-NTA agarose affinity chromatography 
and subjected to N-terminal sequence analysis. This showed 
that the 37 kDa protein represented the procathepsin L (plus 5 
amino acids of the yeast «-factor secretory signal at the N 
terminus) while the 30-kDa component represented an inter­
mediate processed form beginning at residue Leu -4 1  (papain 
numbering) within the propeptide (see Fig. 5).
The amount of the recombinant proteins in the yeast me­
dium increased over the 3 days following induction with meth­
anol; this increase was observed at pH 6.0, 7.0, and 8.0 (Fig. 3). 
However, the relative ratio of the 37 and 30 kDa proteins was 
dependent on the buffering pH of the medium, with the pro­
portion of 37 kDa increasing with increasing pH. A pH profile 
of activity for the recombinant F. hepatica cathepsin L showed 
tha t it was similar to tha t of the native m ature enzyme (38, 43), 
i.e. the recombinant enzyme was active over the pH range 4.0 
to 8.5 but was most active at pH 6.0.3 Therefore, by increasing 
the pH of the yeast medium above the pH optimum for activity 
of the F. hepatica cathepsin L the level of processing of the 
37-kDa form to the 30-kDa intermediate form was reduced.
To address this issue further, yeast cells were cultured at pH
8.0 in the presence and absence of the cathepsin L-specific 
inhibitor Z-Phe-Ala-CHN2 (Fig. 4, A  and B). Although the in­
hibitor was added twice daily at a concentration of 25 /am, 
which is 250-fold greater than its K¿ for cathepsin L (38, 40), 
samples of medium taken daily showed that cathepsin L activ­
ity was not completely inhibited (it is possible that the inhibitor 
is not stable in the medium) (see Fig. 4S). Nevertheless, the 
proportion of 37-kDa component in culture supernatants con­
taining inhibitor was greater than tha t in cultures without 
inhibitor, although the 30-kDa protein was still evident. These 
data support the idea tha t procathepsin L l secreted from P. pas­
toris autoprocesses to an intermediate active form and that this 
autoprocessing is prevented by the cathepsin L protease inhib­
itor Z-Phe-Ala-CHN2. Estimations of yeast cell viability 
showed that at the concentrations used the inhibitor did not 
affect the growth of the yeast cells.3
To examine whether further intermolecular processing could 
take place at a pH lower than 6.0, the 37 kDa procathepsin L l 
and 30-kDa intermediate forms were first purified from pH 8.0 
yeast culture supernatant by affinity chromatography on Ni- 
NTA agarose and dialyzed against PBS (pH 7.3). The pH of
3 P. R. Collins and J. P. Dalton, unpublished data.
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Fig. 4. P ro d u c t io n  o f  p r o c a th e p s in  L l  b y  t r a n s fo rm e d  P. p a s ­
to r is  in  th e  p r e s e n c e  a n d  a b s e n c e  o f  Z -P h e-A la-d iazo m eth y l- 
k e to n e . A , transform ed P. pastoris were cultured  a t  30 °C and pH  8.0 
in  the  presence (+ ) or absence (—) of th e  cysteine protease inhibitor 
Z-Phe-Ala-CHN2 (25 /am ). Aliquots of cultu re  su pernatan t, removed 
after 48 and 72 h, were analyzed by SDS-PAGE. The 37 and 30 kDa 
"bands are  indicated. B, recom binant yeast cu ltured  in  the presence 
(idotted line) and absence (solid line) of 25 /am Z-Phe-Ala-CHNa. Cathep­
sin  L activity in  the  culture  su p e rn a tan t w as m easured  w ith the  flu- 
orogenic sub stra te  Z-Phe-Arg-NHMec. Activity un its  are presented as 
nm ol of NHMec released m in-1 m l-1 .
samples taken from this preparation were then reduced to 5.0 
by the addition of 0.1 m sodium citrate containing 1 mM DTT 
and 1.25 mM EDTA, and then incubated at 37 °C (Fig. 5). 
Analysis of samples removed at various time points over a 
period of 2 h revealed th a t the 37 kDa procathepsin L is 
processed to the 30-kDa intermediate form and then through 
various intermediates th a t eventually give rise to a single 
peptide migrating a t 25.4 kDa. Corresponding with this proc­
essing was the gradual 5-fold increase in the activity of cathep­
sin L by the end of the 2-h incubation period (data not shown). 
N-terminal sequence analysis of the 25.4 kDa product revealed 
two sequences, NRAVP and RAVPD, which are just 2 and 1 
amino acids from the m ature protein processing site, respec­
tively (see Fig. 5). This intermolecular processing was com­
pletely inhibited by adding 1 0  /am Z-Phe-Ala-CHN2 to the sta rt­
ing mix and therefore can be attributed to the action of 
cathepsin L (data not shown).
The cleavage site between Gly- 42-Leu- 4 1  that generated the 
30 kDa intermediate form observed by SDS-PAGE analysis 
(29.6 kDa from amino acid sequence) was of particular interest 
as it occurred within the Gly 42-Xaa-Asn-Xaa-Phe-Xaa-Asp~3H
Fig. 5. A u to c a ta ly tic  p ro c e s s in g  o f p r o c a th e p s in  L l  a t  pH  5.0.
Purified procathepsin L l  (5.0 /Ag) was incubated a t 37 °C for 2 h  in 0.1 
M sodium  citra te  buffer, pH 5.0, containing 2 m M  DTT and 2.5 mM  
EDTA. Sam ples removed a t various tim e points were analyzed by 
SDS-PAGE. The predom inant proteins of 37, 30, and 24.5 kD a were 
subjected to N -term inal sequencing. The schem atic indicates the amino 
acid sequences surrounding the  interm olecular processing sites (ar­
rowed) th a t  generated these components and th e ir location w ithin the 
propeptide of procathepsin L l. The box indicates the  conserved motif 
GXNXFXD.
motif tha t was previously identified as pivotal in the intermo­
lecular processing of papain expressed in the yeast S. cerevi- 
siae. By random mutagenesis studies, and by sequence com­
parisons of various papain-like proteases, Vernet et al. (32) 
showed th a t the Gly- 4 2  and Asp- 3 6  residues within this motif 
were the most constrained and proposed tha t two cleavage 
sites, Gly 42-Leu 41 and Ala :i7-Asp 36 were important for 
proenzyme processing. The latter was considered more signif­
icant because cleavage at this site was predicted to perturb the 
negative charge of the Asp“ 36 residue (32). The Asp“ 36 residue 
is absolutely conserved in non-cathepsin B-like cysteine pro­
teases of helminth parasites, plants and mammals (including 
cathepsin L, cathepsin S, and cathepsin K) and crystallo- 
graphic studies on human cathepsin L showed that it partici­
pates in an important salt bridge between propeptide and ma­
ture enzyme (14).
On inspection of the F. hepatica procathepsin L propeptide 
sequence we found that the Gly_42-Xaa-Asn-Xaa-Phe-Xaa- 
Asp- 3 6  motif is completely conserved in this parasitic helminth 
and in others including F. gigantica and S. mansoni, and in the 
free-living helminth C. elegans (Fig. 6 ). Moreover, the Leu“ 41 
residue is also conserved in all of these sequences thus preserv­
ing the Gly 42-Leu~ 41 bond and implicating its importance in 
propeptide function in these helminths. However, these two 
residues are not conserved in the human, mouse, and ra t ca­
thepsin L sequences where Gly“ 42 is replaced by Glu or Ala and 
Leu - 4 1  is replaced by Met (Fig. 6 ). While it is tempting to 
speculate that the changes at these positions explains why an 
intermediate 30-kDa form was not observed in studies on the 
intermolecular processing of human procathepsin L (15), Mc- 
Queney et al. (25) found tha t the intermolecular processing of 
an inactive m utant form of procathepsin K by activated cathep­
sin K did involve a cleavage between Ala“ 42 and Met-41. As 
pointed out by Coulombe et al. (14), while there may be a direct 
involvement of the Asp- 3 6  in the Gly“42-Xaa-Asn-Xaa-Phe- 
Xaa-Asp_3S motif in the pH-dependant processing of proforms 
of cysteine proteases, cleavage at other peptide bonds within 
this motif could influence the local charge state that then may 
trigger processing.
Expression and Exogenous Processing of Gly26 Procathepsin 
L l—To further study the intermolecular processing of F. he­
patica procathepsin L l we expressed an inactive form of the 
protein by replacing the active site Cys26 with Gly26. Expres­
sion of this recombinant m utant in medium buffered at pH 6.0
17044 Processing o f F. hepatica Cathepsin L l
P a p a  i  n
F .  h apatlca CL1
F .  l ' i o p j r  i i* . j  C L 2  
f .  g i g a n t i c a  CL1 
S . m ji is o n i  CLZ
C .  f i l ü Q . i n s  C P I.1  
M ouse e t.
R a t  C L  
H u m a n  C L
F ig, 6, C o m p a r iso n  o f  th e  ( JA’NA'K.YD m o tif  b e tw e e n  p a p a in  
a n d  c a th e p s in  L  p ro te a s e s  o f  h e lm in th s  a n d  m am m als . The
GXNXT’XD m otif sequence of papain  is identical to th a t  of F. hepatica 
cathepsin  L l and cathepsin L2 and to the  cathepsin Ls of related  the 
trem atodes F. gigantica and S. mansoni (identical residues highlighted 
in black). The arr ow indicates the  position of th e  interm olecular cleav­
age site, between the  Gly 4v-Lou 41 bond (papain num bering), th a t  
generates the in term edia te 30 kD a component of the F. hepatica pro­
cathepsin  L when it is expressed in P. pastoris. The G ly '42 is substi­
tu ted  for Glu in the ra t  and mouse cathepsin  L sequences, and for Ala 
in the  hum an cathepsin L sequence (highlighted in gray, papain 
num bering).
and 8.0 showed tha t it migrates as a single band at 37 kDa in 
SDS-PAGE (Fig. 7). N-terminal sequencing confirmed that the 
37 kDa protein represented the complete procathepsin L l, and 
enzyme assays showed that it lacks activity against the sub­
strate Z-Phe-Arg-NHMec.3 The production of the m utant pro­
cathepsin L l is almost 4-fold greater than tha t of the combined 
37 and 30 kDa components observed in parallel cultures of 
wild-type procathepsin L l (see Fig. 7). Furthermore, the mu­
tan t enzyme did not process to lower molecular size forms when 
incubated at pH 5.0.3
Addition of recombinant wild-type cathepsin L l, which was 
activated as described above, to the m utant procathepsin L, at 
pH 5.0, resulted in the progressive appearance of a minor band 
at —35 kDa over an incubation period of 3 h and a second major 
band at 24.5 kDa tha t co-migrates with fully active cathepsin L 
(the intensity of the 24.5-band increases over the reaction pe­
riod, Fig. 8 ). N-terminal sequencing attem pts were unsuccess­
ful for the 35 kDa protein but a sequence of HGVPY (with less 
than 10% GVPYE) was obtained for the 24.5 kDa protein; the 
cleavage site is therefore located 10 amino acids prior to the N 
terminus of mature cathepsin L l. Experiments in which acti­
vated wild-type cathepsin L l was added to heat-denatured 
m utant procathepsin L showed tha t the la tter was sensitive to 
complete degradation by active cathepsin L l and confirms that 
the expressed m utant is correctly folded (intensity of the 24.5 
does not increase, compare Fig. 8 , A  and B).
An overview of the cleavage sites observed by autoactivation 
by the wild-type enzyme and by intermolecular processing of 
m utant enzyme by exogenously added wild-type cathepsin L l 
is shown in Fig. 9. The cleavage sites determined for the native 
mature cathepsin secreted by F. hepatica parasites in vitro are 
also indicated. It is clear that autoactivation and intermolecu­
lar activation occur by cleavages a t different sites and thus 
processing of procathepsin L l to an active enzyme can be 
achieved by more than one pathway. Of particular note is the 
absence of a cleavage site within the Gly_<12-Xaa-Asn-Xaa-Phe- 
Xaa-Asp-3 6  motif that would generate the 30-kDa intermedi­
ate component by exogenous activation. The dominance of this 
cleavage site in yeast-expressed wild-type cathepsin L and the 
strict conservation of the four relevant residues suggests an 
important role for this motif in the processing of F. hepatica 
procathepsin L l. The importance of this motif in the processing 
of papain was demonstrated by Vernet et al. (32) using various 
m utants in Gly~42-Xaa-Asn-Xaa-Phe-Xaa-Asp~ 36 sequence; 
certain residue replacements gave rise to some non-functional 
incorrectly folded enzymes, while others cause the accumula­
tion of inactive or partly active precursors.
pH 6.0 pH 8.0
F ig. 7. S e c re t io n  o f  th e  m u ta n t  p ro c a th e p s in  L l  fro m  P. pas­
toris. P. pastoris cells transform ed with wild-type procathepsin L l (wt) 
or the procathepsin L l th a t  had the active site Cys2fi replaced by Gly 
(mut) were cultured a t 30 °C in m edia buffered to pH 6.0 and 8.0. After 
48 h of induction w ith  1% (v/v) m ethanol sam ples of culture superna­
ta n t were analyzed by SDS-PAGE. The 30-kDa in term ediate form of 
procathepsin L was observed only in the  wild-type cultures.
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F ig . 8. Intermolecular processing of procathepsin Ll Cys2fi- 
Gly2fl mutant by exogenously added active cathepsin Ll. A, pu­
rified procathepsin  Cys26-Gly26 m u tan t (5.0 /xg) was incubated for up to
3 h in  0.1 M sodium  citra te  buffer, p l l  5.0, containing 1 mM DTT and 
1.25 mM EDTA a t  37 °C in th e  presence of 0.5 ¡xg of wild-type cathepsin 
L l  th a t  w as activated according to procedures shown in  Fig. 5. The 
position of the m atu re  wild-type cathepsin L a t  24.5 kD a (2.5 fig, 
loading) is indicated in  th e  lane labeled wt w ith th e  arrow. B , parallel 
experim ents w ere carried as above b u t in th is case purified procathep- 
sin  Cys26-Gly26 m u tan t (5,0 /xg) w as unfolded by heating  a t  95 °C for 3 
m in prior to the  addition of activated wild-type cathepsin L l.
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F ig. 9. Amino acid sequence of the propeptide of F. h e p a tic a  
cathepsin L l  with cleavage sites that lead to activation indi­
cated. The downward solid arrow indicates th e  cleavage site observed 
w hen native m atu re  cathepsin L l is secreted in vitro by adu lt F. 
hepatica. The first open arrow indicates the  site of cleavage w ithin the  
GXNXFXD m otif (boxed) th a t  gives rise to the  30 kD a interm ediate 
component w hen procathepsin L l is expressed in P, pastoris, and the 
second and th ird  open arrows show the  sites of cleavage when th is is 
fu rther activated in vitro a t  pH  5.0 (see Fig. 5). The upw ard solid arrows 
show the sites of cleavage of procathepsin Cys2fi-Gly2r> m u tan t by exog­
enously added m atu re  cathepsin L l.
Further intermolecular processing and activation of the 30- 
kDa intermediate component and direct activation of proca­
thepsin L l by exogenous enzyme took place in the C-terminal 
portion of the propeptide. Elucidation of the three-dimensional 
structure of human procathepsin L (14) and cathepsin B (29, 
30) revealed th a t this part of the propeptide is less structured 
and is readily accessible to proteases. Testament to this fact is 
the collective data showing tha t papain (32) cathepsin L (14), 
cathepsin B (29, 30), cathepsin S (31), and cathepsin K (25) can 
all be activated to mature enzymes either by cis- or trans- 
cleavage at various bonds within this segment. Cathepsin B of 
the helminth parasite S. mansoni can also be activated by
K K RN-------s Y V V W S  N DR ST K E K YT G
I , R H P I  Æ TjV'T Y T  LH  J |T  *<! ?  F E  F. FK  h K Y I,T 
L RH D LG L  VT V K l I J  L T  F E  E F  K AK Y L I 
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trans-cleavage at this segment (55, 56). However, the sites of 
cleavage of the wild-type and m utant procathepsin L l differed 
suggesting th a t prior cleavage within the Gly_42-Xaa-Asn-Xaa- 
Phe-Xaa-Asp-36 motif of the wild-type enzyme may have al­
tered the accessibility of the C terminus to protease action. It is 
also evident that both processing pathways leave additional 
amino acids a t the N terminus of the m ature enzyme, whereas 
cathepsin L l recovered from the medium in which parasites 
were cultured was fully processed to the characteristic N-ter­
minal residue. This suggests th a t additional protease action, 
possibly by an exopeptidase, may be required to remove these 
additional amino acids.
In the present study we show that the secretion and activa­
tion of F. hepatica cathepsin L l has similarities with tha t of 
their mammalian counterparts. Most importantly, we have 
elucidated th a t cathepsin Ls are secreted into the parasite 
lumen from vesicles synthesized within the gastrodermal epi­
thelial cells and tha t it is possible for these to become active by 
autocatalysis within the slightly acidic environment of the gut. 
The cathepsin L proteases are synthesized in copious amounts 
by F. hepatica parasites (0.5-1.0 /xg per adult parasite per 
hour) and early autoradiographic studies by Hanna (57) esti­
mated that the turnover rate from the synthesis of the contents 
of the secretory vesicles to their liberation into the gut lumen 
was rapid (~1 h). The means by which these enzymes are 
trafficked to the secretory vesicles and the possible involve­
ment of the Gly_<12-Xaa-Asn-Xaa-Phe-Xaa-Asp_36 motif (32) or 
a pH-dependent interaction with a membrane-bound receptor 
(58) requires investigation. A role for carbohydrate moieties 
may be excluded since the F. hepatica procathepsin L studied 
here contains no potential N-glycosylation sites, and studies 
have indicated that the native enzyme is not glycosylated (38, 
42), although homologs from other helminths, such a S, man­
soni, are glycosylated (59).
Mammalian cathepsins play a number of important biologi­
cal functions such as protein turnover, antigen processing and 
tissue remodeling (50). However, they have also been impli­
cated in various pathological conditions including tumor inva­
sion and metastasis (50, 60, 61), osteoporosis (53, 54, 62), and 
chronic inflammatory disease (63, 64). In parasites, cysteine 
proteases perform a number of pivotal functions such as feed­
ing, tissue penetration and immunomodulation tha t allow 
them to infect and establish disease in the host (2, 56). A 
number of studies have demonstrated tha t these enzymes rep­
resent targets at which new chemotherapeutic and immuno- 
prophylactic strategies can be directed (2, 12, 56, 65). While the 
goal of improving our knowledge on the activation mechanisms 
of mammalian cathepsin protease is to provide new ways of 
treating the diseases they cause, similar studies on the para­
site homologs would allow comparative analyses for the pur­
pose of designing parasite-specific treatm ents. The feasibility 
of this approach was demonstrated in our laboratory by show­
ing th a t propeptides of F. hepatica procathepsin Ls are potent 
inhibitors of their cognate enzymes but exhibit little or no 
activity against their mammalian homologs.
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Abstract
Cystatins are cysteine protease inhibitors that are widespread in the plant and animal 
kingdoms. Cystatins are expressed by helminth parasites that may employ these proteins to 
regulate parasite cysteine protease activity and to modulate host immune responses. Here, we 
describe the cloning of a cDNA encoding a high molecular weight protein of Fasciola 
hepatica that contains two domains with significant identity to the cardinal cystatin signatures 
and four domains with degenerated cystatin signatures. This is the first report of a multi­
domain cystatin in an invertebrate species. While cystatins are divided into three evolutionary 
related families, our phylogenic analysis shows that all cystatin domains within this protein, 
like several other helminth cystatins, belong to the cystatin family 2. The DNA region 
encoding the domain 4 that is the best conserved at level of its cystatin signatures was 
expressed in Drosophila cells and recombinant protein was produced and purified. This 
protein was a potent inhibitor of the papain and of the major cysteine protease of F. hepatica, 
the cathepsin LI.
Keywords: Cystatin; Cysteine protease inhibitor; Proteases; Cathepsin LI; Parasites, Fasciola 
hepatica-, Newly excysted juvenile.
1. Introduction
Fasciolosis is an infection caused by the parasitic trematode Fasciola hepatica. This 
parasite is widespread and infects a wide range of wild and domestic mammals including the 
sheep and bovine (Torgerson and Claxton, 1999). The disease causes poor grow performances 
in sheep and cattle that lead to major annual economic looses in agricultural communities in 
both the developed and developing world. Moreover, human fasciolosis is a public health 
problem in several regions including the Peru, Bolivian altiplano and the Nile delta of Egypt 
(Mas-Coma et al., 1999a; Mas-Coma et al., 1999b). Identification of F. hepatica antigens as 
candidates for vaccines and the study of host-parasite interactions has become a major 
research focus since the parasites resistant to chemical treatments have emerged in several 
countries including the United Kingdom, Ireland, the Netherlands and Australia (Gaasenbeek 
et al., 2001). Several vaccination experiments have been performed using proteases, anti­
oxidants or fatty acid binding proteins from adult and immature flukes and elicited significant 
protection rates (30 to 80%) after challenge infection (for review see Spithill and Dalton, 
1998).
There is little data concerning proteins from newly excysted juvenile (NEJ) flukes due 
to the minute amount of material that can be obtained from these stages. In efforts to identify 
potential targets for vaccination in this developmental stage, we screened a subtractive library 
and identified a large number of mRNA fragments specifically or over-expressed by NEJ. 
One of the specific mRNAs was found to possess similarities with motifs that are signatures 
for cystatins. Cystatins are tight-binding inhibitors of papain-like cysteine proteases and are 
widespread in plants and animals. Members of the cystatin super-family are classified into 
three evolutionary related families (Rawlings and Barrett, 1990; Turk and Bode, 1991). 
Members of family 1, termed Stefins, are low molecular weight, single domain cystatins that
do not contain disulphide bridges. Members of family 2 also possess a single cystatin domain 
but their structure contains at least two disulphide bridges. In contrast, the members of family
3 contain three cystatin domains and are typically represented by the mammalian blood 
plasma kininogens. Cystatins are expressed by filarial nematodes such as Acanthocheilonema 
vitae, Brugia malayi (Maizels et al., 2001) and Onchocerca volvulus (Lustigman et al., 1992) 
and intestinal nematodes such as Nippostrongylus brasiliensis (Dainichi et al., 2001). Recent 
work also shows that Schistosoma mansoni express a cystatin related to the family 1 (Morales 
et al., 2004). Filarial cystatins are pathogenicity factors and are thought to play a key role in 
balancing the host-parasite immune relationship (Shierack et al., 2003). Here, we describe the 
characterisation of a cDNA encoding a protein that contains six cystatin-like domains, two of 
which are well conserved while four are degenerate. One of the conserved domains, domain 4, 
suspected to be an active protease inhibitor, was expressed as a recombinant protein in 
Drosophila Schneider 2 cells and shown to be a potent inhibitor of papain and of the major 
cysteine protease, cathepsin LI, of F. hepatica. Phylogenic analyses revealed that the cystatin 
domains all belong to a lineage of cystatins that consist mainly of helminth cystatins that 
belong to the family 2. This protein is the first multi-domain cystatin to be described in 
invertebrates.
2. Material and methods
2.1. Parasites
Fasciola hepatica metacercaria were obtained from in vitro-infected snails Lymnaea 
truncatula maintained in our laboratory. Excystment of juvenile flukes was performed as
tTVici’7riiirlii At q1 A
previously described (Wilson et al., 1998). Adult F. hepatica flukes were recovered from 
naturally infected bovine livers at a local abattoir.
2.2. Construction ofcDNA library from newly excysted juvenile
Total RNA was isolated from 3 adults and from 5000 NEJ F. hepatica with a modified 
caesium chloride purification method of Sambrook (Sambrook et al., 1989). Reverse 
transcription was made with 1 pig of adult total RNA or 500 ng of juvenile worm total RNA 
with the Smart™ PCR cDNA synthesis kit (Clontech) and the Super Script II MMLV reverse 
transcriptase (Invitrogen). NEJ cDNAs (10 n%) were digested with proteinase K (Promega), 
purified, blunted with T4 DNA polymerase (Promega) and size fractionated through a 
Chromaspin 400 column (Macherey Nagel). The cDNAs of more than 500 bp were collected, 
precipitated with ethanol and dissolved in water. The resulting cDNAs were immediately used 
for ligation with Eco i?I adaptators (Promega). The reaction was phosphorylated with T4 
polynucleotide kinase (Promega) and excess adaptator was removed by passage through a 
Chromaspin 400 column. The fractions containing cDNAs were treated with ethanol and the 
resulting precipitated cDNAs were dissolved in water. Two hundred ng of cDNA were used 
for ligation with 500 ng of ATriplEx vector (Clontech) that had been previously digested with 
Eco Rl. The ligation was mixed with 50 pil of packaging extract (Promega) and incubated for 
3h at 22°C to obtain the phage library. The resulting library was plated and titrated using 
standard protocol.
A subtractive cDNA library enriched with specific juvenile cDNAs was made using 
the PCR Select™ Subtraction kit (Clontech). The subtraction products were subcloned into 
the pGEM-T easy vector and the recombinant vectors transfected into competent cells 
(Promega). One hundred and fifty colonies were individually collected and each of the
\Chd7r\c\f\ ii p t al
corresponding DNA was used to probe adult and juvenile total cDNAs in Southern blot. A 
472 bp clone that hybridised cDNA from juvenile worms and not from adult worms was 
selected, sequenced and studied further.
2.3 Screening of the NEJ library
The 472 bp DNA (100 ng) was labelled with 25 ptCi dCTP [aP32 ] (ICN France) using 
random priming kit (Promega) and used to screen the NEJ cDNA library prepared in ATriplEx 
vector and also used to probe cDNAs from adult or NEJ in Southern blot. A total of 4000 
colonies were plated and transferred to nylon membranes (Porablot NY plus, Macherey 
Nagel). These membranes were incubated overnight at 55°C in hybridization solution (6X 
SSC, 1% SDS, 5X Denhardt's and 50% formamide containing 100 pig/ml denatured herring 
sperm DNA) to which the radiolabelled 472 bp probe was added. The membranes were then 
washed twice for 30 min in 3X SSC/1% SDS at 55°C and twice for 30 min in 1.5X SSC/1% 
SDS at 55°C and then placed in contact with X-OMAT AR5 Film (Kodak) for 48h. Following 
a second round of screening, as described above, a 2359 bp cDNA clone was isolated and its 
sequence determined.
2.4 Southern blot analysis
Genomic DNA (gDNA) was extracted from adults using the Aquapure genomic DNA 
isolation kit (Bio-Rad) and 3[xg were digested with EcoRl and Rsal and the products were 
separated on a 1 % agarose gel. Electrophoresis of the cDNAs was performed using the same 
conditions except that 250 ng sample of cDNA from adults and NEJ F. hepatica were used.
The DNA was denatured by incubating the gel 10 min in a 0.2N HC1 solution followed 
by an incubation of 20 min in a denaturing solution (1.5M NaCl, 0.5N NaOH). The DNA was 
then transferred to a nylon membrane in 20X SSC, 3M NaCl, 300 mM sodium citrate (pH 7) 
(Sambrook et al., 1989) and hybridization was performed as described above (section 2.3).
The 472 bp fragment (see section 2.2) was used to probe the membrane with the 
cDNAs and a 336 bp fragment corresponding to cystatin domain 3 was used to probe the 
membrane with the genomic DNA.
2. 5. Semi-quantitation ofmRNA levels by PCR
PCR was performed by using 1 ng adult and NEJ cDNAs obtained as described above 
(section 2.2). The primers used were as followed: 5’ CTG ATG TTG GGT TCC TTG G 3’ 
for the forward primer and 5’ TTA AC A GCT TAT AG A CAA ATC ATG A 3’ for the 
reverse primer corresponding to a fragment of 1368 bp spanning from the beginning of the 
cystatin domain 3 to the stop codon. PCR conditions were: 1 min at 94°C, 30 s at 53°C, 60 s 
at 72°C. A final 10 min extension was performed at 72°C.
2.6, Expression and purification of the recombinant cystatin domain in Schneider 2 cells
The fragment of 336 bp encoding the cystatin domain 4, was generated by PCR with 
the forward (51 CCA TGG TCT CTC ACC GGC GCT CCT C 3' containing the Nco I 
restriction site (underlined)) and the reverse (51 CTC GAG TTA GAA GCG ACG AC A ATT 
ATC C 3' containing the Xho I restriction site (underlined) followed by a stop codon) primers. 
PCR conditions were : 1 min at 94°C, 30 s at 55°C, 60 s at 72°C for 25 cycles. A final 10 min 
extension was performed at 72°C.
The DNA fragment was first inserted into the pGEM-T easy vector (Promega) and 
digested with the appropriate restriction enzymes and then cloned into the expression vector 
pMT/BiP/V5-his (InVitrogen). The recombinant vector was sequenced to ensure that no 
substitutions or alterations occurred in the reading frame. The transfection into Drosophila 
Schneider cells was performed with the Drosophila Expression System (DES) purchased 
from Invitrogen as described (Khaznadji et al., 2003). Transfected cell lines were grown in 
DES culture medium and protein synthesis was induced by the addition of copper sulphate 
(500 jiM. final) for 48 h. The supernatant was harvested and dialysed overnight at 4°C against 
Tris/HCl 25 mM, pH 8.0. The supernatant was loaded onto an anion exchange column (Poros 
20HQ PerSeptive Biosystems) equilibrated in the same buffer. Cystatin domain 4 was 
collected in the column run-through. The cystatin domain 4-containing fractions were 
centrifuged through a 50 kDa filter (Amicon). The cystatin domain 4 was recovered in the 
<50 kDa fraction, concentrated using ultrafiltration units (Centriprep, Millipore) and dialysed 
against 10 mM sodium acetate, pH 5.0. Total protein concentration was determined by BCA 
assay (Pierce, Interchim, France) and purification steps were followed in SDS-PAGE with 
silver staining (Khaznadji et al., 2003). After purification, a faint contaminating band with a 
molecular mass of 50 kDa was observed and cystatin concentration was estimated by 
comparison with human cystatin C in SDS-PAGE after staining with Coomassie blue.
2.7. Enzymatic assays and analysis on non-denaturaredpolyacrylamide gel with gelatin.
The enzymes used were papain (EC3.4.22.2; Sigma) and the recombinant F. hepatica 
cathepsin LI purified from yeast (Collins et al., 2004). Human cystatin C was purchased from 
Calbiochem and Z-Phe-Ala-diazomethylketone (Z-Phe-Ala-CHN2) was purchased from 
Sigma. The colorimetric substrate benzoyl-DL-Arg-p-nitroanilide (Z-DL-Arg-p-nitroanilide)
and the fluorogenic substrate benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin (Z- 
Phe-Arg-AMC) used to assay papain and cathepsin LI, respectively, were from Bachem. The 
enzymatic assay buffer was 100 mM sodium phosphate, containing 1 mM dithiothreitol and 2 
mM EDTA, adjusted to pH 6.5 for papain and to pH 6.0 for cathepsin LI. The reactions were 
performed at room temperature for papain and at 37°C for cathepsin LI. The reactions were 
allowed to proceed for 30 min and then stopped by the addition of 200 ¡a\ of 10 M acetic acid. 
Released p-nitroanilide was measured by spectrophotometry at 405 nm. Z-Phe-Arg-AMC 
hydrolysis was measured by fluorometry with an excitation at 370 nm and emission at 440
The inhibition of F. hepatica cathepsin LI was also visualised on non-denaturated 
polyacrylamide gel containing gelatin substrate. Recombinant cathepsin LI was activated in 
sodium acetate, pH 5.5, for 2 h and dialysed against PBS, pH 7.3 (Collins et al., 2004). The 
activated enzyme (5|jM) was incubated in PBS, pH 7.3, with an equal amount of recombinant 
cystatin domain 4 for 30 min. Samples of cathepsin LI, cystatin and the mixture were then 
applied to 8% polyacrylamide gels that had been set with or without 0.1% (w/v) gelatin 
(Roche et al., 1997). After electrophoresis, the gel without gelatin was stained with 
Coomassie Blue while the other was incubated overnight in sodium acetate buffer, pH 5.5, 
and then stained.
2.8. Databank searches and sequence analyses
The Infobiogen facilities were used for database searches (Genbank release 132, 
updated 11/16/2002, Swissprot release 40 and TrEMBL 21, both updated 12/06/2002), 
sequence alignments and calculations. First, 97 sequences (Table 1) identified from BLAST 
searches and from the PROSITE database were aligned using CLUSTAL W (Thompson et
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al., 1994). The beginning of the sequences was the conserved G residue and the end the last 
conserved C. At each step, the sequences were manually adjusted to facilitate the quality of 
alignment. Phylogenic analyses were performed using the parsimony and Neighbour Joining 
software of the PHYLIP package, version 3.5c (Felsenstein, 1993). Due to the important size 
of the data file, consensus trees were calculated from a sampling of 100 bootstraps.
3. Results
3.1 .Cloning of a cDNA encoding a protein containing six putative cystatin domains
Screening of a subtractive library enriched in NEJ cDNAs of F. hepatica allowed the 
isolation of a 472 bp cDNA fragment that contained a sequence encoding a complete cystatin 
domain. This fragment was then used to isolate a 2359 bp cDNA from a second library that 
contained complete NEJ cDNAs of F. hepatica. The 472 bp cDNA fragment was also used as 
probe to screen adult and NEJ cDNAs on Southern blot (Fig. 1); a cDNA fragment of about 
2359 bp was detected in the NEJ sample but not in adults. The cDNAs from adults and NEJ 
were also used in PCR to compare the cystatin expression in both stages (Fig. 2). In this case, 
a 1368 bp transcript was detectable in the 2 samples. However, semi-quantification by PCR 
showed that while the transcript is detectable after 20 amplification cycles in the NEJ sample 
it was only detectable in adults after 25 cycles. Collectively, this data confirms that the 
mRNAs for the cystatin are more abundant in NEJ stage than in adult stage. To confirm the 
presence of the gene in the parasite, Southern blot was performed on genomic DNA (Fig.3). 
Adult genomic DNA was digested and probed with a 336 bp fragment. The probe corresponds 
to the EcoR l-Rsa I restriction fragment of the cDNA and recognized a major fragment of
about 374 bp as expected. A fragment of about 250 bp hybridized less intensively. This 
fragment may correspond to a region with weaker homology.
Analysis of the 2359 bp cDNA isolated from the complete NEJ library, revealed the 
presence of several potential open reading frames (ORF) and one of 2072 bp that encodes a 
putative protein of 690 amino acids. This ORF is flanked at its 3’ extremity by a 287 bp 
untranslated region that contained a typical polyadenylation signal located 23 bp upstream to 
the polyA tail. The 5’ region is not complete and lacks the typical consensus sequence for 
initiation of transcription and the start codon.
Search for similarities between the amino acid sequence of the protein encoded by the 
2072 bp ORF and the databases revealed that the protein contained two putative cystatin 
domains of 106 amino acids from amino acid 238 to 343 (domain 3) and 355 to 460 (domain 
4), respectively. The best hits found with these two domains were observed with the mouse 
kininogen (25% identity) and for the ovarian cystatin from the common carp (29% identity) 
for domains 3 and 4, respectively. Search for similarities within the amino acid sequence of 
the protein encoded by the 2072 bp ORF revealed the presence of six tandemly repeated 
domains that spanned along all the protein length (Fig. 4). The six domains exhibited low 
sequence similarities to each other (15.5 to 29%) and their extremities were difficult to define 
since no significant similarities were found between the residues located at their C and N- 
termini. While these observations indicate that these six domains may have originated from a 
single ancestral cystatin domain, domain 4 was the only to contain the three cardinal 
signatures of a cystatin domain (Fig. 4): the N-terminal glycine (referred as G355 for domain 
4), the highly conserved central motif QxVxG that was located in the first hairpin loop of the 
protein and corresponded to the papain-binding site, and the second C-terminal hairpin-loop 
containing the PW motif. This domain also contained four cysteine residues. All other 
domains lacked one or several of these features. Domain 3 lacked the proline residue of the
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PW motif and showed a R/Q substitution within the QxVxG motif. The domains 2, 5 and 6 
lacked the QxYxG motif and the conserved G in their N-termini. Only domain 2 showed the 
C-terminal loop PW, the two others lacking the conserved W residue. Domain 1 was 
incomplete at its N-terminus and only contained the conserved motif QxVxG. Finally, the 
domains 1 and 2 had two and three cysteine residues whereas the four others had four cysteine 
residues.
3.2. Expression and purification of the cystatin domain 4
Since the cystatin domain 4 has conserved papain-binding sites we suspected that it 
might be a potent inhibitor of cysteine proteases. To demonstrate this property the region of 
cDNA that encodes this domain was transformed into Drosophila S2 cells using a vector that 
directs expressed products into the culture medium. Recombinant domain 4 was secreted in 
the S2 cells media at levels of approximately 10 mg/L. The cystatin domain 4 was purified by 
a single anion exchange chromatography step followed by ultra-centrifugation through a 50 
kDa cut-off filter. The molecular mass of the recombinant purified protein was around 19 kDa 
as shown in Fig. 5.
3.3. Inhibitory activity o f cystatin domain 4 against papain and F. hepatica cathepsin LI
The purified F. hepatica cystatin domain 4 was assayed for inhibitory activity against 
the cysteine protease papain and the major F. hepatica cathepsin LI protease. Five piM of 
cystatin domain 4 completely inhibits (>98% inhibition) 1 piM of papain as measured by Z- 
DL-Arg-p-nitroanilide hydrolysis. In a similar assay with the recombinant F. hepatica 
cathepsin LI, the recombinant cystatin inhibits completely the Z-Phe-Arg-AMC hydrolysis.
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Figure 6A shows the inhibition of gelatinolytic cathepsin LI activity by domain 4 in 
polyacrylamide gel under non-denaturating conditions. In these gels, cathepsin L migrates as 
a smear and a corresponding broad band of gelatinolytic activity in polyacrylamide gel 
containing gelatin (Fig. 6A, compare lanes 1). Cystatin remains at the top of the gel (Fig. 6A, 
Panel a, lane 3) but when mixed at equimolar ratios with cathepsin LI it complexes with the 
enzyme and completely inhibits its gelanolytic activity (Fig. 6A, compare lanes 2).
The inhibition profile of domain 4 in comparison with human cystatin C and the 
cathepsin L-specific inhibitor Z-Phe-Ala-CHN2 is shown in Fig. 6B. The decrease of 
cathepsin LI activity with cystatin concentration followed the hyperbolic inhibition curve of 
the tight-binding inhibitors. This inhibition profile demonstrated that domain 4 has a similar 
potency to these inhibitors, i.e. an inhibition of 95% at an equimolar ratios, suggesting that the 
recombinant domain 4 is produced as a fully functional correctly-folded protein. Similar 
studies were carried out with domain 3; however, its expression in insect cells was low 
making purification difficult. A partially purified fraction obtained after anion exchange 
chromatography exhibited inhibition of papain and cathepsin L but kinetic data could not be 
established (data not shown).
3.4. Phylogenic relationship with other cystatins
In an attempt to further characterize each of the F. hepatica cystatin domains, 
phylogenic analyses were developed using sequences available in databanks. Overall, our 
calculations were done with a data comprising of 97 cystatin sequences identified in the 
genomes of plants, insects, nematodes, trematodes and cold- and warm-blood vertebrates. 
Phytocystatins were used as outgroup to root the trees as previously described (Margis et al., 
1998).
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Consensus trees obtained using the parsimony and Neighbour-Joining methods were 
similar in topology and in the bootstrap values at nodes.
The consensus tree developed with the parsimony method and a sampling of 100 
bootstraps is presented in Fig. 7. It revealed four animal cystatin lineages that were named 
family 1 to 4. Their existence is sustained by significant bootstrap values ranging from 62 to 
97% at nodes located on the root of each of these 4 families. Family 1 to 3 correspond to 
those previously described (Rawlings and Barrett, 1990; Turk and Bode, 1991) and our 
analyses demonstrated that each of them is composed of two sub-lineages comprising 
cystatins from invertebrate or vertebrate origin, respectively. Surprisingly, our data also 
revealed a fourth family so far never described and that is presently only composed of 
proteins from invertebrate origin. Concerning the six domains of the F. hepatica polycystatin, 
we observed that all belong to the invertebrate sub-lineage of the Family 2. Their clustering 
within a single branch indicates that each domain originated from a single ancestral cystatin 
by duplication.
4. Discussion
The present study describes the sequence of a novel multi-domain cystatin that is over­
expressed in the infective NEJ stage of F. hepatica. The only other molecules with multiple 
cystatin domains are the mammalian kininogens, although these are members of the family 3 
cystatins. Kininogens are multi-functional proteins containing three cystatin domains and 
biologically active bradykinin domains that are potent vasodilators (Kaufmann et al, 1993). 
However, while two of the cystatin domains of kininogen are potent inhibitors of cysteine 
proteases the other is degenerate and lacks inhibitory activity (Salvesen et al., 1986). Fasciola 
hepatica multi-cystatin shows similar structural features of the kininogens with functional and
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degenerated domains, however our phylogenic analysis suggests that it is more related to 
family 2 cystatins. The family 2 cystatins represented by human cystatin C and chicken egg 
cystatin are secretory proteins with one cystatin domain and two characteristic disulphide 
bridges. While human cystatins E and F also belong to the family 2 cystatins they exhibit a 
closer relationship with domain 3 of kininogen and, contrary to most cystatins, they have a 
restricted pattern of expression (Ni et al., 1998). Nematode cystatins have also been classified 
in the family 2 cystatin but only contain one disulphide bridge. A new subgroup of the family 
2 cystatins, cystatin-related epididimal spermatogenic (CRES) proteins, that have tissue- 
specific expression (reproductive tract), was recently described by Cornwall and Hsia (2003). 
These cystatins contain only the PW site but lack the conserved QxVxG motif. Therefore, it is 
becoming clear that family 2 cystatins now consists of several groups and sub-groups. In the 
phylogenic study, we show that F. hepatica cystatins and the nematode cystatins are included 
in the invertebrate sub-group of the family 2.
Cystatins have a papain-binding site that binds to the catalytic site of papain-like 
proteases and inhibits them reversibly (Abrahamson, 1994). This site is created by several 
conserved regions of the protein coming together including, a glycine in the N-terminal 
region, a central motif QxVxG in the first hairpin loop of the protein and a PW motif in the 
second hairpin loop in the C terminal region (Abrahamson et al., 1987; Bjork et al., 1996; 
Hall et al., 1993). The F. hepatica cystatin domains 3 and 4 contain a glycine in the N- 
terminal part, and the highly conserved tryptophan in the C-terminal region. However, 
domain 3 lacks the proline residue of the PW motif of the second hairpin loop but this clearly 
does not affect its inhibitory activity. The domain II of human kininogen also lacks this 
proline residue but is, nevertheless, a potent inhibitor of cysteine proteases (Salvesen et al., 
1986). A second tryptophan residue is present in the F. hepatica cystatins three amino acids 
before the PW motif where a tyrosine residue is usually conserved within the cystatin super
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family. However all the nematode cystatins and the human cystatin F possess a tryptophan 
and hence this substitution might be associated with a specific function (Lustigman et al., 
1992; Ni et al., 1998). The central motif QxVxG is conserved for the domain 4, however, the 
domain 3 contains a positively charged arginine (RIVAG) in this motif which is unusual but 
similarly found in the human cystatin F (Ni et al., 1998), and may affect the target specificity. 
The F hepatica cystatin domains 3 and 4 both possess the four highly conserved cysteine 
residues toward the C-terminal end, corresponding to those that form disulphide bridges 
within the cystatin members of the families 2 and 3 (Rawlings and Barrett, 1990). Therefore 
we assume that these bridges are intact in these proteins. The F. hepatica cystatin domains 1,
2, 5, and 6 lack one or several features of the papain-binding site. Domains 1 and 2 possess, 
respectively, the conserved central and the C-terminal motif. Additionally, they contain only 
one conserved disulphide bridge like nematode cystatins (Maizels et al., 2001). Cystatin 
domains 5 and 6 lack the 3 conserved regions and only show the 2 putative conserved 
disulphide bridges. A similar configuration is found in the human kininogen; the cystatin 
domain 1 of this molecule lacks all the three parts of the papain-binding site but have two 
conserved disulphide bridges. This degenerated domain does not exhibit inhibitory effect on 
cysteine proteases (Salvesen et al., 1986).
Given that we have shown that two cystatin domains of the NEJ multi-domain protein 
described here exhibit the ability to inhibit in vitro cathepsin L activity it is natural to suspect 
that the multi-cystatin is involved in regulating cysteine protease activity in this stage of 
parasite. The NEJ is the invasive stage of the parasite but remains in a protease-free 
environment until it is ingested into the intestines. NEJ of F. hepatica express copious 
amounts of cathepsin B (Wilson et al., 1998) and cathepsin L proteases (Harmsen et al., 
2004). Within a short period after excystment the expression of both cathepsin B and 
cathepsin L cysteine proteases are switched on to allow the rapid penetration of the host
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intestinal wall (Wilson et al., 1998; Mulcahy et al., 1999); hence cystatins may be required to 
protect the NEJ from its own proteases.
An additional function of the cystatin may be the modulation of host immune 
responses. Parasite nematode cystatins are involved in immune evasion such as antigen 
presentation inhibition (Dainichi et al., 2001; Manoury et al., 2001), polyclonal activation and 
induction of a Th2 immune response (Schonemeyer et al., 2001). A similar function for at 
least the two functional cystatin domains of the multi-cystatin may be expected. However, the 
inhibition of host antigen presentation by nematode cystatins is mediated by the legumain 
inhibitory motif within the cystatin. The legumain inhibitory motif is distinct from the papain 
binding motif and compounded by three essential amino acids: serine, asparagine and aspartic 
acid (Alvarez-Fernandez et al., 1999). Since the F. hepatica cystatin domains are devoid of 
any legumain-binding motif, we suggest that the F. hepatica multi-cystatin is not involved in 
the inhibition of host antigen presentation.
Fasciola hepatica has been shown to polarize the host cytokine response to a Th2 
profile. Analysis of cytokine production in infected mice (O’Neill et al., 2000) and rats (Tliba 
et al., 2002) have shown that only Th2 cytokines (IL4, IL10) and little or no IFNy are 
produced. Tliba et al. (2002) have studied the very early response in the liver where only 
juvenile and immature flukes are present and showed that an increase in IL10 production and 
a reduced proliferative response of liver mononuclear cells occurs soon after infection. Filarial 
cystatins were shown to induce the massive production of IL10. This production of IL10 has 
been involved in the induction of an anti-inflammatory environment with a strong inhibition 
of cellular proliferation, which favours the survival of the worms (Hartmann and Lucius, 
2003). Fasciola hepatica cystatins produced by NEJ may have such an effect and this 
immunoregulatory function may, as described for filarial cystatins (Schierack et al., 2003), be 
a specific adaptation to the parasitic life style.
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Table 1. Cystatins used for the phylogénie study.
Protein Name Species Acc. N°. Tree name
Cysteine proteinase inhibitor Zea mays Q41897 CystlZeaM
Cystatin II Zea mays Q41825 Cyst2ZeaM
Cysteine proteinase inhibitor Zea mays P93627 Cyst3ZeaM
Cystatin I precursor Zea mays P31726 Cyst4 ZeaM
Cystatin A Helianthus annuus Q10992 Cyst-HelA
Multicystatin precursor Solanum tuberosum P37842 Cystlto Cyst8 SolT
Putative cysteine proteinase inhibitor B Arabidopsis thaliana 022202 Cystl-AraT
Cysteine proteinase inhibitor Arabidopsis thaliana Q41906 Cyst2-AraT
Cysteine proteinase inhibitor like Arabidopsis thaliana 023494 Cyst3-AraT
Cysteine proteinase inhibitor Arabidopsis thaliana Q41916 Cyst4-AraT
Cysteine proteinase inhibitor Sorghum vulgare Q41294 Cyst-SorV
Cysteine protease inhibitor Pyrus communis 024462 Cyst-PyrC
Cysteine proteinase inhibitor Brassica campestris Q39268 Cystl-BraC
Cysteine proteinase inhibitor Brassica campestris Q39270 Cyst2-BraC
Cysteine proteinase inhibitor Brassica campestris Q42380 Cyst3-BraC
Cysteine proteinase inhibitor Glycine max 004720 Cystl-GlyM
Cysteine proteinase inhibitor Glycine max Q39840 Cyst2-GlyM
Cysteine proteinase inhibitor Glycine max Q39841 Cyst3-GlyM
Cysteine proteinase inhibitor Glycine max Q39842 Cyst4-GlyM
Cysteine proteinase inhibitor Ambrosia artemisiifolia Q38678 Cystl-AmbA
Cysteine proteinase inhibitor Ricinus communis Q43635 Cyst-RicC
Cysteine proteinase inhibitor Carica papaya Q39561 Cyst-CarP
Oryzacystatin-I Oryza sativa P09229 Cystl-Ory-S
Oryzacystatin-II Oryza sativa P20907 Cyst2-Ory-S
Cysteine proteinase inhibitor Vigna unguiculata Q06445 Cyst-VigU
Cystatin precursor Ornithodoros moubata AAS01021 Cyst-OmM
Putative secreted cystatin Ixodes scapularis Q8MVB6 Cyst-IxoS
Putative cystatin Ixodes ricinus CAD68002 Cyst-IxoR
Cystatin Lepydoglyphus destructor Q8WQ46 Cyst-LepD
Cystatin Theromyson tessulatum Q8IT43 CystB-TheT
Cystatin-like protein Drosophila melanogaster P23779 CystL-DroM
Cystatin Drosophila melanogaster 1702209A Cyst-DroM
Sarcocystatin A precursor Sarcophaga peregrina P31727 CystA-SarP
Sarcocystatin B Sarcophaga crassipalpis Q8TYOY1 Cyst-B-SarC
Sarcocystatin A Sarcophaga crassipalpis BAB88880 Cyst-A-SarC
Cystatin precursor Tachypleus tridentatus JC4536 Cyst-TacT
Cysteine protease inhibitor like (cli-1) Caenorhabditis elegans 061973 Cyst-CaeE-clil
Cysteine protease inhibitor like (cli-2) Caenorhabditis elegans Q9TYY2 Cyst-CaeE-cli2
Cystatin-1 Haemonchus contortus 044396 Cyst-HaeC
Nippocystatin Nippostrongylus
brasiliensis
Q966W0 Cyst-NipB
Ls-cystatin precursor Litomosoides sigmodontis Q9NH95 Cyst-LitS
CPI-1 Brugia malayi P90698 Cystl-BruM
CPI-2 Brugia malayi 016159 Cyst2-BruM
Cystatin Acanthocheilonema vitae Q17108 Cyst-AcaV
CPI-1 Onchocerca volvulus Q9UA1 CPI 1-One V
cystatin Onchocerca volvulus Q25620 Cyst-OncV
Onchocystatin precursor Onchocerca volvulus P22085 CystX-OncV
Cysteine protease inhibitor Schistosoma mansoni AAQ16180 Cystl-SchM
Cystatin homolog Schistosoma mansoni A48570 Cyst2-SchM
Dopamine receptor Fugu rubripes Q90517 Cyst-FugR
Cystatin Acipenser sinensis AAK16731 Cyst-AciS
Cystatin precursor Cyprinus carpio P35481 Cyst-CypC
Cystatin Bitis ariensis P08935 Cyst-Bit A
Cystatin Bitis gabonica AAR24527 Cyst-BitG
Protein Name Species Acc. N°. Tree name
Family-2 cystatin precursor Onchorhynchus keta Q98967 Cyst-OncK
Cystatin precursor Onchorhynchus mykiss Q 91195 Cyst-OncM
Cystatin Gallus gallus P01038 Cyst-GalG
Cystatin 8 Mus musculus AAH49753 CRES-MusM
Hypothetical cysteine proteases inhibitor 
containing protein
Mus musculus Q9DAP1 CRES-l-M usM
Stefin 1 Mus musculus P35173 Cystl-M usM
Stefin 2 Mus musculus P35174 Cyst2-MusM
Stefin 3 Mus musculus P35175 Cyst3-MusM
Stefin B Mus musculus Q62426 CystB-MusM
Cystatin C Mus musculus P21460 CystC-MusM
Leukocystatin Mus musculus 089098 CystF-MusM
Kininogen domain 2 Mus musculus 008677 KNG2-MusM
Kininogen domain 3 Mus musculus 008677 KNG3-MusM
Cystatin A Rattus norvegicus PO1039 CystA-RatN
Stefin B Rattus norvegicus P01041 CystB-RatN
Cystatin C Rattus norvegicus P14841 CystC-RatN
Cystatin S Rattus norvegicus P I9313 CystS-RatN
Kininogen domain 2 Rattus norvegicus P08934 KNG2-RatN
Kininogen domain 3 Rattus norvegicus P08934 KNG3-RatN
Rat T-kininogen Rattus norvegicus PO1048 T-KNG2-RatN
T-KNG3-RatN
Major acute phase alpha-1 protein Rattus norvegicus P70517 M AAPl-RatN
MAAP2-RatN
Cystatin C Oryctolagus cuniculus 097862 Cyst-OryC
Stefin A1 Sus scrofa Q28988 Cystl-SusS
Stefin A5 Sus scrofa Q28986 Cyst5-SusS
Stefin A8 Sus scrofa Q28987 Cyst8-SusS
Stefin B Sus scrofa Q29290 CystB-SusS
Stefin D1 Sus scrofa P35479 Cysti-SusS
Stefin B Ovis aries 010994 CystB-OviA
Stefin A Bos taurus P80416 CystA-Bos
Stefin B Bos taurus P25417 CystBl-Bos
Cystatin C Bos taurus PO1035 CystB2-Bos
Stefin C Bos taurus P35478 CystO-BosT
Kininogen Bos taurus 
Bos taurus
PO1044 KNG2-BosT
KNG3-BosT
Cystatin C Saimiri scìureus 019093 CytC-SaiS
Cystatin C Macaca mulatta 019092 CytC-MacM
Stefin A Homo sapiens PO1040 CystA-HomS
Stefin B Homo sapiens P04080 CystB-HomS
Cystatin C Homo sapiens PO 1034 CystC-HomS
Cystatin D Homo sapiens P28325 CystD-HomS
Cystatin SN precursor Homo sapiens PO1037 CystN-HomS
Cystatin E Homo sapiens Q15828 CystM-HomS
Cystatin S precursor Homo sapiens PO1036 CystS-HomS
Cystatin SA precursor Homo sapiens P09228 CystT-HomS
Leukocystatin Homo sapiens 076096 Cyst7-HomS
Cystatin 8 Homo sapiens 060676 Cyst8-HomS
CS13 Homo sapiens Q8WXU6 Cystl 1-HomS
Kininogen Homo sapiens PO1042 KNG2-HomS
KNG3-HomS
Legends to figures
Fig.l. Southern blot analysis o f adult and juvenile cDNA. cDNAs from adult and juvenile 
parasite were separated by agarose gel electrophoresis, transferred onto nylon membrane and 
probed with radiolabelled 472 bp probe.
Fig.2. PCR amplification on adult and juvenile cDNA. cDNAs (1 ng) from adult (lanes 1,3 5, 
7) and juvenile (lanes 2, 4, 6, 8) parasite were submitted to 15 (lanes 1, 2), 20 (lanes 3, 4), 25 
(lanes 5, 6) and 30 cycles (lanes 7, 8, 9) of PCR. Lane 9 is the control without DNA. PCR 
products were electrophoresed on agarose gel and stained with ethidium bromide. Molecular 
sizes of the DNA ladder (M) are in bp.
Fig.3. Southern blot analysis o f genomic DNA. Genomic DNA was digested and the digestion 
products were electrophoresed on agarose gel and stained with ethidium bromide (lane 1) and 
transferred onto nylon membrane and probed with radiolabelled 336 bp probe and exposed for 
24h (lane 2). Molecular sizes of the DNA ladder (M) are in bp.
Fig. 4. Alignment o f F. hepatica cystatin domains. The six domains were aligned using 
ClustalW and adjusted manually. The three parts of the papain binding domain are framed. 
Disulphide bridges are shown with brackets and cysteine residues are in pale grey. Numbering 
corresponds to the amino acids of each domain.
Fig.5. Expression and purification of the recombinant F. hepatica cystatin domain 4. A 15% 
SDS-polyacrylamide gel was loaded with Drosophila supernatants before induction (lane 1) 
Drosophila supernatants after induction with copper sulphate (lane 2), fractions eluted from 
the anion exchange chromatography (lane 3), and fractions recovered from the 50 kDa filter 
(lane 4). Molecular mass markers (M) are indicated in kDa. Gels were stained with silver 
nitrate.
Fig.6. Inhibitory activity o f recombinant cystatin. A. Purified and activated recombinant 
cathepsin LI (lanes 1) was complexed with an equal amount (5[xM) of cystatin (lanes 2) and 
analysed by non denaturated polyacrylamide gels prepared in the absence (panel a) and 
presence (panel b) of gelatin. Gels were stained immediately after electrophoresis (panel a) or 
were incubated overnight before staining to observe gelatinolytic activity (panel b). Lanes 3 
show recombinant cystatin alone. B. 1/<M of recombinant F. hepatica cathepsin LI was 
incubated 30 min with increasing concentrations of recombinant F. hepatica cystatin domain
4 ( • ) ,  human cystatin C (■ )  and cathepsin L inhibitor Z-Phe-Ala-CHN2 (A). Residual 
activities were monitored by Z-Phe-Arg-AMC hydrolysis.
Fig.7. Phylogenic relationship o f F. hepatica within the 3 cystatin families. Consensus tree 
illustrating the phylogenic relationship of F. hepatica domains (Cystl-6-FasH) with other 
known cystatin proteins. The tree is based on amino acid sequences of the mature proteins 
beginning at the conserved G at the C-terminal end of the protein and ending at the conserved 
C at the N-terminal end of the protein (this corresponds to amino acid 37 to 142 of human 
cystatin C). Only bootstrap values at nodes higher than 40% are represented. The references 
for each protein are given in the Table 1.
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